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viii
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MVEC microvascular endothelial cells
NO nitric oxide
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PC protein C
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PS protein S
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SEM scanning electron microscopy
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TAFI thrombin activatable fibrinolysis inhibitor 
tF tissue factor
TFPI tissue factor pathway inhibitor 
TGF-β transforming growth factor β
TM thrombomodulin
tPA tissue type plasminogen activator
TXA2 thromboxane A2
uPA urokinase
vWF von Willebrand Factor
Introduction and objectives
1
2The best treatment for limb threatening ischaemia is an autologous vein
bypass. In case a suitable vein is not available, prosthetic grafts, endarterecto-
my, or percutaneous transluminal angioplasty (PTA) sometimes offer a solu-
tion.
The superior results of a vein bypass are attributed for an important part to the
presence of a confluent endothelial cell (EC) layer on the luminal surface. To
improve the results of prosthetic grafts, the idea of seeding of EC on grafts
was introduced more than 20 years ago.
The use of veins as a source of EC has a long history. Using this source of EC,
culture is required to obtain sufficient cells to cover the graft confluently.
Disadvantages of the use of cultured cells are growth and infection problems
and the procedure not being suitable for emergency cases. Moreover, it is
costly to perform cell culture under conditions of good manufacturing practice
(GMP). To avoid these problems other sources of EC have been explored.
Fat tissue is well-vascularized, abundant, and it can be obtained relatively
easy via liposuction. A simple procedure including enzymatic digestion and
centrifugation results in microvascular endothelial cells (MVEC) with a yield
high enough to make culture of the cells before seeding unnecessary.
The seeding of fat derived MVEC on prosthetic grafts in animal models result-
ed in a confluent EC layer without visible platelet aggregation and fibrin depo-
sition, and good patency.
However, until now the results in humans have been disappointing, because
of development of intimal hyperplasia and thrombus formation. A thickened
intima was also found in animal studies. A possible role of contaminating cells
in the development of intimal hyperplasia has been suggested.
The central question of this thesis is whether subcutaneous fat tissue is suit-
able as an alternative source of EC for the seeding of prosthetic grafts and
deendothelialized surfaces. This question led to the following objectives:
1 To establish incidence, composition, and progression of intimal hyperplasia
after seeding of MVEC in an in vivo dog model, and to study whether seeded
cells contribute to development of intimal hyperplasia (chapter 3);
2 To examine whether it is possible to seed MVEC isolated from fat tissue onto
deendothelialized surfaces after PTA in an in vivo rabbit model (chapter 4);
3 To investigate the purity of cells isolated from human fat tissue and whether
these cells can be purified further (chapter 5);
4 To determine whether the purity of the seeded human cells influences
thrombogenicity and intimal hyperplasia of seeded grafts in vitro (chapter 6);
3ch
a
p
te
r 
1
In
tr
o
d
u
ct
io
n
 a
n
d
 o
b
je
ct
iv
e
s
5 To develop an in vitro model to study seeding of deendothelialized vessels,
and to test different types of seeded cells in this model (chapter 7);
6 To set up a clinical grade method for the purification of human fat derived
MVEC (chapter 8);
7 To make a proposal for a patient study to establish whether the results of
prosthetic grafts in patients can be improved by seeding of purified MVEC
from fat tissue (chapter 9).
4
The evolution of endothelial cell seeding
from challenging concept to established
prototype of tissue engineering
2
6Introduction
The original idea behind endothelial cell (EC) seeding was to improve the
patency of small diameter vascular grafts by establishing a functional biologi-
cal lining on the luminal surface.
In vascular surgery, four options for arterial-occlusion exist: the vein bypass,
the prosthetic bypass, percutaneous transluminal angioplasty (PTA) and
endarterectomy.1 Despite a successful initial revascularization, a considerable
number of the reconstructions will suffer from luminal stenosis when used for
occlusion of small (<6 mm) diameter vessels.2
For small diameter bypass techniques, the autologous saphenous vein is the
graft material of first choice. The four-year patency rate of saphenous vein
femoro-tibial bypass grafts is about 75%, while that of prosthetic grafts is only
55%.1 Many patients however do not have suitable veins due to severe varico-
sis, earlier thrombosis or previous use of venous material for bypasses.
The majority of luminal stenose is caused by either thrombosis3 or intimal
hyperplasia.4 The large difference in patency between prosthetic and autolo-
gous vein grafts has been attributed to the presence of viable EC on the lumi-
nal surface of autologous veins.5 EC were once thought to be a mono-layer of
passive cells lining the vasculature. Meanwhile EC have shown to actively
inhibit thrombosis and intimal hyperplasia.6
In laboratory animals, grafts spontaneously endothelialize along the entire
length of the graft within months after implantation.7 Prosthetic grafts and
deendothelialized surfaces in men do not re-endothelialize more than one
centimetre away from the anastomosis.8 The establishment of a human EC lin-
ing on the entire luminal surface of a prosthetic graft is therefore challenging.
In the first part of this chapter the properties making EC valuable to cover the
inside part of blood vessels are depicted. In the second part the history of EC
seeding is described and the development into the broader field of tissue
engineering.
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EC and thrombogenicity
EC and platelet aggregation
When vessel wall damage occurs, proteins present in the subendothelial
matrix (von Willebrand Factor (vWF), collagen and fibronectin) are exposed9,10
and proteins from the circulation (particularly fibrinogen) are absorbed to the
subendothelial matrix.11 The circulating proteins also bind to prosthetic grafts.
EC neighbouring the damaged vessel wall or prosthetic graft begin to express
P-selectin.12
Platelets respond by establishing adhesive interactions with the exposed pro-
teins present in the subendothelial extracellular matrix. Platelets become acti-
vated through contact with thrombogenic surfaces or by locally released or
chemical agonists. Platelet activation is a sine qua non for platelet adhesion
and aggregation.
Various pathways are involved, culminating in firm adhesion, depending on
the level of shear stress. P-selectin can be used by platelets to roll on the stim-
ulated endothelium.13 Platelets adhere to fibrinogen bound to the wall of the
injured vessel through their integrin αIIbβ3 receptors. The receptors α2β1 and
glycoprotein (GP) VI are involved in the adhesion of platelets to collagen.14
VWF is absolutely necessary for firm adhesion under conditions of high
intravascular shear forces, such as present in arteries. The free-flowing
platelets adhere to vWF via their GP Ib-IX-V receptorcomplexes.13 Binding of
platelets to GP Ib-IX-V leads to the interaction of fibrinogen with αIIbβ3.15
Platelet aggregation is mediated by the αIIbβ3 receptor. Fibrinogen binds to two
αIIbβ3 receptors present on two platelets, thereby bridging two platelets.
Activation of platelets is associated with the exposure of negatively charged
phospholipids, which have high potential to bind coagulation factors.
Activated platelets release vasoactive substances like adenosine diphosphate
(ADP), adenosine triphosphate (ATP), serotonin (5-HT), thromboxane A2
(TXA2) and platelet activating factor (PAF),16 inducing vasoconstriction and fur-
ther activation of platelets (fig. 1).17
Under normal circumstances EC have an antithrombogenic function. First, the
negative charge of the surface of EC formed by glycocalyx prevents platelets
to adhere.18 Second, nitric oxide (NO) (through cyclic guanosine monophos-
phate (cGMP)) and prostacyclin (PGI2) (through cyclic adenosine monophos-
phate (cAMP)), both produced by EC, inhibit platelet adhesion and
aggregation and cause blood vessel dilatation.17,19 The counterpart of PGI2 is
8TXA2, produced by platelets. In an intact vessel more PGI2 than TXA2 is pres-
ent, which helps control platelet reactivity on the surface of EC. Third, the EC
surface ectonucleotidases metabolize ADP to prevent platelet recruitment and
form adenosine. This in turn, can elevate platelet cAMP levels and further
inhibits platelet reactivity (fig. 2).20
EC and coagulation
Clot generation occurs when fibrinogen is converted into fibrin by thrombin.
Thrombin is generated as a result of a series of ordered reactions (fig. 3).6
In vivo, the initiation of coagulation in response to trauma occurs via the expo-
sure of tissue factor (tF) (the extrinsic pathway).21,22 TF is a membrane bound
protein abundantly present in cells surrounding the vascular bed.23 It binds
factor (F) VII and in a smaller part fVIIa.
The FVIIa-tF complex, in turn, can activate FX in two ways.24 Direct activation
occurs and indirect activation via FIX, which forms a complex with FVIIIa and
phopholipds. FVIII circulates bound to vWF, after activation, FVIIIa dissociates
from vWF.
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Figure 1
Platelet adhesion, aggregation and activation.
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Figure 2
Endothelial cell inhibition of platelet activation.
Figure 3
Coagulation cascade.
10
FXa, its cofactor FVa (activated by FXa) and anionic phospholipids activate
prothrombin. FXa is the only known enzym which can activate prothrombin
(FII). Once thrombin (FIIa) is formed, it diffuses into the surrounding plasma or
interstitial fluid and produces fibrin strands by cleaving fibrinogen.10
Recent studies have shown that after primary thrombin generation, induced
through tF, more thrombin generation takes place via the ‘FXI loop’ (the for-
mer intrinsic pathway). FXI, activated by thrombin (FIIa), results in the genera-
tion of additional FIXa, which in turn activates FX, which in turn further
activates more FII.22,25
Most of the thrombin generation occurs after the formation of a fibrin clot.24
This thrombin is important for generation of additional fibrin, FXIII, and throm-
bin activatable fibrinolysis inhibitor (TAFI). FXIII stabilizes the clot by covalent
cross-linking of fibrin.6 TAFI inhibits fibrinolysis by cleavage of a fibrin part
essential for binding and activation of plasminogen.26
EC have binding sites for different coagulation factors.27 Normally, an intact
layer of no activated EC does not express tF.28 Inflammation, trauma,
cytokines, bacterial endotoxin, oxidized LDL and thrombin can induce tF
expression in EC.19,29,30
Situated between the blood and the vascular wall, endothelium serves as a
anticoagulant surface.31 Tissue factor pathway inhibitor (TFPI) is an important
inhibitor of coagulation produced by EC. TFPI forms a complex with Xa, which
then combines with the VIIa-tF complex, thereby inactivating both FVIIa and
FXa.32
Thrombomodulin (TM) is a glycoprotein present on the EC membrane which
binds thrombin.10 Bound to TM, thrombin fails to activate platelets, fibrinogen,
FV, and FVIII. Furthermore, the ability of thrombin to activate protein C (PC) is
enhanced more than 1000-fold.33 Activated protein C (APC) binds the
endothelial cell protein C receptor (ECPCR) and inactivates FVa and FVIIIa,
which results in inhibition of the coagulation system. Protein S (PS) promotes
the PC interaction with FVa and fVIIIa.34 Both are produced by liver cells,35 but
PS is also produced by EC.10
Heparan sulfate, a heparin-like proteoglycan is present on the surface of EC
and potentiates the effects of antithrombin III (ATIII) and heparan cofactor II.36
The bound pool of ATIII is 1000-fold more active to inhibit FXa, thrombin,37
FIXa38 and FXIa.39 Heparan cofactor II also inhibits thrombin but requires a ten-
fold higher concentration of heparin than ATIII.40
11
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Further control of the clotting mechanism occurs at the level of fibrinolysis.
This process occurs via the proteolytic enzym plasmin. Plasminogen is con-
verted to plasmin by two plasminogen activators, tissue type plasminogen
activator (tPA) and urokinase (uPA).41 In vivo, resting EC synthese only tPA,42
but when stimulated by a variety of cytokines they also synthese uPA. EC also
produce two plasminogen activator inhibitors, type 1 (PAI-1) and 2 (PAI-2).43 In
an intact vessel more tPA than PAI-1 is present. Thrombin, APC, interleukin-1
(IL-1) and endotoxin, however, can stimulate PAI-1 in such a way that the net
effect is inhibition of activation of plasminogen (fig. 4).44-46
EC and Intimal hyperplasia
Proliferation and migration of smooth muscle cells (SMC), present in the
media, are thought to play a fundamental role in early stages of intimal thick-
ening (fig. 5).47 Different types of vessel injuries stimulating intimal hyperplasia
exist.
Figure 4
Anticoagulant and profibrinolytic function of endothelial cells.
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PTA and endarterectomy
An artery is readily injured by passage of a balloon embolectomy catheter or
endarterectomy instrument.48 The EC are removed and the media is stretched.
Platelets adhere, aggregate and degranulate. The initial events, SMC prolifera-
tion in the media and migration into the intima, are triggered by two different
growth factors, basic fibroblast growth factor (bFGF) and platelet derived
growth factor (PDGF). BFGF is released from damaged EC and arterial SMC
and stimulates proliferation of SMC in the media. Platelets α-granules are the
major source of PDGF, but also EC secrete PDGF. Two isoforms of PDGF
exist. One isoform stimulates migration of SMC into the intima, the other stim-
ulates proliferation of SMC in the media.48 Besides PDGF and bFGF, insulin
growth factor 1 (IGF-1) and thrombospondin, secreted by the EC, affect SMC
and fibroblast proliferation and migration.49
Proliferation of SMC starts 24h after injury. At the same time, monocytes from
the circulation migrate into the intima and differentiate into macrophages,
releasing peptides which further stimulate SMC proliferation and alter their
phenotype from a contractile one into a matrix-synthesizing one. Four days
Figure 5
Development of intimal hyperplasia.
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later, SMC migrate into the intima where 50% of them remains proliferative.
This proliferative response reaches a peak at 4 weeks. The deposition of
matrix around the cells, composed of collagen, elastin and proteoglycans, fur-
ther increases the intimal thickening.50 In favourable outcomes, matrix deposi-
tion stabilizes 4-6 months post injury.51
Vein grafts with an EC layer
A second type of intimal hyperplasia is associated with the implantation of a
vein graft. Although the vein graft is treated carefully, operative manipulations
injure the intima and media.52 At the anastomoses, where the endothelium is
denuded, platelets, micro-thrombi, and leucocytes adhere. By two weeks, the
denuded surface is completely recovered with EC. This is when intimal hyper-
plasia begins to develop. In contrast to the healing of injured arteries, SMC
migration and proliferation occur underneath the EC layer.53,54 The main
sources of growth factors after reendothelialization are SMC55 and necrotic or
injured EC.56
The development of intimal hyperplasia can be considered as a healing
process, a response of the vessel to reach an optimal relationship between
the vein graft and the native artery at the anastomoses.54,57
Prosthetic grafts
The prosthetic graft induces an inflammatory reaction with activation of
platelets and macrophages. This induces the release of growth factors and
cytokines necessary for SMC proliferation. Furthermore the difference in com-
pliance between the native artery and the prosthetic bypass graft leads to tur-
bulence and variable shear stress.4 As a consequence of turbulence and
variable shear stress further SMC proliferation and matrix deposition occur on
the graft and in the regions of the anastomoses.
Uninjured endothelium has a protective function with respect to intimal hyper-
plasia.58 Cells form a barrier to the influx of growth factors and release
inhibitors of SMC proliferation.59 The baseline antiproliferative influence of EC
on the underlying SMC might be mediated via PGI2 and heparan sulfate.60,61
EC produce NO. NO reduces the expression of adhesion molecules on the EC
and so the recruitment of inflammatory cells, which are a source of growth fac-
tors.62 Besides NO inhibits SMC proliferation and might even induce apoptosis
of these cells.63,64 Furthermore NO decreases synthesis of collagen.65 EC pro-
14
duce transforming growth factor-β (TGF-β). TGF-β stimulates EC production of
proteoglycans, collagen, fibronectin and regulate the receptors of these pro-
teins.27 Besides TGF-β can decrease the secretion of proteases and increase
the formation of protease inhibitors by the EC, which results in stabilization of
the connective tissue matrix.27 Furthermore TGF-β is a potent inhibitor of DNA
synthesis of medial SMC (fig. 6).66
EC seeding
The interest in the establishment of a functional biological lining on the luminal
surface of prosthetic grafts, to improve the patency of small diameter vascular
grafts EC seeding, started in 1975 with work of Mansfield.67 He used granula-
tion tissue from the bed of a pedicled skin flap as a cell source to seed a mix-
ture of EC, fibroblasts and macrophages onto patches of polyester.
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Figure 6
Protective function of unstimulated endothelial cells with respect to intimal hyperplasia.
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In the late seventies, when it became possible to isolate and culture EC, fur-
ther progress was made.68 Since then, different sources and types of cells,
isolation methods, graft materials, graft sizes, coatings of grafts, animal mo-
dels, antithrombotics and methods of follow up have been used.
Venous endothelial cells
In 1978, Herring at al reported the first succesful seeding of prosthetic grafts in
dogs.69 Mechanical isolated venous EC were mixed with blood. This mixture
was used to preclot Polyester grafts, implanted as infrarenal abdominal aorta
interposition grafts. After 2-8 weeks, the thrombus-free surface area was found
to be significantly smaller in the seeded than in the nonseeded grafts.
Subsequently, many additional studies with dogs have been performed.70-79
EC were no longer harvested mechanically but enzymatically with a solution of
trypsin and collagenase, first from everted vessels and later from clamped
cannulated vessels. It was soon shown that not only preclotting of polyester
grafts with a mixture of EC and blood, but also seeding of EC onto the luminal
surface of PTFE resulted in surface endothelialization in dogs. A condition for
successful seeding was a precoating of the graft with a protein matrix.71,73,76 To
improve the patency further, aspirin and dipyridamole were administrated to
the dogs.80
A compilation of the results of EC seeding in animal trials using 4mm inner
diameter polymer grafts showed that although not all animal experiments pro-
vided statistical significant results, cell seeding was able to accelerate the for-
mation of an EC lining on the luminal surface of polymeric grafts and to
complete luminal healing within 4-6 weeks.81
The first human study was reported by Herring et al.82 Isolated venous cells
were seeded onto preclotted polyester prosthetic grafts. Only in non-smokers
seeded femoro-popliteal grafts performed better than nonseeded grafts. A
randomized trial of EC seeding versus no seeding was initiated, using 6mm
ePTFE grafts into the femoro-popliteal position.83 After 1 and 2 years, the
patency rates of the seeded grafts were significantly improved compared to
that of the nonseeded grafts. Again patency was better in non-smoking
patients. In a multi-institutional study comparing autologous vein grafts and
seeded PTFE grafts, the patency after 30 months was greater for vein grafts.
PTFE grafts failed due to anastomotic hyperplasia.84
16
Orthenwall et al seeded one limb of a preclotted polyester aorto-bifemoral
graft. Radiolabeled platelet uptake after 12 months was significantly lower in
the seeded limb.85 Similar experiments using PTFE femoro-popliteal grafts
showed a lower platelet deposition in the seeded grafts, 1 and 6 months after
implantation.86 Zilla et al found no significant difference between EC-seeded
and nonseeded ePTFE femoro-popliteal grafts.87
The following suggestions were brought up for the failure of a considerable
amount of the human studies with vein derived EC. The amount seeded cells
was small. A high instantaneous cell loss of freshly seeded EC could occur.88
The growth potential of human EC could be lower than that of canine EC.89
Experiments with cultured adult EC began in the 80s after the discovery of two
substances that stimulate EC growth: endothelial cell growth factor (ECGF)
derived from the bovin pituary gland90 and heparin as a necessary cofactor for
heparin binding growth factor.91
Leseche et al, implanted ePTFE grafts as femoro-popliteal bypasses with cul-
tured EC.92 The two-stage technique proved to be feasible in 69% of the
patients not requiring emergency recontruction.
In addition to regular culturing before seeding, in vitro culturing of cells on the
prosthetic graft was introduced. This technique was not only introduced to
increase the amount of cells, but also to allow maturation of the cytoskeleton,
deposition of extracellular matrix93 and resistance of seeded cells to shear
stress.75 Both a canine94 and a primate model.95 showed that in vitro lined
endothelium on fibrin glue coated ePTFE grafts was persistent and of low
thrombogenicity.
Between 1989 and 1991 a randomized clinical trial was performed in which
seeded and nonseeded ePTFE grafts were used for femoro-popliteal by-
passes. Seeded grafts were cultured in vitro for at least 9 days. The total peri-
od between EC isolation and graft implantation was 37 days. After 32 months
the patency was 85% for the seeded and 55% for the nonseeded graft.96 The
persistence of a confluent endothelium was proven from two specimens.97,98
Magnometschnigg et al performed a not randomized study, in vitro seeded
ePTFE grafts were used for crural repeat reconstructions. A 30 days patency
of seeded grafts of 92% and of nonseeded grafts of 53% was found.99
Swedenborg et al evaluated in a pilot-study the feasibility of in vitro endothe-
lialized PTFE grafts, used as interposition arteriovenous (AV) fistulas in
uraemic patients. In this highly problematic patient group, results were pro-
mising with EC coverage after 5 weeks of implantation.100
17
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Recently, the 9-year follow-up of the initial randomized study by Zilla et al and
the 5-year follow-up of the routine clinical endothelialization program were
reported.101 The patency rates were significantly greater for the seeded grafts
(65%) than for the nonseeded control group (16%). The 5-year patency rate
for all in vitro endothelialized infrainguinal reconstructions was 68% (66% for
above the knee and 76% for below the knee grafts) and comparable to the
rates of reversed saphenous vein grafts (68% after 5 years).1
Despite strong evidence that in vitro EC lining improves the patency of small-
diameter vascular grafts, a major shortcoming of all studies is its restriction to
elective cases. This is owing to the 4- to 5-week delay between cell harvest
and graft implantation. Furthermore, growth- en infection problems can occur
and the costs of cell culture are substantial especially when performed under
‘good manufacturing practice’ (GMP).30,96 To avoid these problems, a
research for other cell types and for other sources of EC has been started.
Mesothelial cells
In 1984, Clarke et al were the first to discover that pieces of mesothelium
exposed to in vitro blood flow were non-thrombogenic.102 They implanted
polyester grafts seeded with mesothelial cells (MC) in dogs. One month later,
a confluent layer of MC without platelets was found.103 After the discovery that
MC secreted high amounts of tPA,104 additional dog experiments with MC-
seeded polyester prostheses in the femoral position were performed.105 This
time no improvement in thrombus-free area nor luminal cell cover was found.
A better analysis of the results suggested the amount of seeded cells was too
low and the time for the cells to attach to the graft too short.
Previous research in our laboratory by Pronk and Verhagen focussed on the
use of MC as an alternative for seeding EC. A method was developed to iso-
late enough pure cells from omental fat.106 The amount of cells that remained
attached to the prosthesis was large enough and the cells appeared to have
the same flow-resistant properties in vitro as EC.107 Moreover, the short period
of culturing, necessary to enlarge the yield,108 increased the expression of tis-
sue factor (tF) on the cells.109 Changing the culture conditions reduced tF
expression with 90%, to the same level as that of EC.110 Furthermore, MC
express a large amount of the antithrombogenic thrombomodulin on their sur-
face, even more than EC.111 In vivo experiments in dogs, however, did not
show the wanted antithrombogenic and profibrinolytic properties of MC-coa-
ted grafts nor absence of intimal hyperplasia.112
Microvascular endothelial cells
In 1986, Jarrell and Williams applied a modification of a technique to harvest
MVEC from fat tissue previously developed by Wagner113 to synthetic graft
seeding.114 The intitial source of fat was omental tissue. This source of fat was
found to be highly vascularized with an EC density of approximately 106
cells/gram tissue.114
A significant controversy was established when Visser et al reported that
omental tissue contained predominantly MC and not EC.115 The confusion was
clarified by the establishment of the existence of ‘omentum’ and ‘omental fat’.
Both are histologically and anatomically distinct tissues. Cells typically isola-
ted from the omentum are not EC but MC.116,117 After careful dissection of the
covering serosa, omentum-associated adipose tissue represented an abun-
dant source of EC for vascular graft seeding.81,118
Baitella et al concluded that omental fat-derived MVEC seeded polyester pros-
theses were able to generate a vascular wall resembling the wall of a normal
artery.119 Pasic et al noticed an improvement of the patency of small diameter
polyester grafts in 30 dogs after 26 weeks, with a one-stage EC-seeding pro-
cedure with omental fat.120 An automatic method for the isolation of EC provid-
ed comparable results to the manual method.
A major improvement in the isolation of MVEC was the use of liposuction-
derived subcutaneous fat as a source of MVEC.121 These fat-derived cells were
characterized to be 85% endothelium prior to tissue digestion, and pure
endothelium following digestion and separation of adipocytes.117
The term ‘sodding’ was originally introduced to indicate that EC were seeded
onto a preestablished clot, in contrary to the originally technique of seeding by
which prosthetic surfaces were preclotted with EC in platelet-rich plasma.122
Nowadays, sodding is used for the process by which cells are brought into a
graft in suspension, followed by an overload of sodding medium (culture
medium with serum) by which cells are pressed into the crevices of the grafts.
Seeding is nowadays used for the lining of a graft with cultured EC using grav-
ity. The graft can be further cultured in vitro or implanted immediately.123
MVEC have been used successfully to endothelialize prosthetic grafts in dogs.
Since dogs do not have subcutaneous fat, falciform ligament fat was used.
Four mm diameter ePTFE grafts were implanted as carotid interpositions. A
significant improvement due to sodding was found.118 A lining with character-
istics of EC was present. Mid-graft samples of pressure sodded PTFE grafts
used for AV fistulas also showed an intact EC lining.124 In all cases underneath
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this lining a distinct multilayer of non-
EC was found.118
In 1997, Hedeman Joosten started a
project focussing on subcutaneous
fat-derived MVEC. MVEC proved to
keep their antithrombogenic proper-
ties in vitro, also after seeding onto
prosthetic graft material.125 MVEC
showed to be resistent against physi-
ological shear forces and showed to
express little prothrombogenic activity
after perfusion with non-anticoagulat-
ed blood.126 Seeded grafts, implanted
as carotid interpositions in dogs,
showed a confluent EC layer above a
multilayer of myofibroblasts, without
fibrin and platelet deposition.
Nonseeded grafts, on the other hand,
were covered with platelets and fibrin
(fig. 7).127
Despite successful patency rates
obtained in animal experiments,
human studies have been sparsely
performed and the results were dis-
appointing. In a case-report a seeded
mesoatrial polyester graft was
implanted.128 Histology of the midpor-
tion, obtained after 9 months because
of a mechanical stricture, showed a
substantial subendothelial layer.
Another group used PTFE grafts
seeded with subcutaneous fat tissue
derived MVEC for peripheral vascular
reconstruction in 34 patients.129 The
cumulative patency at 36 months was
19%, similar to other studies using
nonseeded grafts. Recently, Williams
Figure 7
A. Normal vessel from a dog (magnification,
x 600);
B. Non-seeded graft implanted as a carotid
interposition graft in a dog-model for 4
months (magnification, x 600);
C. Seeded graft implanted as a carotid inter-
position graft in a dog-model for 4 months
(magnification, x 600).
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et al published the results of an initial safety study with 11 patients with signifi-
cant vascular disease who received MVEC sodded ePTFE bypasses in the ilio-
or femoro-peroneal or tibial region.130 Of the original 11 patients, seven were
available for follow up at four years, while four expired prior to this time due to
nongraft related causes. The cumulative patency at 4 years was 55%.
The results of human studies with fat derived MVEC have been less convinc-
ing than those of animal studies with fat derived MVEC, and of human studies
with cultured vein derived EC. Two causes have been suggested. First, the
formation of a confluent endothelium might be delayed in a single-stage pro-
cedure. Second, a high percentage of contaminating non-endothelial cells
might be present.131,132 Although a purity of 100% has been claimed for fat
derived EC after isolation,121 this purity was not always obtained by other
groups.133
Additional purification methods have been described. For example a Percoll
density gradient separation.114 Percoll mediated isolation is not very specific
for purification of EC from fat tissue and it is thought that Percoll influences EC
function.134 More specific ways of MVEC purification are Ulex europaeus-1
(UEA-1)-135 or anti-CD31-coated Dynabeads.133,136 These magnetic Dynabeads
attach to the EC via UEA-1 or anti-CD31, the Dynabead-EC combinations are
then removed with a magnetic device. Currently, purified cells have not been
tested in human cell seeding studies.
EC seeding on denuded surfaces
EC seeding has been proposed as a possible intervention to control thrombo-
sis and development of intimal hyperplasia after percutaneous transluminal
angioplasty (PTA) and endarterectomy.137-139 The surface of deendothelialized
arteries has been suggested to be superior towards a the surface of a pros-
thetic graft for EC adhesion, since proteins like collagen and fibronectin are
expressed, for which EC have special receptors.140,141
Rapid reendothelialization of deendothelialized surfaces in dogs, baboons,
and rabbits proved to accelerate restorations of the EC monolayer138,142,143 and
to decrease subsequent platelet deposition and intimal hyperplasia.137,138,143-147
The only human studies with EC seeded onto deendothelialized surfaces were
in vitro studies.140,148-150 Smyth et al showed that human EC seeded onto
endarterectomy specimens released significant amounts of PAI-1, suggesting
that they retain functional integrity. They concluded that where femoral
endarterectomy is appropriate, EC seeding potentially will offer a method of
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reducing thrombogenicity and intimal hyperplasia, and so improving paten-
cy.140
A few differences exist between seeding of deendothelialized surfaces and
prosthetic grafts. First, after PTA or endarterectomy EC-adhesive proteins are
exposed. Coating of the surface as in case of prosthetic grafts is not really
necessary anymore. Second, seeding is performed in vivo and not in vitro as
is in the case of prosthetic grafts. Third, cells can not be applied in the pros-
thetic wall, using pressure since the vessel wall is impervious. Application is
gravity dependent. For the in vivo seeding of deendothelialized surfaces a lot
of studies have used a double balloon catheter with two introduction ports,
one to inflate the balloons, one to introduce the cell suspension between both
balloons.151
Tissue engineering
The last several years the field of tissue engineering has emerged. Tissue
engineering is an interdisciplinary field aimed at the restoration or modification
of tissue function through the delivery of living elements which become inte-
grated into the patient.152 The three major approaches are guided tissue
regeneration using engineered matrices alone, the injection of allogenic or
xenogenic cells alone and the use of cells placed on or within matrices.152 The
matrix guides the development of the new tissue and provides structural sup-
port.
EC seeding is a classic example of tissue engineering. EC seeding is restrict-
ed to the construction of a cell layer on the luminal surface of a prosthetic
graft. The scaffold, the prosthetic graft, remains in situ. One step further in the
vascular tissue engineering is the construction of total blood vessel. The
advantage of the construction of a total blood vessel is that no foreign pros-
thetic material is present and that the vessels can adapt to changes in it envi-
ronment
Recently, the construction and testing of total blood vessels have been report-
ed.153-158 For the attachment of the cells and for the determination of the shape
of the vessel, temporary scaffolds are used. In the ideal situation the time
before resorption of the scaffold occurs is equal to the time necessary to
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establish the number of cells and matrix to take over the function of the scaf-
fold.
Weinberg and Bell were the first to construct a tissue-engineered blood vessel
composed of SMC, fibroblasts and and EC layer. These constructs were
unable to attain adequate burst strengths for in vivo applications.153
L’Heureux et al improved the mechanical strength of these constructs by alter-
ations in culture conditions. Human SMC were cultured with ascorbic acid and
produced a cellular sheet placed around a tubular support to produce the
media of the vessel. A sheet of fibroblasts was wrapped around the media to
serve as the adventitia and EC were seeded in the lumen after a period of cul-
turing. The vessel had a burst strength of more than 2,000 mmHg, which is
comparable to human vessels. The vessels were implanted in mongrel dogs
and remained patent in 50% at 1 week.154
Teebken et al created decellularized matrix tubes by enzymatic cell extraction
of porcine aortas and subsequently seeded these natural grafts with human
EC and myofibroblasts. These grafts were exposed to pulsatile flow condi-
tions.155
Niklason et al combined bovine SMC and EC with a biodegradable polymer,
using a bioreactor. Vessels, cultured under pulsatile conditions, showed
acceptable rupture strengths. After implantation in a miniature swine, patency
was up to 24 days.156
Watanabe et al constructed tissue engineered autografts by seeding a mixed
cell population obtained from femoral veins of mongrel dogs onto biodegrad-
able polymer scaffolds. After 1 week, the inferior vena cavas of the same dogs
were replaced with the graft. Follow up was 3-6 months. Neither occlusion nor
aneurysma formation was found. EC were present on the luminal surface.158
Recently, a tissue-engineered vessel graft was used to reconstruct the pul-
monary artery of a four year old girl.157 As a scaffold, a tube of a biodegrad-
able polymer was used. Ten days after seeding the scaffold with EC, the graft
was implanted. The graft was patent after 7 months.
Important new developments in tissue engineering involve the use of the stem
cells and gene therapy. Stem cells have the potency to differentiate into sever-
al types of mature cells. Gene therapy of transplanted cells can be used to fur-
ther improve the qualities of these cells. EC precursors are present in bone
marrow and in a smaller concentration in peripheral blood.159,160 Graft
endothelialization has been demonstrated using bone marrow,161 bone mar-
row derived pluripotent stem cells,162 and bone marrow derived CD34 cells.163
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Additionally, the mesenchymal stem cell seems to be a candidate as a precur-
sor cell for the other vascular cells, the SMC, and the fibroblast.164 Possible
candidates for gene therapy concerning vascular grafts are tPA,165 uPA,166 and
eNOS.167 Genes therapy can be used for stem cells as wel as mature cells.
Summary
The luminal surface of a damaged vessel wall or prosthetic graft is prone to
thrombus formation and development of intimal hyperplasia. Normal EC func-
tion is of great importance for the inhibition of these complications. In men, a
prosthetic graft or damaged vessel surface will not endothelialize sponta-
neously.
In the last 30 years, steps have been taken to establish confluent EC layers on
prosthetic grafts. Different cell types have been investigated. Vein derived EC
can be obtained with a high purity, but culturing is necessary to obtain a yield
high enough for seeding cells confluently. Mesothelial cell obtained from the
omentum, proposed as an alternative, do not inhibit thrombogenicity and inti-
mal hyperplasia when used in vivo. MVEC from subcutaneous fat tissue are
another alternative. They can be obtained abundantly, however questions
have been raised about the purity of these cells. Contaminating cells might be
present.
Tissue engineering of whole blood vessels is outside the scope of this thesis.
Nevertheless, the possibility to obtain a pure and abundant EC population is
of an utmost importance for whole blood vessel engineering.
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Abstract
Objectives: Seeding prosthetic grafts with fat-derived microvascular endo-
thelial cells (MVEC) results not only in a nonthrombogenic EC layer, but also
in intimal hyperplasia. Here we investigated incidence, composition, pro-
gression, and cause of this intimal hyperplasia.
Design: EPTFE grafts with MVEC were implanted as carotid interpositions
in 6 dogs with 1 mo, and in 3 dogs with 4, 8 and 12 months follow-up. Grafts
sodded without cells, implanted in the contralateral carotid, served as a con-
trol. In another 3 dogs labelled cells were seeded to investigate the contribu-
tion of the seeded cells (2-3 wk).
Materials and methods: MVEC were isolated from the falciform ligament.
Cells were pressure sodded on ePTFE grafts. Labelling was performed
using retroviral gene transduction. The grafts were analyzed with immuno-
histochemical techniques.
Results: After 1 month, all patent nonseeded grafts (5/6) showed fibrin and
platelet deposition, and all patent seeded grafts (5/6) were covered with a
confluent endothelial monolayer on top of a multilayer of myofibroblasts,
elastin and collagen. After long term follow-up, all nonseeded grafts were
occluded, all patent seeded grafts (4 and 12 months) were covered with an
EC-layer with intimal hyperplasia underneath. The thickness of the intima
did not progress after 1 month. Transduced cells were found in the endothe-
lial monolayer, hyperplastic intima and luminal part of the prosthesis.
Conclusions: MVEC seeding in dogs results in intimal hyperplasia in all
patent grafts, which contains myofibroblasts. Contaminants from the trans-
plant contribute to this intimal hyperplasia.
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Introduction
Seeding autologous endothelial cells onto prosthetic small diameter bypasses
has been developped to improve patency.1 This technique has been studied
extensively over the past years with vein-derived EC. Initial results were disap-
pointing as the number of cells harvested appeared to be too low to cover
grafts confluently. First culturing the cells and subsequently implantating the
seeded graft in a second procedure, resulted in favorable outcomes in animal
models2-4 and in humans.5-7 Due to the need for cell culture, however, it fails to
become popular among vascular surgeons. Culture makes the procedure
unsuitable for urgent cases, cells may grow poorly or may become contami-
nated, and the procedure is expensive.5 For this reason investigators have
looked for other sources of EC.
Our group first investigated the possibility of using mesothelial cells (MC) as
an alternative for EC. Despite hopeful in vitro results, final in vivo experiments
showed that these cells did not have the desired antithrombogenic and fibri-
nolytic properties.8 Subcutaneous fat tissue was found to be a source of large
amounts of microvascular endothelial cells (MVEC).9 In vitro experiments with
cultured cells, statically and under blood flow conditions showed expecting
results.10,11
Via a pressure sodding technique, MVEC can be inserted directly into the
crevices of polymeric grafts,9 resulting in a graft ready for implantation within a
few minutes. In dogs, MVEC sodding of small diameter expanded polytetraflu-
oroethylene (ePTFE) vascular grafts resulted in a statistically significant
improvement in graft patency.9,12 So far only a limited amount of human stud-
ies have been published13-15 with quite disappointing results.13,15 The few sam-
ples available for histologic evaluation showed EC on top of a progressively
concentric intimal thickening.13,14 Intimal hyperplasia has also been found in
dogs,9,12 but seems to expand more progressively in humans,13,14 ultimately
leading to graft occlusion.
Aim of this study was to investigate specific characteristics of this MVEC seed-
ing related intimal hyperplasia, such as the incidence, composition and pro-
gression in time, and the contribution of the seeded cells.
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Methods
Design of the study
EPTFE grafts with falciform derived MVEC were implanted as carotid interposi-
tions in dogs.
A We studied the incidence and composition of the intimal hyperplasia, using
six dogs with a follow-up of 1 month.
B Three more dogs with a follow up of 4, 8 and 12 months were used to inves-
tigate the progression in one year.
C To determine whether the seeded cells contribute to the intimal hyperplasia,
genetically marked MVEC were seeded in three additional dogs. Follow up
was 2 weeks for one and 3 weeks for the other two dogs.
Acetylsalicylic acid, 80 mg a day starting one week before the experiment,
was given the first month to prevent platelet aggregation.9 The three dogs
whose cells were genetically marked before seeding were also given immuno-
suppression, azathioprine, 25-50 mg a day starting one week after implanta-
tion of the grafts, as expression of marker peptides on the cell surface results
in the development of cytotoxic T-cells.16
All grafts were implanted as paired grafts, where one graft served as a control.
The relation of intimal hyperplasia to MVEC seeding could be established by
implantation a nonseeded graft on the other side. Possible differences in cell
behaviour due to genetic marking and immunosuppression could be demon-
strated by implantation a graft seeded with non-labelled cells on the other
side.
Animal care
Animal experiments were approved by the ethics committee of the University
of Utrecht. The animal care complied with the Guide for the Care and Use of
Laboratory Animals, Institute of Laboratory Animal Resources, Commission on
Life Sciences, National Research Council. Washington: National Academy
Press, 1996. Twelve mongrel dogs, weighing 10-40 kg, were used.
Anaesthesia
All surgical procedures were carried out as described before.8 Just before the
first incision, antibiotics (amoxicilline) were administered, and just before
clamping of the vessels, heparin (100 IE/kg) was given, both i.v.
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Postoperatively pain medication (buprenorfine) and antibiotics (amoxicilline)
were administrated i.m., for 4 days.
Isolation of microvascular endothelial cells
MVEC were isolated from the falciform ligament.9 Amounts of fat were incubat-
ed for 30 min at 37° C under continuous vigorous shaking with equal volumes
of crude collagenase obtained from Clostridium histolyticum (Sigma-Aldrich
Chemie, Steinheim, Germany) (0.4% w/v), BSA (Sigma) (0.4% w/v) in
Phosphate Buffered Saline (PBS), pH 7.4. The digested fat was sieved and
centrifuged (1200 rpm; 12 min; room temperature (RT)). The pellets were
resuspended in Medium 199 (Gibco BRL, Life Technologies, Paisley,
Scotland). The cellsuspension was centrifuged again (1100 rpm; 5 min; RT)
and the pellet was resuspended in sodding medium (Medium 199 with autolo-
gous serum in a ratio of 6:1).
The cells used immediately for seeding were suspended to a concentration of
2x105 cells/cm2 of graft surface. The cells used for identification were seeded
in a concentration of 1x105 cells/cm2 on fibronectin-coated glass coverslips.
The cells used for of genetic labeling were seeded in the same concentration
on Retronectin®-coated (Takara Biomedical Group, Shuzo Co, Shigo, Japan)
non-tissue-culture-treated plates.
Identification of isolated cells
MVEC were cultured in EBM-MV2 Bulletkit culture medium (Clonetics,
BioWhittaker, Verviers, Belgium)/ 0.5 µM dibutyryl cAMP (Sigma). After conflu-
ence, cells were fixed with 3.5% paraformaldehyde (PFA)/ 0.1% Tween. Stains
were performed with sheep anti-canine von Willebrand Factor (vWF) (Kordia,
Leiden, The Netherlands), mouse anti-human α-actin (DAKO, Glostryp,
Denmark), mouse anti-human vimentin (DAKO) and for visualization FITC-con-
jugated goat anti-mouse antibody (Becton and Dickinson, Bedford, Mass.,
USA) or -rabbit anti-sheep antibody (DAKO). Incubations were done for 45 min
at 37°C, followed by three wash-steps of 10 min. Cells were visualized with
confocal laser microscope (Leica TCS nt, Leica, Heidelberg, Germany).
Retroviral gene transduction of isolated cells
We used retroviral gene transduction, gene delivery via a replication deficient
retrovirus, to tag cells with a marker gene which is readily detectable.17 No
species-specific canine marker was available, therefore we initially employed
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the widely-used green fluorescent protein (GFP) marker. Because of autofluo-
rescence of the prosthesis, GFP fluorescence was difficult to detect and a
GFP-specific antibody was used. Cells of another two dogs were transduced
with truncated low affinity nerve growth factor receptor (LNGFR), a human
receptor. Two days before start of the transduction, producer cells (Phoenix-
GFP, titer 1-2x106 or Frapé-1, 1x107 IU/ml) were plated in different concentra-
tions.17 After 24h, producer cells with the highest concentration were covered
with EBM-MV2 Bulletkit culture medium without hydrocortison. The next day
this MVEC-medium was harvested, filtered, and after addition of cAMP and
hydrocortison, applied to the MVEC. Transductions were repeated for four and
three successive days in case of GFP- and LNGFR-transduction, respectively.
One week after isolation transduced and mock(non)-transduced cells were
trypsinized, washed and resuspended for seeding as mentioned above.
Small amounts of cells were withheld to determine the transduction efficiency,
defined as the percentage of cells that express the marker gene. LNGFR-
transduced cells were stained with mouse anti-human LNGFR (200-3-G6-4
(20.4)) (American Type Culture Collection, Manassa, VA, USA)/ PerPE-conju-
gated rabbit anti-mouse IgG1 (Southern Biotechnology Association, Allebama,
USA). Transduction efficiency was established with a flow cytometer (Calibur,
Becton and Dickinson, San José, CA, USA).
Graft preparing and sodding
Standard ePTFE grafts (8 cm length, 4 mm diameter, 30 µm fibril length; gen-
erous gift from WL Gore & Associates, Flagstaff, Arizona, USA) were used. On
both ends luerlock connectors were attached. Half an hour before MVEC-sod-
ding, the grafts were filled under pressure, one end closed, with sodding
medium to replace trapped air in the interstices of the graft. The cell suspen-
sion was introduced into the graft with a lumbar puncture needle, from bottom
to top. Subsequently, a syringe filled with sodding medium, four times the vol-
ume of the prosthesis, was attached to the luerlock connector. The medium
was pressed through the graft in about 1 to 2 minutes. Earlier experiments
with a pressure gauge mounted in the system, had shown that so the neces-
sary pressure of 5 pounds per square inch (psi) was obtained and main-
tained.9
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Graft implantation
Graft implantation was performed as described before.8 A 3 to 4 cm piece was
removed and, to match the retraction, a 5 cm graft was implanted.
Assessment of graft patency
The patency of the grafts during follow-up was assessed in three ways. A
Doppler investigation was done, for the first 9 dogs after 1 and 4 weeks and
then once a month, for the 3 dogs of the transduction experiment weekly.
Selective angiography was performed of all dogs with a follow-up of one
month and of the dog with a follow-up of 12 months, just prior to explantation.
In all dogs, an incision was made in the native artery distal to the graft after
more distal cross-clamping, just before termination.
Graft explantation
Graft explantation was performed as described before.8 The grafts were fixed
for histology and scanning electron microscopy (SEM).
Scanning electron microscopy
Sections of the graft were prepared as described before,8 and examined with
a scanning electron microscope (Philips, Eindhoven, The Netherlands).
Histopathology and immunohistochemistry
Paraffin slides were made. Haematoxylin and eosin (HE), elastic von Gieson
(EvG) and immunohistochemical stains were performed. For each dog the inti-
mal thickness was determined as follows: For every graft, 4 cross sections
were taken at a distance of 0.3 cm. For every cross section, at a regular dis-
tance of 300 µm, the thickness was measured. For every cross section, 32
measurements were obtained. The cell density in the hyperplastic intima was
determined by counting nuclei in circumscribed areas of the same cross sec-
tions (4 measurements/cross section). Measurements were performed with a
light microscope equipped with a JAC-CCD camera (Copenhagen, Denmark)
coupled to a matrox frame grabber (Matrox Electronic systems Ltd., Quebec,
Canada) using Optimas 6.0 software (DVS, Breda, The Netherlands).
Immunohistochemical stainings were preceded by endogenous peroxidase
blocking and citrate boiling, or Triton-serum blocking as in the case of GFP-
and LNGFR-staining. Endogenous peroxidase blocking was performed with
1.5% H2O2 in phosphate-citrate buffer (citric acid mono-hydrate 8.32 g/l,
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Na2HPO4 21.52 g/l; pH 5.8±0.1) for 15 min. Citrate boiling was done in citrate
buffer (Na3citrate dihydrate 2.94 g/l; pH 6.0) for 10 min. Triton-serum blocking
was done with 0.4% Triton X-100/5% horse serum in PBS for 1 hour. As pri-
mary antibodies sheep anti-canine vWF, mouse anti-human α-actin, mouse
anti-human vimentin, mouse anti-GFP (Clonetech Laboratories, Palo Alto, CA,
USA), mouse anti-human LNGFR and mouse anti-human CD3 (DAKO) were
used. Peroxidase/DAB stainings were done with Vectastain Elite ABC Kit and
DAB kit for peroxidase staining (Vector Laboratories, Burlingame, CA, USA),
according to the manufactures’ recommendations.
Statistical analysis
Results are presented as the median (1st-3rd quartile range).
Results
Isolation and identification of microvascular endothelial cells
From the falciform ligament 15-40 grams of fat were obtained. The yield of
MVEC was 7 (6.5-8) x105 cells/gram. No growth failures were observed.
Immunocytochemical staining of cells cultured on glass coverslips showed
besides vWF-positive cells, some α-actin-positive cells and cells solely positive
for the marker vimentin. The vWF- and vimentin-positive cells were identified
as EC. The percentage of EC was estimated to be between 50 and 60%,
based on immunocytochemistry and morphology. The α-actin- and vimentin-
positive cells were identified as myofibroblasts. The cells solely positive for
vimentin were identified as fibroblasts, based on their morphology, elongation
with branched shoots without contact inhibition, and the absence of α-actin
expression (fig. 1a-c).
A. Incidence and composition of intimal hyperplasia after one
month of follow-up
Patency: All of the grafts were palpated and found to be open just prior to clo-
sure of the wound. In one dog no doppler signals were found on both sides
after one week, while in the other five dogs bilateral doppler sounds remained
present until the end of the follow-up. Angiography at termination showed
bilateral occlusion in the dog without doppler signals. All other grafts were
patent without any signs of stenosis. No angiographic difference existed
between the MVEC sodded grafts and the controls. Macroscopic examination
at the time of explantation showed that the occluded grafts had a bluish color
representative of thrombus, no pulsations were present. The other grafts had
a white color and clear pulsations.
Figure 1
Immunocytochemistry of a confluent
layer of first passage canine MVEC.
A. Cells positive for the marker against
vWF, and so identified as EC (magnifi-
cation, x 340).
B. Cells positive for the marker against
α-actin, and so identified as myofibrob-
lasts (magnification, x 340).
Cells solely positive for the marker
vimentin, identified as fibroblasts, based
on their morphology (elongated cells
with branched shoots, without contact
inhibition) and the absence of α-actin
expression (magnification, x 310). 
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Figure 2 (colour version: addendum, page 186)
Histopathology and immunohistochemistry of the open seeded graft (4 months).
A. HE staining: The cell density of the neointima (magnification, x 85)
B. EvG staining: The fibers present in the intima are elastin (grey) and collagen (red) (magnifica-
tion, x 85).
C. vWF-staining: All cells present in the luminal monolayer are positive (brown) and so identified
as EC (magnification, x 85). 
D. α-actin-staining: All cells present in the intima are positive (brown) and so classified as myofi-
broblasts (magnification, x 85). 
E. vimentin-staining: All cells present are positive (brown) (magnification, x 85).
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Histopathology: All patent seeded grafts were covered with a neointima, con-
sisting of an intact cell monolayer, with characteristics of EC, on top of a multi-
layer of cells and fibers (fig. 2a). The fibers present in the intima were identified
as collagen and elastin (fig. 2b). The neointima found in all patent seeded
grafts showed a variable thickness in axial as well as transversal direction. The
intimal thickness was 143 (116-152) µm and the cell density 2.9 (2.9-4.1)
x103/mm2 (table 1). All patent nonseeded grafts showed a covering consisting
of fibrin and platelets. Both occluded grafts, the MVEC sodded and the con-
trol, were filled with a thrombus consisting of platelets and fibrin.
SEM: The patent seeded grafts were covered with a smooth confluent cell
layer with EC-morphology. No fibrin formation was seen, nor signs of platelet
aggregates. The occluded grafts and all nonseeded patent grafts showed acti-
vation of coagulation (fibrin and platelet deposition). No endothelialization was
present in the patent nonseeded grafts except for the peri-anastomotic pan-
nus.
Immunohistochemistry: Cells present in the inner monolayer of the neointi-
ma which covered all patent seeded grafts were all vimentin- and vWF-posi-
tive, identifying them as EC (fig. 2c,e). Cells present in the multilayer between
the monolayer of EC and the prosthesis were all vimentin- and α-actin-positive,
classifying them as myofibroblasts (fig. 2d,e).
Table 1
follow up 1 mo 4 mo 8 mo 12 mo
dog number 1 2 3 4 5 6 7 8 9
median n.a. 152 188 116 143 9 21 n.a. 21
thickness (µm)
quartile range n.a. 98-192 154-230 100-140 89-174 5-30 6-93 n.a. 9-47
median cell density n.a. 2.1 4.3 2.9 2.9 4.1 3.6 n.a. 1.7
(x103/mm2)
quartile range n.a. 1.9-2.7 3.5-5.1 2.4-3.1 2.3-3.5 2.6-5.3 2.9-5.1 n.a. 0.6-2.2
Median (1st-3rd quartile range) thicknesses and median (1st-3rd quartile range) intimal cell densities
of the sodded grafts with 1-12 months follow up. The results of two dogs (1 and 8 months follow up)
were not available (n.a.), due to occlusion of the sodded grafts.
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B. Changes in thickness and composition of the neointima
during a follow-up of 12 months
Patency: Immediately after implantation, the grafts in the three dogs with a
follow-up of 4, 8 and 12 months, respectively, were palpated and found to be
open. At the time of explantation two of the three seeded grafts were patent.
All non-seeded ones and the seeded one with a follow-up of 8 months were
occluded (fig. 3). Doppler investigation showed that the occlusions had
occurred between 1 and 4 weeks of follow-up. Angiography of the dog with a
follow-up of 12 months showed a patent seeded graft without any signs of
stenosis and an occluded nonseeded graft.
Histopathology: The patent seeded grafts with a follow-up of 4 and 12
months showed an intact cell monolayer, with characteristics of EC, covering
a multilayer of cells and fibers (fig. 2a,b). The intimal thicknesses after 4 and
12 months were 21 (6-93) µm and 21 (9-47) µm, and the cell densities were 3.6
(2.9-5.1)x103/mm2 and 1.7 (0.6-2.2)x103/mm2, respectively (table 1). No differ-
ences were found in identity of fibers between a follow-up of one month and
the longer follow-ups of 4 and 12 months (fig. 2b). Simular to one month of fol-
low up, a variable thickness in axial as well as transversal direction was found.
All nonseeded grafts and the graft with a follow-up of 8 months were occluded
with an organized thrombus, consisting of connective tissue, cells and
microvessels.
SEM: Again, the patent seeded grafts were covered with a smooth confluent
cell layer with EC-morphology, without deposition of fibrin and platelet aggre-
gates.
Immunohistochemistry: No differences were found in identity of cells
between follow-up of one month and the longer follow-ups of 4 and 12 months
(fig. 2c-e).
Figure 3
Macroscopy just after explantation of the
grafts (left: open graft sodded with MVEC,
right: occluded graft sodded without
MVEC).
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C. Contribution of the seeded cells to the intimal hyperplasia
Transduction efficiency: Transduction efficiency of the GFP-transduced
cells was 35% (fig. 4a’), while the transduction efficiency of the LNGFR-trans-
duced cells was 80% (75-85%) (fig. 4b’).
Figure 4 (colour version: addendum, page 187)
A. Immunohistochemistry of a graft sodded with GFP-transduced cells. The intima is visible with
positive cells (brown) (magnification, x 250). 
A'. Flow cytometry analysis of GFP-transduced cells. Fluorescence of transduced cells (filled)
compared with that of mock-transduced cells (open).
B. Immunohistochemistry of a graft sodded with LNGFR-transduced cells. Positive cells (black)
are visible in the EC monolayer, the intima and the luminal part of the prosthesis (magnification,
x 165). 
B'. Flow cytometry analysis of LNGFR-transduced cells. Fluorescence of transduced cells (filled)
compared with that of mock-transduced cells (open). 
C. Immunohistochemistry of a graft sodded with transduced cells. A large T-cell infiltrate is pre-
sent (brown) (magnification, x 165). 
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Patency: All grafts seeded with marker-transduced cells were similar to all
grafts seeded with mock-transduced cells in that they remained patent, as
suggested by Doppler investigation and later proven after explantation by inci-
sion in the native artery distal to the graft.
Histopathology, SEM and immunohistochemistry: In all dogs, the grafts
seeded with transduced cells showed a similar EC-layer with intimal hyperpla-
sia underneath as the grafts seeded with mock-transduced cells on the other
side, and as the seeded grafts of both above mentioned experiments without
labelled cells.
Destination of transduced cells: In all three dogs, marker-positive cells
could be detected in the EC monolayer, multilayer of myofibroblasts and lumi-
nal part of the prosthesis (fig. 4a,b). No such marker-positive cells were found
in the prosthesis sodded with mock-transduced cells.
Immunoreaction against transduced cells: A distinct T-cell infiltrate was
present in the neointima covering the graft, sodded with marker-transduced
cells, and in the graft itself (fig. 4c), but not in mock-transduced grafts. This T-
cell infiltrate was less abundantly present in the graft with a follow-up of 2
weeks than in the grafts with a follow-up of 3 weeks. The infiltrate was not
present in the grafts sodded with mock-transduced cells.
Discussion
Seeding of venous EC has been used to increase the patency of prosthetic
grafts. Although the results were satisfactory, the technique did not find gener-
al acceptance. The mean reason is that low yield of EC from veins makes cell
culture necessary. To avoid problems due to cell culture, alternative cells and
sources for EC have been explored. Subcutaneous fat has been introduced as
a source of large numberss of MVEC,9-11 being able to form a nonthrombo-
genic luminal EC layer in vivo. A fat-derived MVEC seeding related problem,
however, is the development of a thickened intima, which can result in occlu-
sion of the graft.
The intimal hyperplasia found after seeding of MVEC is much more extensive
than after seeding of more pure vein-derived EC, both in humans,18 and in
other species.3 An until now unproven suggestion is that the neointima, found
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after seeding of MVEC, exists of cells seeded on the graft as impurities of the
transplant.5,12
Aim of this study was to investigate specific characteristics of MVEC seeding-
associated intimal hyperplasia in terms of incidence, composition, and pro-
gression in time, and the contribution of the seeded cells. We found that
MVEC, isolated from the falciform ligament, consisted of a combination of EC,
fibroblasts and myofibroblasts. In all patent seeded grafts a confluent EC lin-
ing as well as intimal hyperplasia was present. The thickened intima consisted
of a multilayer of myofibroblasts, elastin and collagen. Thickness and cell den-
sity of the intima did not progress after one month. All patent non-seeded
grafts were covered with platelets and fibrin and did not show any intimal
hyperplasia. After marking the seeded cells we found that the transplanted
cells were present in the EC monolayer, the intima, and the luminal part of the
prosthesis.
Here we have shown for the first time that contaminants of the transplant con-
tribute to MVEC seeding related intimal hyperplasia. Using a fluorescent dye,
it has been shown that after 3 weeks of follow up, EC lining prosthetic grafts
originate from the seeded cells.19 In another study no evidence was found,
however, for the hypothesis that intima formation is due to seeded cells.20 The
differences compared to our study were that the seeding density was much
lower than the recommended density we used;6,9 that the polyester used was
more porous and such more easily populated from the surrounding tissue;20
and that venous EC were used which are more pure than MVEC.
Retroviral transduction did not affect the results of cell seeding, as could be
established by using a graft sodded with non-labelled cells as a control.
Furthermore the immunosuppression, given to the dogs of the transduction
experiment, did not affect the structure of the EC-layer and intimal hyperplasia
present on the grafts. No differences existed compared to the EC-layer and
intimal hyperplasia present on the seeded grafts of both other experiments
without immunosuppression.
Not all cells present in the EC monolayer, intima and inner third of the prosthe-
sis expressed the marker. The transduction efficiency was not 100%, besides
the transduced cells can be destroyed by cytotoxic T-cells present, despite
immunosuppression. Furthermore we can not exclude the contribution of cells
coming from both vessel ends or from tissue around the prosthesis. The con-
tribution of these endogenous cells is higher, however, when a very porous
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prosthesis is used than when a less porous prosthesis is used, as we did in
our study.20
Although it is possible that the positive myofibroblasts present in the intima
are transdifferentiated MVEC, it is most likely that the positive myofibroblasts
are contaminants from the transplant. First, fibroblast-like cells are present in
isolates of canine fat-derived MVEC. Second, a neointima forms less exten-
sively after the seeding of vein-derived EC, which contain less contaminating
cells.3,4 And third, single cell culture studies have shown that although certain
cell types (e.g. interstitial EC from heart valves) can transdifferentiate, human
umbilical cord EC and dermal MVEC cannot.21,22
The myofibroblasts present in the neointima showed other characteristics than
the impurities present in the transplants, because they stained all positive for
α-actin. The expression of myofibroblast-specific characteristics can be
induced by the surroundings, as a time-dependent maturation of myofibrob-
lasts present in the neointima has been found.23 Immediately after implanta-
tion cells resemble fibroblasts, afterwards they gradually change into smooth
muscle cells with an increased expression of α-actin.12
As mentioned before,24 all thickened intimas showed a variable thickness in
axial as well as transversal cross-section, which might be explained by varia-
tions in bloodflow,25 density of graft material, or velocity of the formation of a
confluent EC layer.26,27
From the present study we conclude that contaminants from the transplant
contribute to intimal hyperplasia associated with microvascular endothelial cell
seeding. Further purification of fat-derived MVEC should reduce intimal hyper-
plasia. Hopefully, this will lead to a smaller degree of stenosis and thrombosis
and improve results of MVEC seeded grafts used for bypass and other vascu-
lar surgery.
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Abstract
Background: Seeding venous endothelial cells (EC) onto damaged vascu-
lar surfaces attenuates the development of intimal hyperplasia. Unlike
venous EC, fat derived microvascular endothelial cells (MVEC) do not requi-
re a culture step to increase the yield. In this in vivo study we investigated
whether fat derived MVEC are suitable to reduce intimal hyperplasia and to
increase patency after PTA.
Methods: Five rabbits were subjected to PTA of both iliac arteries. MVEC
were isolated from the perirenal adipose tissue. One side was seeded trans-
luminally with autologous MVEC, using a double balloon catheter. The
contralateral side was sham seeded, and served as a control. Follow up was
4 weeks. Another rabbit was used for a feasibility experiment. This rabbit
was subjected to a one-sided seeding procedure and was sacrificed after 1
week. In a seventh rabbit, a one sided PTA was transformed, and auto-
logous labelled cells were injected in the distal aorta instead of seeded, fol-
low up was 1 week. After sacrifice, vessels were removed for histologic
investigation.
Results: The MVEC seeded artery of the pilot experiment was patent. All
sham seeded arteries (5), with a follow-up of 4 weeks, except for one were
patent. The patent ones showed moderate intimal hyperplasia. MVEC see-
ding (5), with a follow up of 4 weeks, resulted in two occlusions. In the
patent MVEC seeded arteries intimal hyperplasia was present more exten-
ded than in the sham seeded arteries. Histology of the occluded vessels
showed an organized thrombus. Both the patent MVEC- and sham seeded
arteries were covered with an EC layer. Injected labelled MVEC were not
found again on the deendothelialized artery.
Conclusion: In this study seeding of fat derived MVEC on damaged native
arteries results in an increased development of intimal hyperplasia and a
decreased patency. One of the reasons may be the presence of non-EC in
the seeded cell population.
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Introduction
Restenosis after percutaneous transluminal angioplasty (PTA) or endarterecto-
my is a common clinical problem. Intimal hyperplasia, responsible for the
chronic aterial renarrowing, is a result of the migration and subsequent prolif-
eration of vascular smooth muscle cells with associated deposition of extracel-
lular matrix.1,2
Endothelial cell (EC) seeding was originally introduced as a method to
improve the patency of small diameter vascular prostheses.3 Since then, it has
been demonstrated to decrease thrombogenicity and increase patency of vas-
cular grafts.4,5
EC seeding has also been proposed as a method to control the development
of intimal hyperplasia after PTA and endarterectomy.6 Promising results were
obtained in a small number of studies performed in rabbits or dogs. In these
studies venous EC were seeded on deendothelialised carotid or ilio-femoral
arteries.7-11
A disadvantage of using veins is the limited yield of EC prohibiting immediate
seeding after isolation.12 Cell culture is necessary in a special facility. This cul-
ture procedure is laborious and expensive, and cells cannot be used for an
emergency intervention in case of an acute vessel occlusion.13,14
Subcutaneous fat is a source of microvascular endothelial cells (MVEC).15 The
yield is high enough and additional culturing is unnecessary. After seeding
these cells on prosthetic grafts, in a dog model, thrombogenicity was
reduced.16 A confluent EC layer was present on the grafts. A neointima still
developed but less progressively.
Recent studies demonstrated that circulating EC (progenitors), from bone
marrow, can contribute to angiogenesis and to covering of prosthetic grafts
and deendothelialized surfaces.17,18
The aim of this study was to investigate the effect of seeding fat-derived MVEC
on damaged native arteries, and whether these cells can home to the dam-
aged surface.
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Methods
Animals
Rabbits, New Zealand Whites, weighing 3-3‘ kg, were used. They were given
free access to water and standard rabbit chow, and were housed in an animal
laboratory with alternating light and dark cycles. Presence of parasites or
micro-organisms was checked every month, investigating blood, stool and
coat of fur. Animal experiments were approved by the ethics committee of the
University of Utrecht. The animal care complied with the Guide for the Care
and Use of Laboratory Animals, Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council. Washington:
National Academy Press, 1996.
Design of the study
A seeding procedure of the common iliac arteries after angioplasty was per-
formed using perirenal fat derived MVEC.
A One rabbit was used for a feasibility experiment: seeding of MVEC after uni-
lateral PTA of the common iliac artery. The follow up was one week.
B Twelve rabbits were subjected to bilateral PTA of the common iliac arteries.
One side was seeded transluminally with autologous MVEC, using a double
balloon catheter. The contralateral side was sham seeded and served as a
control. The follow up was 4 weeks.
C Three rabbit was subjected to a one-sided PTA. Autologous labelled MVEC
were not applicated directly on the deendothelialized surface, but injected into
the distal aorta, to investigate homing. The follow up was 1 week.
Anaesthesia
Identity number and weight were registered. Premedication, acetylpromazin
and methadone, were given intramuscularly. Intravenous (i.v.) access was
applied in the ear. I.v. anaesthesia, etomidate, was administrated by means of
titration. Subsequently, intubation was performed and inhalation anaesthesia,
O2/NO2 and halothane, were administrated. The animals were monitored by
electrocardiography, intra-arterial blood pressure, capnography and body
temperature. Before the incision an antibiotic (amoxicilline) were given i.v. and
just before the PTA heparin was given i.v.
Postoperatively an analgesic, buprenorfine, was give, twice a day, on day 0, 1
and 2, and long acting amoxicilline was given on day 1 and 3.
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Isolation and culture of MVEC
Blood, 10 ml was taken to obtain autologous serum. MVEC were isolated from
the perirenal fat.15 Amounts of fat were incubated for 30 min at 37° C under
continuous vigorous shaking with equal volumes of crude collagenase
obtained from Clostridium histolyticum (Sigma-Aldrich Chemie, Steinheim,
Germany) (0.4% w/v), BSA (Sigma) (0.4% w/v) in Phosphate Buffered Saline
(PBS), pH 7.4. The digested fat was sieved and centrifuged (1200 rpm; 12
min; room temperature (RT)). The pellets were resuspended in Medium 199
(Gibco BRL, Life Technologies, Paisley, Scotland). The cell suspension was
centrifuged again (1100 rpm; 5 min; RT) and the pellet was resuspended in
sodding medium (Medium 199 with autologous serum in a ratio of 6:1).
The cells used for seeding were resuspended in such a way that the seeding
density would be 5x105/cm2. We assumed the seeding surface to be 1.9 cm2
(2 x π x radius x length). An exact cell count could not be made after the isola-
tion procedure, since a counter was not available in the animal laboratory.
Therefore, the yield of cells was estimated to be 106/g of fat. A final count was
made after finishing the seeding procedure.
The cells used for identification were seeded in a concentration of 105
cells/cm2 on fibronectin-coated glass coverslips. The cells used for of genetic
labelling were seeded in the same concentration on Retronectin® (Takara
Biomedical Group, Shuzo Co, Shigo, Japan)-coated non-tissue-culture-treat-
ed plates.
MVEC were cultured in EBM-MV2 Bulletkit culture medium (Clonetics,
BioWhittaker, Verviers, Belgium)/ 0.5 µM dibutyryl cAMP (Sigma).
Identification of isolated cells
Cells were incubated with Dil-Ac-LDL 10 µg/ml in culture medium for 4 hours.
After several wash steps, cells were fixed with 3.5% paraformaldehyde (PFA).
For immunohistochemical staining cells were fixed after confluence with 3.5%
PFA/ 0.1% Tween. Rabbit anti-human von Willebrand Factor (vWF) (Dako,
Glostryp, Denmark) was used and for visualization FITC-conjugated goat anti-
rabbit antibody (Becton and Dickinson, Bedford, Mass., USA). Incubations
were done for 45 min at 37°C, followed by three wash-steps of 10 min. Cells
were visualized with confocal laser microscope (Leica TCS nt, Leica,
Heidelberg, Germany).
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Retroviral gene transduction of isolated cells
We used retroviral gene transduction, gene delivery via a replication deficient
retrovirus, to tag cells with a marker gene which is readily detectable.19 Cells
were transduced with truncated low affinity nerve growth factor receptor
(LNGFR), a human receptor. Two days before start of the transduction, pro-
ducer cells (Frapé-1, 1x107 IU/ml) were plated in different concentrations.19
After 24h, producer cells with the highest concentration were covered with
EBM-MV2 Bulletkit culture medium without hydrocortison. The next day this
MVEC-medium was harvested, filtered, and after addition of cAMP and hydro-
cortison, applied to the MVEC. Transductions were repeated for three days.
One week after isolation transduced and mock(non)-transduced cells were
trypsinized, washed and resuspended for seeding as mentioned above. In
total 3.8x106 cells were injected.
Small amounts of cells were withheld to determined the transduction efficien-
cy, defined as the percentage of cells that express the marker gene. Cells
were stained with mouse anti-human LNGFR (200-3-G6-4 (20.4)) (American
Type Culture Collection, Manassa, VA, USA)/ PerPE-conjugated rabbit anti-
mouse IgG1 (Southern Biotechnology Association, Allebama, USA).
Transduction efficiency was established with a flow cytometer (Calibur, Becton
and Dickinson, San José, CA, USA).
Angioplasty and cell seeding
A piece of perirenal fat tissue was excised through a dorsolateral subcostal
incision. After achieving haemostasis, the wound was closed with absorbable
sutures (vicryl 4-0).
The right carotid artery was exposed, ligated distally, and a 5F sheath
(Terumo Europe, Leuven, Belgium) was inserted through which a 3F curved
catheter (Cordis Europe, Roden, The Netherlands) was introduced and posi-
tioned in the descending aorta, using contrast fluid, Telebrix (Laboratoire
Querbet, Aulnay-sous-bois, France). The sheath was advanced over the
catheter. To obtain an angiogram of the distal aorta and iliac arteries, the
curved catheter was positioned into the distal aorta and contrast fluid was
injected by hand. Angiograms were made using a C-arm (Philips Medical
Systems, Best, The Netherlands) and the vascular tree was inspected to find a
suitable spot for an artery without side-branches for at least the length of the
segment excluded from the circulation when the balloons were inflated (2 cm).
Position was documented using a radiopaque ruler. Subsequently the curved
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catheter was exchanged for a 3 mm balloon angioplasty catheter (Savvy,
Cordis; balloon length 2 cm). The angioplasty catheter was introduced over a
guide wire. We started at random with PTA of the right or left iliac aftery,
depending on the artery in which the balloon angioplasty catheter was
advanced first. Dilatation was performed by inflating the balloons to 8 atmos-
pheres pressure for 30 seconds. Post-angioplasty angiograms were made,
and the seeding catheter was introduced.
The seeding procedure was performed transluminally using a double balloon
catheter as described by Nabel et al.20 A 4F double balloon catheter (Hutson
dual balloon catheter, H-4F.DB, Krijnen Medical, Beesd, The Netherlands) was
modified by R. Mansfeld Beck, University Medical Center Utrecht, The
Netherlands. This final catheter existed of two compartments. Through one
compartment, two low pressure latex balloons could be filled. The distance
between both balloons, when filled, was 2 cm, the exact length of the dam-
aged artery after PTA. Through the other compartment, the medium with cells
or without cells (sham seeding) could be introduced between both filled bal-
loons. We started at random with EC seeding or sham seeding, depending on
whether the isolation procedure of cells had finished already.
The balloons of the seeding catheter were filled with contrast and inflation was
performed to 2 atm. A volume of 0.2 ml was introduced into the isolated arteri-
al segment, followed by 0.1 ml every 5 min in case of lost resistance to replen-
ish lost by leakage. The incubation was performed for 30 min with the animal
in various positions to obtain circular distribution of EC. After this the blood
flow was restored by deflating the balloons and removing the catheter. PTA
and seeding of the contralateral side was performed using the same proce-
dure.
In case of the ‘homing experiment’ cells were injected in the distal aorta.
At the end the sheet was removed and the proximal carotid artery ligated. The
skin was closed using absorbable sutures.
Rabbits were heparinized during catheterisation (100 IU/kg), no anticoa-
galants were give postoperatively.
Sacrifice
The rabbits were premedicated and i.v. access was obtained. Heparin was
administrated iv. Termination was performed using sodium pentobarbital. A
midline abdominal incision was made and the distal aorta and iliac arteries
were dissected. One canula was introduced into the distal aorta and the proxi-
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mal aorta was ligated. Another canule was introduced into the caval vein and
the proximal part was ligated also. The distal arterial tree was first flushed with
PBS for 10 min, followed by in situ pressure perfusion with 2% paraformalde-
hyde at 80 mmHg for 20 min. The terminal aorta and iliac arteries were
excised and placed in 4% formaldehyde for at least 24 hours.
Histopathology and immunohistochemistry
Paraffin slides were made. For every vessel, 6-8 cross sections were taken
over a the length of 2 cm where PTA and seeding were performed.
Haematoxylin and eosin (HE) and immunohistochemical stains were per-
formed.
For each rabbit the intimal thickness was determined as follows: For every
cross section (6-8 per vessel), at a regular distance of 300 µm, the thickness
was measured. Measurements were performed with a light microscope
equipped with a JAC-CCD camera (Copenhagen, Denmark) coupled to a
matrox frame grabber (Matrox Electronic systems Ltd., Quebec, Canada)
using Optimas 6.0 software (DVS, Breda, The Netherlands).
Immunohistochemical stains were preceded by endogenous peroxidase
blocking and citrate boiling, or Triton-serum blocking as in the case of
LNGFR-staining. Endogenous peroxidase blocking was performed with 1.5%
H2O2 in phosphate-citrate buffer (citric acid mono-hydrate 8.32 g/l, Na2HPO4
21.52 g/l; pH 5.8±0.1) for 15 min. Citrate boiling was done in citrate buffer
(Na3citrate dihydrate 2.94 g/l; pH 6.0) for 10 min. Triton-serum blocking was
done with 0.4% Triton X-100/ 5% horse serum in PBS for 1 hour. As primary
antibodies mouse anti-human CD31 (DAKO), mouse anti-human α-actin
(DAKO) and mouse anti-human LNGFR were used. Peroxidase/DAB stainings
were done with Vectastain Elite ABC Kit and DAB kit for peroxidase staining
(Vector Laboratories, Burlingame, CA, USA), according to the manufactures’
recommendations.
Statistical analysis
Results are presented as the median (quartile range).
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Results
Isolation and identification of
MVEC
From the perirenal fat 8 (7.4-10)
grams of fat was obtained (n=16).
The yield of MVEC was 9.1 (7.2-11.5)
x105 cells/g (n=16). When a part of
the cells were cultured, no growth fail-
ures were observed.
The percentage of EC was estimated
to be between 30 and 40% based on
fluorescence for vWF, and uptake of
Ace DiI. In fat derived cell cultures
MVEC were situated in groups (fig. 1).
The other cells had a fibroblast-like
morphology, elongation with branch-
ed shoots without contact inhibition.
The seeding density was 6.4 (4.6-9.2)
x105/cm2 (table 1).
Operative outcome
Nine rabbits of the 16 died during the
procedure: blow out rupture of the
stomach (n=1), dissection of the
aorta (n=2), dissection of one of the
iliac vessels (n=3), technical failure of
the ventilator (n=1), aorta spasm
(n=1), and rupture of the carotid
artery during removal of the sheet
(n=1). Seven of the rabbits that had
died were intended for an unilateral
MVEC seeding procedure and a con-
tralateral sham seeding procedure,
and two rabbits were intended for an
injection procedure with labelled cells.
Figure 1 
Immunocytochemistry of a confluent
layer of first passage rabbit MVEC.
Cells were identified as EC by:
A. Uptake of Dil-Ac-LDL (magnifica-
tion, x195)
B. Positivity for the EC-specific marker
against vWF (magnification, x 305)
A
B
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Dissection of the aorto-iliac tract was
related to the seeding catheter twice.
One time, one of the balloons emptied
into the other. The other time, adhe-
sion of the double balloon catheter to
the vessel wall occurred.
In the other seven rabbits (including
one feasibility experiment) the proce-
dure was uncomplicated, leaving five
rabbits for the ‘seeding procedure’
and one for the ‘homing procedure’
(fig. 2).
Patency of the MVEC and sham
seeded arteries
The MVEC seeded native artery of the
rabbit from the preliminary study with
a follow up of 1 week was patent.
Of the five rabbits present for analyses
of MVEC seeding, with a follow up of 4
weeks, one rabbit had a short-term
parese of the left lower paw. In three
rabbits both the MVEC- and the sham
seeded native arteries were patent. In
one rabbit the sham seeded artery
was patent, but the MVEC seeded
artery occluded. In another rabbit,
both the MVEC- but also the sham
seeded arteries was occluded. All
occlusions occurred exactly at the
side of the PTA. Both occlusions of
the EC seeded artery occurred in the
rabbits with the highest EC seeding
densities (table 1).
Figure 2
Fluoroscopy:
A. Normal aorto-iliacal tree
B. PTA process
C. Seeding process, using a double
balloon seeding catheter
A
B
C
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The deendothelialized iliac artery of the rabbit of the ‘homing experiment’
remained patent after one week of follow up.
Histopathology
In case both the MVEC seeded and the sham seeded vessels were patent
(n=3), the median intimal thicknesses were compared. For the sham seeded
arteries the median intimal thicknesses were 60, 61, and 59 µm. For the EC
seeded arteries the median intimal thicknesses were 123, 105, and 92 µm,
respectively (table 1).
Immunohistochemistry
All patent seeded and sham seeded native arteries were covered with an
almost confluent CD31-positive EC layer. Cells present in the neointima were
α-actin-positive, classifying them as myofibroblasts (fig. 3).
The occluded native arteries were filled with SMC, myo-fibroblasts, connective
tissue, and neovascularization.
Homing of MVEC to damaged native surfaces
The transduction efficiency of MVEC with LNGFR was 93% (fig. 4). After one
week, in none of the 6 cross-sections over the length of 2 cm, where deen-
dothelialization of the common iliac artery had been performed, labelled cells
were found.
Table 1
nr. rabbit 1 2 3 4 5
seeding density per cm2 6x105 6.7x105 4.1x105 12x105 10x105
MVEC-seeding:
median thickness (mm) (range) 123 (59-202) 105 (53-214) 92 (60-151) n.a. n.a.
sham-seeding:
median thickness (mm) (range) 60 (12-87) 61 (22-119) 56 (33-108) 81 (11-188) n.a.
Seeding density and median intimal thicknesses of the MVEC and sham seeded deendotheliali-
zed arteries with 4 weeks follow up. The results of  the MVEC seeded arteries of two rabbits and
the sham seeded artery of one rabbit were not available (n.a.), due to occlusion of the arteries.
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Figure 3 (colour version: addendum, page 188)
Immunohistochemistry of a patent MVEC and sham seeded deendothelialized artery of the
same rabbit with 4 weeks follow up (magnification, x85):
A. Anti-CD31 staining of the MVEC seeded artery: Most of the cells present in the luminal mono-
layer are positive (brown) and so identified as EC.
B. Anti-α-actin staining of the same artery: The cells present in the intima are positive (brown)
and so classified as myofibroblasts.
C. Anti-CD31 staining of the sham seeded artery: Most of the cells present in the luminal mono-
layer are positive (brown) and so identified as EC.
D. Anti-α-actin staining of the same artery: The cells present in the intima are positive (brown)
and so classified as myofibroblasts.
A
C
B
D
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Discussion
EC seeding, introduced to reduce thrombogenicity of vascular grafts, has also
been proposed to reduce intimal hyperplasia and thus to increase patency of
deendothelialized surfaces.6 Promising results were obtained with venous EC
in animal models.7-11 In this study we have investigated, in a rabbit model,
whether fat derived MVEC are suitable as an alternative to reduce intimal
hyperplasia and increase patency of deendothelialized surfaces.
We found that MVEC, isolated from the perirenal fat, consisted of a combina-
tion of EC and fibroblast-like cells. Of the five MVEC seeded arteries two were
occluded, and of the five sham seeded arteries one. In all patent MVEC seed-
ed arteries intimal hyperplasia was present more pronounced than in the
patent sham seeded arteries. After injection of labelled EC in another rabbit, to
investigate homing, injected MVEC were not found on the deendothelialized
surface. Nine rabbits intended for treatment as well did not survive the proce-
dure. Only in two of the nine cases dead was directly related to the seeding
procedure.
Histology of the occluded arteries showed that the occlusion existed almost
completely of myofibroblasts, SMC, connective tissue, and neovasculariza-
tion. No signs were observed in the rabbits when an iliac artery was occluded.
So it was impossible to conclude whether early thrombus formation had
occurred, which subsequently organized, or late occlusion had taken place
due to accelerated development of intimal hyperplasia.
The occlusions and accelerated formation of intimal hyperplasia of MVEC
seeded native arteries seems to be related to the seeding procedure. In this
rabbit model, it appears that the procoagulant and growth stimulating func-
100 101 102 103 104
0
25
Figure 4
Flow cytometry analysis of LNGFR-transdu-
ced cells. Fluorescence of transduced cells
(filled) compared with that of mock-transdu-
ced cells (open).
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tions of the seeded cells overpowered the expected anticoagulant and growth
inhibiting functions. In a dog study we showed seeding of MVEC on prosthetic
grafts is successful.16 The thrombogenicity decreased and surfaces were cov-
ered with a smooth layer of EC. On the other hand, we also showed that con-
taminating cells were present in the transplant, and that these cells
contributed to development of intimal hyperplasia. In the isolates of rabbit
MVEC contaminants were present as well. Seeding of pure venous EC on
deendothelialized surfaces reduced intimal formation and increased paten-
cy.7,10 We postulate therefore that the presence of contaminating cells in the
EC-isolates contributed to the increase of intimal hyperplasia after seeding of
deendothelialized surfaces.
Not only the presence of contaminating cells in the population of seeded cells
but also the number of seeded MVEC seems to influence the development of
intimal hyperplasia. In most studies using venous EC, a seeding density of
2x105 was used.21,22 We planned to use a density around 5x105, as a previous
study has shown that a confluent layer could be formed in 30 min, when at
least 5x105 cell/cm2 were seeded.23 In addition, not all of our cells were EC, so
we decided to use a higher seeding density to be sure that EC were still seed-
ed at a density high enough to reach confluently. In some rabbits the amount
of seeded cells was larger than 5x105/cm2, since we could only count the cells
after the seeding procedure. Occlusions occurred related to the higher seed-
ing densities.
Both the MVEC seeded as well as the sham seeded arteries were covered
with an almost confluent EC layer. This means that on the sham seeded arter-
ies spontaneous reendothelialization occurred, as was demonstrated earlier
by Conte et al, who found 70% recovery of EC covering.21 Animals are known
to reendothelialize easily.24 EC originate from the adjacent intact native artery,
from the circulation, or from the tissue surrounding the vessel.
In case of seeding prosthetic grafts a ‘pressure sodding technique’ is used.15
Cells are pressed into the crevices of the graft. A deendothelialized artery is
not porous so that the pressure sodding technique cannot be used. The most
obvious way to perform attachment of the cells to the vessel is transluminal
seeding of a temporary closed vessel segment using gravity. An alternative is
based on recent publications about circulating progenitor EC, originating from
bone marrow. Studies demonstrated that these cells can contribute to angio-
genesis and covering of prosthetic grafts and deendothelialized surfaces.17,18
We could not demonstrate the homing of injected MVEC to the damaged arte-
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rial surface. However, only one rabbit was available and a follow up of one
week might have been too short. Moreover, an immunogenic marker was
used and cells might have been removed by the immune system.25 In addi-
tion, only EC progenitors might be capable of homing and not mature EC.
Finally, the presence of labelled cells might have been missed, since only one
slide was made every 0.33 cm.
From the present study we conclude that seeding deendothelialized arteries
after PTA with fat derived MVEC results in an increase of intimal hyperplasia
and in a reduced patency. We could not demonstrate the occurrence of hom-
ing of mature MVEC. Contaminants from the transplant likely contribute to inti-
mal hyperplasia associated with fat derived MVEC seeding. The procedure
should be repeated with purified fat-derived MVEC.
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Text
Endothelial cell (EC) seeding improves the patency of small diameter vascular
grafts.1 Subcutaneous fat is an attractive source for large amounts of
microvascular EC (MVEC),2 circumventing the need for additional cell cultur-
ing. Together with human MVEC, however, (myo)fibroblastlike cells or peri-
cytes and macrophages are isolated.3,4 We established that 39±3% (mean ±
SEM, n=6) of fat derived cells are EC (fig. 1a), about 2% macrophages, and
all others fibroblastlike cells. Here we have introduced an additional purifica-
tion step to deplete fat-derived MVEC of the contaminants. Immediately after
the classic isolation procedure, a combination of dynabeads coated with
fibroblast- and macrophage-specific antibodies are added. The purity is
increased to 91±1% (mean ± SEM, n=6) (fig. 1b).
M450 GαM dynabeads (Dynal A.S., Oslo, Norway)) were washed twice with
sterile phosphate buffered saline (PBS)/0.1% bovine serum albumin (BSA)
(Sigma-Aldrich Chemie, Steinheim, Germany). Beads were coated with with
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0
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Figure 1
Flow cytometry of nonpurified and purified cells. Cells were stained with the mouse anti-human
EN4. Fluorescence of stained cells (filled) was compared with that of control cells, only exposed
to the second antibody (FITC-conjugated goat anti-mouse) (open).
A. Nonpurified cells;
B. Purified cells.
A B
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mouse monoclonal antibody 11FIBRAU (F11) (Imgen, ITK Diagnostics,
Uithoorn, the Netherlands/Serotec, Oxford, UK)5 1.5 µg/107 beads in 100 µl
PBS/BSA, and with mouse monoclonal antibody against CD14 (DAKO,
Glostryp, Denmark) 0.25 µg/107 beads in 100 µl PBS/BSA, for 30 min at 4°C on
a roller bank, followed by four washsteps.
The specificity of F11 to bind fibroblast-like cells and not to bind MVEC was
shown with immunohistochemistry of frozen sections of subcutaneous fat tis-
sue and with flow cytometry of nonpurified cells double-stained with F11 and
CD31, an EC marker. The cellspecific binding capacity of the F11-coated
beads was established with cultured lung fibroblasts, and the CD14-coated
beads were tested with freshly isolated monocytes. Our procedure was first
tested on a mixture of cultured cells: 65% fibroblasts, 30% human umbilical
vein EC (HUVECs) and 5% monocytes.
Liposuction fat, obtained after informed consent, was centrifuged (3000 rpm;
15 min) to remove the liposuction fluid. Amounts of fat were mixed with equal
volumes of crude collagenase from Clostridium histolyticum (Sigma Chemie)
(0.4% w/v)/BSA (0.4% w/v) in PBS, pH 7.4.2 After incubation for 30 min at 37°C
under continuous vigorous shaking, the digested fat was centrifuged (1200
rpm, 12 min, room temperature (RT)). The pellets were then resuspended in
Medium 199 (Gibco BRL, Life Technologies, Paisley, Scotland). The cell sus-
pension was centrifuged again (1100 rpm, 5 min, RT), and the pellets were
resuspended in RPMI/1% fetal bovine serum (FBS). The cell suspension was
sieved (pore size: 0.6-0.7 mm) and the cells were counted.
Cells, 2x106/ml, were added to 107 F11-beads and 1.25x106 CD14-beads,
incubations were performed for 20 min at 4° C on a rollerbank. ‘Bound’ and
‘nonbound’ cells were separated with a Magnetic Particle Concentrator (MPC)
(Dynal). Bound cells were resuspended in RPMI/1% FBS and cells were sepa-
rated for a second time. Supernatants with nonbound cells were transferred to
clean tubes and the separation was repeated to remove any remaining beads.
Bound and nonbound-cells were collected in EBM-MV2 Bulletkit (Conetics,
BioWhittaker, Verviers, Belgium) with 0.5 µM cAMP (Sigma).6 Nonpurified,
purified (nonbound) and removed (bound) cells were seeded (105/cm2) on
human fibronectin-coated culture plates.
The identity of the isolated cells was established with immunocytochemistry
and flow cytometry, using: FITC-conjugated mouse anti-human CD31
(Pharmingen, Leiden, The Netherlands), mouse anti-human CD31 (DAKO),
EN4 (Monosan, Sanbio, Uden, the Netherlands), vWF (DAKO), CD14, α-actin
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Figure 2 (colour version: addendum, page 189)
A. Immunohistochemistry of frozen sections of subcutaneous fat tissue. On the left, two sections
stained with mouse anti-human CD31; on the right, two identical sections stained with mouse
anti-human F11 (magnification, x 85);
B. Flow cytometry analysis of nonpurified cells. Cells were double-stained with FITC-conjugated
mouse anti-human CD31 (horizontal) and with mouse anti-human F11, visualized with PE-conju-
gated goat anti-mouse (vertical). 
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(DAKO), vimentin (DAKO), F11, ICAM
(DAKO) (after TNFα-stimulation) and
for visualization FITC-conjugated
(Becton and Dickinson, Bedford,
Mass., USA) and PE-conjugated
(Southern Biotechnologies, USA) goat
anti-mouse. Nuclei were stained with
propidium Iodide (Sigma).
The yield of the depletion method was
compared to that of three positive
selection methods, using the EC-spe-
cific antibody EN4, the antibody
against CD31 and lectin Ulex
europaeus-1 (UEA-1) (Sigma), 1.5 µg
of both antibodies and 0.5 mg UEA-1
per 107 beads.3,7 Nonpurified cells,
2x106 in 400 µl, were added to 4x106
EN4-, CD31- and UEA-1-beads. The
cellspecific binding capacity was
determined with HUVEC.
The F11-antibody did not recognize
MVEC as shown with immunohisto-
chemistry (n=3) (fig. 2a) and with flow
cytometry (n=3) (fig. 2b). The cellspe-
cific binding capacities of the F11-
and CD14-coated beads were 94±0%
and 98±3%, respectively (mean ±
SEM, n=3). After using our purifica-
tion method on a combination of
HUVEC, fibroblasts, and monocytes,
93±4% of the depleted cells and
1.7±0.9% of the removed cells were
HUVEC (mean ± SEM, n=3).
The average yield of purified cells
obtained with our depletion method
was 3.2±0.2x105 cells/g (33±2% of
the nonpurified cells) (mean ± SEM,
Figure 3
Immunocytochemistry of purified cells
and removed cells.
A. Purified cells, positive for the EC mar-
ker against CD31 (magnification, x 70);
B. Purified cells, positive for the EC mar-
ker against vWF (magnification, x 70);
C. Removed cells, positive for the fibro-
blast marker F11 (magnification, x 70).
A
B
C
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n=6). The amount of EC in the purified population was 91±1%, as determined
with CD31- or EN4-expression (mean ± SEM, n=6) (fig. 1b, 3a). EC also
expressed ICAM and most of them vWF (fig. 3b). About 7% of the purified cells
showed a positive reaction with F11, none with the marker against CD14. Of
the removed cells about 3% were macrophages, 11±2% (mean ± SEM, n=6)
MVEC and all the rest fibroblasts (fig. 3c). All purified and removed cells
showed a slightly positive reaction with the mesenchymal precursor marker
vimentin, none with the smooth muscle marker against α-actin. The isolation
time increased from 110.5±1.5 min to 154±2.5 min (mean ± SEM, n=3).
The cell-specific binding capacities of the EN4-, CD31- and UEA-1-beads,
were 95±2%, 52±21%, and 93%±2%, respectively (mean ± SEM, n=3). The
yields of the positive selection methods were 74±15%, 14±3% (p<0.05) and
37%±9% (p<0.05), respectively, of the yield obtained with the depletion
method (mean ± SEM, n=3).
Positive selection-specific problems are avoided with our depletion method,
an excess of beads can be added without harming the target cells, and beads
do not need to be removed.7 An explanation for the smaller yield obtained with
positive selection might be the loss of EC-specific antigens from the surface
due to enzymatic digestion.3
In this study we have introduced a novel method to purify fat-derived MVEC
using a combination of dynabeads directed against fibroblasts and
macrophages. The purity is increased from 40% to over 90%. The yield is larg-
er than after positive selection. Cells are free of beads and can be immediately
used for cell seeding.
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Abstract
Introduction: Fat derived microvascular endothelial cells (MVEC) seeded
on prosthetic vascular grafts, improve patency in animals. Results in
humans were disappointing, due to thrombogenicity and progressive intimal
hyperplasia. Also in animals intimal hyperplasia was found. We postulate
that contaminating cells present in the transplant are involved in the intimal
hyperplasia. We developed a method to further purify human MVEC from 40
to 90%. Here we tested the effects of enrichment upon thrombogenicity and
seeding-related intimal hyperplasia.
Methods: Liposuction fat was enzymatically digested and centrifuged. To
enrich MVEC, contaminating macrophages and fibroblasts were removed
with dynabeads coated with macrophage- and fibroblast-specific antibodies.
Thrombogenicity was assessed by measuring tissue factor and thrombomo-
dulin activity, presence of endothelial nitric oxide synthase and via perfusion
of the cells with whole blood. To investigate seeding-related intimal hyper-
plasia, PTFE grafts were sodded with the cells and cultured for 3 weeks.
Results: Tissue factor activity of purified cells was reduced compared to
nonpurified cells. Purified cells showed thrombomodulin activity and eNOS
expression. Fragment 1+2 and Fibrinopeptide A generation after perfusion
of purified cells were significantly lower than after perfusion of nonpurified
cells, and only nonpurified cells were covered with platelets and fibrin.
Prostheses sodded with nonpurified cells showed an EC monolayer above a
multilayer of myofibroblasts, prostheses sodded with purified cells only sho-
wed a single EC monolayer. Mixing experiments with human umbilical cord
EC (HUVEC) and fibroblasts showed that when more than 25% HUVEC
were present a confluent EC layer was formed. When the amount of fibrob-
lasts was 25% or less, no development of a subendothelial multilayer of
myofibroblasts was found within 3 weeks.
Conclusion: Reduction of non-endothelial cell contamination of microvas-
cular endothelial cell seeded grafts decreases thrombogenicity and might
prevent seeding-related intimal hyperplasia.
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Introduction
The patency of small diameter prosthetic vascular grafts in humans is low due
to the thrombogenicity of the material and the lack of spontaneous endothe-
lialization. Seeding of vascular grafts with endothelial cells (EC) has been
developed to improve patency.1,2 In contrast to studies in dogs, initial results
of studies in humans have been inconsistent.3-5 The main problems were that
the EC yield from human veins is too low to seed a graft with a confluent layer
of cells,6 and that the proliferation rate of human EC is low.7
In principle, two strategies have been introduced to increase the amount of
EC: in vitro endothelialization of grafts and finding a more abundant source of
EC.8 Promising results have been obtained with in vitro endothelialized PTFE
grafts.9 A disadvantage is the necessity of a 4-week culture period which
requires the patient to undergo an additional operation, and increases the risk
of infection.8,10
Subcutaneous fat tissue is a source of large amounts of microvascular EC
(MVEC), and in vitro culturing is not necessary. The results of animals studies
were promising,11 however, clinical trials in humans have shown inferior
results as compared to the in vitro endothelialization procedure using
veins.6,12-14 Progressive concentric intimal thickening, sometimes together with
thrombosis was found in the grafts.12,13,15 Intimal hyperplasia was also found
when the grafts were tested in animals, but to a lesser extent.16,17 In an earlier
animal study, we found that the myofibroblasts in the intimal hyperplasia origi-
nated predominantly from contaminants of the seeded cell population.18
In human MVEC isolates, (myo)fibroblast-like cells or pericytes and
macrophages were found as contaminating cells.6,19-22 We have developed an
additional purification step to deplete these fibroblasts and macrophages,
resulting in a cell population of 90% MVEC.23
The aim of this study was to investigate the effect of purification of MVEC iso-
lates upon thrombogenicity and intimal hyperplasia in in vitro models.
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Methods
Isolation and purification of MVEC
Nonpurified and purified MVEC were isolated as described before.23
Nonpurified, purified and removed cells were counted and seeded on human
fibronectin-coated culture plates, glass coverslips, Thermanox® coverslips or
polytetrafluoroethylene (ePTFE) grafts. Cells were cultured in EBM-MV2
Bulletkit culture medium (EBM-2 supplemented with EGM-2-MV SingleQuots
containing hEGF, hydrocortisone, fetal bovine serum, VEGF, hFGF-B, R3-IGF-
1, Ascorbic Acid, GA-1000) (Clonetics, BioWhittaker, Verviers, Belgium) with
0.5 µM cAMP (Sigma).24
Human umbilical cord endothelial cells (HUVEC)
HUVEC were isolated according to Jaffe et al.25 with some minor modifica-
tions26 and cultured in EBM-2 Bulletkit culture medium (EBM-2 supplemented
with EGM-2 SingleQuots (hEGF, hydrocortisone, fetal bovine serum, VEGF,
hFGF-B, R3-IGF-1, Ascorbic Acid, GA-1000, heparin) (Clonetics). Second or
third passage cells were used.
Fibroblasts
Human fetal lung fibroblasts (MRC) were used (Biowhittaker) and cultured in
minimum essential medium (Gibco BRL, Life Technologies, Paisley,
Scotland)/ 10% fetal calf serum/ 4 µg/ml fungizone (Gibco BRL)/ 100 IU/ml
penicillin/ 100 µg/ml streptomycin (Gibco BRL)/ sodiumpyruvate (Gibco BRL)/
non-essential amino acids (Gibco BRL). Cells of the 5-7th passage were used.
Effect of purification with regard to thrombogenicity
Tissue factor activity
Nonpurified, purified and removed cells (2x105/cm2) and HUVEC (2x104/cm2)
were grown in 48-wells plates. Previous publications have shown that for cells
immediately after isolation, a seeding density of 2x105 needs to be chosen,
because the initial adherence of these EC ranges from 10 to 40 percent of the
applied EC.17,27 For HUVEC we have used a density based on the number of
cells/cm2 culture flask. Tissue factor activity was measured as described
before (factor Xa generation assay).28 The reaction was stopped after 15 min.
To quantify tissue factor activity, a calibration curve was made using different
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dilutions of tissue factor (Innovin) (Baxter, Unterschleissheim, Germany) under
the same conditions as used for factor Xa generation on EC. Tissue factor was
expressed as dilution of Innovin (arbitrary units, 1 unit is defined as 1000/dilu-
tion of Innovin).
Thrombomodulin activity
Purified MVEC (2x105/cm2) and HUVEC (2x104/cm2) were grown in 48-wells
plates. As soon as the cells had reached confluence, half of the wells were
incubated with 29 µg/ml mouse monoclonal antibody against thrombomodulin
(DAKO) (1h). Protein C activation was measured as described before.29
Thrombomodulin activity was determined by subtraction the results of Protein
C activation obtained after pre-treatment with anti-thrombomodulin antibody
from results obtained without pre-treatment with anti-thrombomodulin anti-
body. To quantify thrombomodulin activity a calibration curve was made with
different dilutions of purified thrombomodulin (American Diagnostica,
Greenwich, CT).
Endothelial Nitric Oxide Synthase expression
Purified cells were grown on a fibronectin-coated coverslips (105/cm2). After
confluence, cells were fixed fixed with 3% PFA in RPMI buffer (0.1 g/l Ca(NO3)
2.4H2O, 0.4 g/l KCl, 0.1 g/l MgSO4.7H2O, 0.6 g/l NaCl, 2 g/l NaHC3, 0.8 g/l
Na2HPO4; pH7.4), and quenched for free aldehyde groups with 20 mM NH4Cl.
Cells were then incubated with 5% normal goat serum/0.1% saponin (30 min),
followed by incubation with mouse anti-human endothelial Nitric Oxide
Synthase (eNOS) (Transduction Laboratories, Becton Dickinson, Lexington,
KY, USA). For visualization cells were stained with FITC-conjugated goat anti-
mouse. Cells incubated without the first antibody were used as a control.
Examination was performed with confocal laser microscope (Leica TCS nt,
Leica, Heidelberg, Germany).
Perfusion of confluent cell layers with whole blood
Nonpurified, purified and removed cells (105/cm2) and HUVEC (104/cm2) were
seeded on thermanox® coverslips. When confluence was reached, cells were
perfused with anti-coagulated blood (20 U/ml final concentration low molecu-
lar weight heparin) under non-pulsatile flow conditions using a modified small
perfusion chamber.30 After 5 min flow (shear rate of 300 s-1) the perfusate was
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collected in 10 mM final concentration EDTA. Samples were taken and stored
at -20° C.
Light microscopy: Coverslips were rinsed with a Hepes buffer (10 mM
Hepes, 145 mM NaC, pH 7.35) and fixed with PBS/0.5% glutardialdehyde (30
min). Coverslips were incubated with methanol (5 min) and stained with May-
Grünwald twofold diluted in Sörensen buffer (1.58 mM KH2PO4, 1.75 mM
Na2HPO4.2H2O, pH 6.9) (3 min) and Giemsa eightfold diluted in Sörensen
buffer (15 min). Slides were rinsed with aquadest and mounted.
FPA generation: FPA was measured by enzyme linked immune sorbent
assay (ELISA) according to a protocol of Affinity Biologicals Incorporated
(director Hugh Hoogendoorn), Hamilton, Canada, with the exception that we
used bentonite instead of ethanol precipitation to extract fibrinogen from plas-
ma.31 Small adaptations were performed after personal communication with
Dr. JM Stassen, PhD, Dept. of Cardiovascular and Metabolic Research,
Boehringer Ingelheim Pharma KG, Biberach an der Riss, Germany. A 96-wells
plate (Immulon-4 microtiterplates, Dynex, Breda, The Netherlands) was coat-
ed with 100 µl synthetic FPA (Bachem, Bubendorf, Switzerland) (10 µg/ml in
50 mM Na2CO3, pH 9.5) at 4° C. After overnight incubation the plate was
blocked for 2h at RT with PBS/2%BSA (Boseral, Kordia). In the meantime plas-
ma samples were treated with one half of their volume bentonite (Sigma) (0.5
gr/5 ml TSO buffer (0.5 M Tris, 0.10 M NaCl, pH 8.9; 0.1% ovalbumin)) on a
roller bank for 10 min at RT, to remove fibrinogen.31 Plasma/bentonite samples
were centrifuged (10,000 rpm, 10 min) and supernatants were transfered to
clean 1.5 ml tubes. Plasma/bentonite sample and dilutions of FPA in HBS-
BSA-T20 buffer (10 mM Hepes, 0,15 M NaCl, 1% Boseral, 0.1% Tween, pH
7.4), for the calibration curve, were mixed with an equal volume of sheep anti-
FPA, affinity purified IgG (Kordia) (1 µg/ml in HBS-BSA-T20 buffer). Hundred
µL of this mixture was added to the plate after four wash steps with 0.1%
Tween in PBS and incubated overnight at 4° C. The plate was rinsed for anoth-
er four times with 0.1% Tween in PBS and 100 µl rabbit anti-sheep, affinity
purified IgG, peroxydase conjugated (Kordia) (0.5 µg/ml in HBS-BSA-T20
buffer) was added and incubated for 1 h at room temperature. After four wash
steps, the plate was developed with OPD substrate and absorbence was
measured (490 nm, endpoint measurement) in a Vmax kinetic micro plate
reader.
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F 1+2 generation: F 1+2 was measured by a commercially available immu-
noenzymoassay (Enzygnost F 1+2, Behring, Germany) according to the
instructions of the manufacturer.
Sodding of ePTFE grafts
Standard ePTFE grafts with a length of 4 cm were used. On both ends of ster-
ilized grafts luerlock connectors were attached. One hour before cell sodding,
the grafts were filled under pressure, one end closed, with PBS to replace
trapped air in the interstices of the graft. Then the graft was filled under pres-
sure with 50 µg/ml human fibronectin. Incubation was performed for one hour
at 37° C.
Before sodding the prostheses were washed with PBS and medium under
pressure. Nonpurified, purified and removed cells were sodded. As a control,
HUVEC, fibroblasts and different combinations of HUVEC and fibroblasts
(HUVEC/fibroblasts: 100%, 75/25, 50/50, 25/75 and 0/100) were used. The cell
suspension (2x105/cm2) was introduced into the graft with a syringe from bot-
tom to top. Subsequently, medium, four times the volume of the graft, was
forced through the graft in about 1 min. After half an hour, the period that nor-
mally elapses between sodding and graft implantation in vivo, both ends were
cut off and the graft was opened longitudinally and fixed in the silicon coated
glass petri dishes with small needles. Culture was performed for 2‘ - 3 weeks.
Histopathology and immunohistochemistry: Paraffin slides were made for
haematoxylin and eosin (HE) and immunohistochemical stains. Pro-celloidin
moistened with 35% ethanol (Sigma) was used to keep the graft-material fixed
on the slides during staining. In short, during deparafinization, after the
ethanol 100% steps, slides were brought in and out the celloidin 1% in
ethanol/ether 1:1 in vertical direction. Slides were dried for 30 seconds, and
brought in ethanol 70%.
Immunohistochemical staining were preceded by endogenous peroxidase
blocking and citrate boiling. Endogenous peroxidase blocking was performed
with 1.5% H2O2 in phosphate-citrate buffer (citric acid mono-hydrate 8.32 g/l,
Na2HPO4 21.52 g/l; pH 5.8±0.1) for 15 min. Citrate boiling was done in citrate
buffer (Na3citrate dihydrate 2.94 g/l; pH 6.0) for 10 min.
The primary antibodies that were used were mouse anti-human vWF, mouse
anti-human CD31, mouse anti-human α-actin, mouse anti-human vimentin
(DAKO). Peroxidase/DAB stainings were done with Vectastain Elite ABC Kit
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and DAB kit for peroxidase staining (Vector Laboratories, Burlingame, CA,
USA), according to the manufactures’ recommendations.
During dehydration, after the ethanol 100% steps, slides were brought in
ethanol:ether 1:1 for 5 min to remove celloidin, after which further dehydration
and mounting with depex were performed.
For each celltype, the mean intimal thickness was determined by measuring
the thickness on a regular distance with a light microscope equipped with a
JAC-CCD camera (Copenhagen, Denmark) coupled to a matrox frame grab-
ber (Matrox Electronic systems Ltd., Quebec, Canada) using Optimas 6.0 soft-
ware (DVS, Breda, The Netherlands).
Statistical analysis
Results are presented as the median (1st-3rd quartile range). A non-parametric
test was used to determine significant differences between groups (Mann-
Whitney U-test). A p-value <0.05 was considered significant.
Results
Purification of microvascular endothelial cells
After enzymatic digestion and centrifugation the yield of nonpurified cells was
10.0 (9.0-11.7) x105/g fat (n=6). Of these nonpurified cells, 41 (34-42) % (n=6)
were EC, as determined with CD31-expression using flow cytometry. After
purification with F11-/CD14-coated dynabeads the yield of purified cells was
3.2 (3.1-3.8) x105/g fat (n=6). Of these purified cells, 91 (89-93) % (n=6) were
EC. Of the cells removed by the beads, 10 (8-14) % (n=6) were EC.
Effect of purification with regard to thrombogenicity
Tissue factor activity
Tissue factor activity of purified cells, 0 (0-0.06) arbitrary units (n=50 out of 5
different isolations), was significantly reduced (p<0.001) compared with non-
purified cells, 1.14 (0.77-1.45) arbitrary units (n=50 out of 5 different isola-
tions). Tissue factor activity of removed cells, 1.22 (0.87-1.52) arbitrary units
(n=50 out of 5 different isolations), was slightly higher than that of nonpurified
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cells. Tissue factor activity HUVEC was not detectable (n=30 out of 3 different
isolations).
Thrombomodulin expression and activity
Thrombomodulin activity of purified MVEC was 44.9 (21.8-72.2) fmol/cm2
(n=20 out of 5 different isolations), similar (p=0.331) to that of HUVEC, which
was 46.8 (24.7-67.6) fmol/cm2 (n=20 out of 5 different isolations).
ENOS expression
MVEC stained positive for eNOS (fig. 1). Omission of the anti-eNOS antibody
did not result in a positive staining.
Perfusion of confluent cell layers with whole blood
Light microscopy: After 5 min perfusion with whole blood, no platelet aggre-
gates and fibrin were visible on HUVEC and purified MVEC, whereas nonpuri-
fied and removed cells were covered both with platelets and fibrin (fig. 2).
FPA generation: FPA generation after perfusion over a surface of purified
MVEC was 52.7 (16.6-80.8) ng/ml (n=27 out of 3 different isolations, perfused
with blood from 3 different other donors), significantly lower (p<0.001) than
after perfusion over a surface of nonpurified cells, 778.4 (520.2-1047.5) ng/ml
(n=27 out of 3 different isolations, perfused with blood from 3 different other
donors), and over a surface of removed cells, 1033.0 (512.0-1161.5) ng/ml
(n=27 out of 3 different isolations, perfused with blood from 3 different other
donors). FPA generation after perfusion of purified MVEC was similar
Figure 1
Presence of eNOS in MVEC purified with the
depletion method. Cells were stained with
mouse anti-human eNOS antibody followed
by staining with a FITC-conjugated goat
anti-mouse antibody (magnification, x 340).
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(p=0.113) to that of HUVEC, 29.0 (9.6-71.0) ng/ml (n=27 out of 3 different iso-
lations, perfused with blood from 3 different other donors).
F1+2 generation: F1+2 generation after perfusion of purified MVEC was 2.0
(1.4-2.2) nM (n=27 out of 3 different isolations, perfused with blood from 3 dif-
ferent other donors), significantly lower (p<0.001) than after perfusion of non-
purified cells, 8.4 (6.4-10.0) nM (n=27 out of 3 different isolations, perfused
with blood from 3 different other donors), and after perfusion of removed cells,
12.2 (5.3-14.3) nM (n=27 out of 3 different isolations, perfused with blood from
3 different other donors). F1+2 generation after perfusion of purified MVEC
Figure 2
Confluent cell layers after perfusion with LMWH-anti-coagulated blood. Stainings were perfor-
med with Giemsa and May-Grünwald (magnification, x 395).
A. HUVEC
B. Purified cells
C. Nonpurified cells
D. Removed cells 
A
B
C
D
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was significantly larger (p=0.008) than after perfusion of HUVEC, 0.9 (0.7-2.0)
nM (n=27 out of 3 different isolations, perfused with blood from 3 different
other donors).
Sodding of ePTFE grafts
Histopathology: The grafts seeded with purified MVEC showed a thin
cell(mono)layer. Grafts seeded with nonpurified cells and removed cells were
covered with a multilayer of cells. This neointima showed a variable thickness
in longitudinal as well as transversal direction. The mean thickness of the
mulilayer was 4.1 (3.3-5.7) µm (n=134 out of 6 different isolations) for the
grafts seeded with purified MVEC, 13.8 (8.1-21.8) µm (n=141 out of 6 different
isolations) for the grafts seeded with nonpurified cells and 13.4 (8.1-20.1) µm
(n=128 out of 6 different isolations) for the grafts seeded with removed cells.
The mean thickness of the intima after seeding of purified MVEC was signifi-
cantly smaller than after seeding of nonpurified and removed cells (p<0.001).
The grafts seeded with pure HUVEC and with the combination HUVEC/fibro-
blasts: 75/25 were covered with a thin cell(mono)layer. The grafts seeded with
the other combinations of HUVEC and fibroblasts and with pure fibroblasts
were covered with a multilayer. In fig. 3 the median (1st-3rd quartile range) inti-
mal thicknesses of HUVEC: fibroblasts combinations are shown.
Immunohistochemistry: Grafts sodded with nonpurified cells were covered
with a multilayer of (myo)fibroblasts (vimentin- and most of them α-actin-posi-
tive) (fig. 4a). This multilayer was for the largest part covered with a EC-mono-
layer (fig. 4b). Parts of the multilayer were not covered with an EC-monolayer,
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The median (1st-3rd quartile range) intimal
thicknesses of HUVEC/fibroblasts combina-
tions.
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but filled with groups of EC, forming vessel-like structures (fig. 4c). Cells pres-
ent in the covering monolayer of grafts seeded with purified cells were
vimentin-, vWF- and CD31-positive, which gave them the identity of EC (fig.
4d). Sporadically a myofibroblast (α-actin- and vimentin-positive) was present
in the subintimal layer. The grafts sodded with removed cells were covered
with a multilayer of (myo)fibroblasts with scattered small groups of EC, form-
ing vessel-like structures.
The grafts seeded with 100% HUVEC were covered with a monolayer of EC,
positive for the above mentioned markers. The graft seeded with
HUVEC/fibroblasts: 75/25 were also covered with a monolayer of EC, with
scattered myofibroblasts in the sublayer, as seen after seeding of purified
cells. The grafts seeded with HUVEC/fibroblasts: 50/50 were covered with a
Figure 4 (colour version: addendum, page 190)
Immunohistochemistry of cell sodded and cultured grafts (magnification, x 95).
A. Grafts sodded with nonpurified cells, the cells present in the multilayer stained positive with
mouse anti-human a-actin antibody.
B. Grafts sodded with nonpurified cells, the cells present in the covering monolayer stained
positive with mouse anti-human vWF antibody.
C. Grafts sodded with nonpurified cells, groups of cells present in the multilayer stained positive
with mouse anti-human CD31 antibody.
D. Grafts sodded with purified cells, covered with a monolayer of cells positive for mouse anti-
human vWF antibody.
A
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multilayer of (myo)fibroblasts, partly covered with a monolayer of EC and part-
ly filled with groups of EC, as seen after seeding of nonpurified cells. Grafts
seeded with HUVEC/fibroblasts: 25/75 were covered with a multilayer of
(myo)fibroblasts with scattered small groups of EC, as seen after seeding of
removed cells. The grafts seeded with pure fibroblasts were covered with a
multilayer of (myo)fibroblasts.
Discussion
Seeding of grafts with EC is an old idea to improve patency of small diameter
vascular grafts.1,2 An important problem in the set-up of EC seeding studies is
the source and the amount of autologous EC necessary to seed the graft with.
A very attractive source for EC is liposuction fat, as this source can supply
enough cells to immediately cover the graft with a confluent layer of EC with-
out additional in vitro culturing.11 The results of clinical studies with fat derived
MVEC seeded grafts in humans, however, have been less convincing than
that of animal studies.6,12,13,15 The problems found with these fat derived MVEC
were a progressive intimal hyperplasia and thrombotic complications.
Recently, we have shown that cells contaminating the isolated EC were incor-
porated in the newly formed intima of the graft.18 We speculated that the pres-
ence of these contaminants contributes to the formation of the intimal
hyperplasia. Here we have tested this hypothesis.
We have performed an additional purification step, using cell-specific antibo-
dies to deplete contaminating cells, that increases the content of EC in the iso-
late from 40% to 90%.23 We tested both the nonpurified and the purified
human MVEC in vitro, in thrombosis models and a model to study intimal
hyperplasia. As only antibodies specific for human antigens were available,
we could not test the consequences of purification in in vivo animal models
and therefore used these in vitro models.
We found that tissue factor activity of purified cells was significantly reduced
compared to nonpurified cells. Thrombomodulin activity and eNOS expres-
sion were present in purified cells. ENOS was localized in a perinuclear
region, which is in accordance with the data of Sessa et al.,32 who showed that
eNOS is associated with the perinuclear Golgi complex in cultured bovine aor-
tic cells, as well as in intact blood vessels. F1+2 and FPA generation after per-
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fusion of purified cells with whole blood were significantly lower than after per-
fusion of nonpurified cells, and only nonpurified cells were covered with
platelets and fibrin. These results suggest that the thrombogenicity of the
seeded cells is primarily due to the expression of tissue factor by the contami-
nating cells. Purification of the seeded cells would result in less thrombogenic-
ity.
Prostheses sodded with nonpurified cells were covered with a EC monolayer
above a multilayer of (myo)fibroblasts, prostheses sodded with purified cells
showed a single EC monolayer without a multilayer of (myo)fibroblasts. With
different combinations of HUVEC and fibroblasts, used as a control, we found
that to establish a confluent EC-monolayer covering the graft, the purity of the
seeded cells should be more than 25%, and to prevent the development of a
subendothelial multilayer of (myo)fibroblasts, the purity should be at least
75%. The experiments described here showed that the lower the number of
contaminating cells, the thinner the intima. Our in vitro experiments were per-
formed for only 2‘ - 3 weeks, so that the development in time of intimal hyper-
plasia from the remaining contaminating cells could not be excluded.
Therefore, we would recommend to seed cells with a purity as high as possi-
ble, at least 90% or more.
It has been postulated that cell seeding related intimal hyperplasia is the result
of transdifferentiated EC.33,34 The absence of intima hyperplasia when purified
MVEC are seeded or when in a combination of HUVEC and fibroblasts the
percentage of HUVEC is 75% or more, suggests that intimal hyperplasia does
not develop from transdifferentiated EC.
Development of intimal hyperplasia can also be attributed to cells originating
from both vessel ends and from the tissue around the vessel grafts. We can-
not exclude that this process also contributes to intimal hyperplasia. The spe-
cific advantage of our model is, however, that the individual contribution of the
contaminants in the seeded cells to the intimal hyperplasia can be demon-
strated.
An additional advantage of all the in vitro models is the suitability to test the
effects of gene therapy on intimal hyperplasia and thrombogenicity.35,36 Effects
can be measured, the procedure is much cheaper than the use of laboratory
animals and unwanted effects caused by rejection, due to species differences
between the gene and the laboratory animal, are not a problem.
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The fact that after cell seeding on a prosthesis a multilayer is formed with a
confluent EC monolayer on top, might explain why the major MVEC seeding
related problem is intimal hyperplasia and not thrombogenicity. The EC layer
can disrupt due to irregularities of surface and as a result of flow. As a result,
the thrombogenic subendothelial layer is exposed, which can explain the late
thrombogenicity found in humans. Reasons for the more progressive intimal
hyperplasia in humans compared to that found in animals might be the lower
growth velocity of human EC,7,12,15 the lower purity of seeded cells20 or the
decreased adhesion capacity of human EC,7 which may all be age related.
In this study we found that reduction of non-endothelial cell contamination of
MVEC seeded grafts decreases thrombogenicity and intimal hyperplasia.
Based on these results we would recommend not to use fat derived MVEC for
EC seeding studies in humans, without purification to at least 90%.
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Abstract
Introduction: Seeding fat derived microvascular endothelial cell (MVEC) on
deendothelialized surfaces results in the development of intimal hyperplasia.
We have suggested non-endothelial cells co-isolated from fat tissue might
play a role here. If so, the development of intimal hyperplasia should be
reduced after seeding a purified cell suspension. The aim of this study was
to evaluate a new in vitro flow model to investigate cell seeding on denuded
arteries, and to test different types of seeded cells in this model.
Methods: Femoral arteries were obtained from pigs. Deendothelialization of
the arteries was performed with a catheter and the side branches were sutu-
red. The effectiveness of the deendothelialization was investigated using
scanning electron microscopy (SEM). Then, in a static model we investiga-
ted whether reendothelialization of deendothelialised pig arteries with EC
was possible. The flow model, consisted of a roller pump, a reservoir with
flow medium, and a home-made seeding chamber. Pig MVEC, human non-
purified MVEC, human purified MVEC, umbilical cord EC (HUVEC), or a
combination of HUVEC and fibroblasts were seeded. Different seeding pro-
cedures were investigated to find the optimal procedure. Seeding was follo-
wed by perfusion with culture medium for one week. The arteries were
investigated using SEM and immunohistochemistry.
Results: The arteries could be completely deendothelialized (n=3).
Reendothelialization of a deendothelialized artery did not occur spontaneous-
ly (n=3). In the static model reendothelialization of a deendothelialized artery
segment could be obtained (n=20). As soon as the optimal seeding procedu-
re (rotation by 90° every 5 min for a total of 20 min, followed by a stationary
incubation for 20 min) was found, reendothelialization of all 4 quadrants of the
surface of a circular artery was obtained (n=8). Intimal hyperplasia was more
pronounced after seeding of human nonpurified MVEC or a mixture of HUVEC
and fibroblasts then after seeding of human purified MVEC or HUVEC.
Conclusion: With our model an artery could be treated and seeded easily
and kept sterile for one week. A complete coverage of a deendothelialized
artery could be obtained. The extent of the intimal hyperplasia was depen-
dent on the purity of the seeded cells.
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Introduction
In the treatment of peripheral artery occlusive disease, vein bypasses result in
a better patency than prosthetic bypasses.1 An important reason for the better
patency of vein bypasses is the presence of an intact endothelial cell (EC)
layer.2 EC seeding of prosthetic vascular grafts has been demonstrated to
increase the patency, both in animal and human studies.2,3.
On a smaller scale, the technique of EC seeding has also been applied to
denuded arteries to improve the results after percutaneous transluminal
angioplasty (PTA) and endarterectomy.4-6 Damage to the EC monolayer dur-
ing these interventions may initiate early arterial thrombosis by exposure of a
prothrombogenic subendothelial matrix.7,8 Furthermore, loss of the inhibitory
influence of the intact EC monolayer on underlying vascular smooth muscle
cells may be partly responsible for the development of myointimal hyperpla-
sia.9-11
Originally, EC cultured from veins were used for cell seeding.12
Subcutaneous fat tissue is an alternative source of EC, microvascular
endothelial cells (MVEC).13 The results after seeding MVEC on prosthetic
grafts were better in animals than in man. In both settings intimal hyperplasia
was a problem, but in humans this intimal hyperplasia was more extensive
and more frequently associated with thrombosis.14-16 We have found that
besides MVEC, fibroblasts and macrophages were co-isolated from fat tis-
sue,17 and demonstrated that these contaminating cells contributed to MVEC
seeding related intimal hyperplasia.18 Purification of human MVEC reduced
MVEC seeding related thrombogenicity and intimal hyperplasia on prosthetic
grafts in vitro.19
All studies, in which EC seeding on denuded arteries was investigated, have
been performed with venous EC.4,20-23 In most studies EC seeding resulted in
an decreased development of intimal hyperplasia and increased patency
compared to sham seeding. We performed an in vivo study in which fat
derived MVEC were seeded on denuded arteries after PTA.24 Development of
intimal hyperplasia was increased and patency was decreased compared to
sham seeding.
Based on our previous results, we suggested that one of the reasons of the
increased intimal hyperplasia is the presence of non-endothelial cells (non-
EC) in the seeded cell population. The development of intimal hyperplasia
might be reduced after seeding a purified EC isolate.
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The aim of this study was to develop an in vitro flow model of cell seeding on
denuded arteries, and to test different types of cells in this model.
Methods
Design of the study
Pig arteries were deendothelialized to replicate an arterial luminal surface after
PTA or endarterectomy.
A We investigated whether our deendothelialization method resulted in com-
plete removal of EC and whether spontaneous reendothelialization from
remaining cells occurred.
B The seeding of EC on denuded pig arteries was investigated in a static
model. In this model artery segments were fixed in horizontal position.
Seeding was performed with pig MVEC, human nonpurified MVEC, human
purified MVEC, or HUVEC.
C A flow model was developed to study cell seeding on a denuded circular
artery. Different seeding procedures were tested until the optimal program
was found. Using this procedure different types of cells were seeded; pig
MVEC, human nonpurified MVEC, human purified MVEC, HUVEC, and a com-
bination of MVEC and fibroblasts.
Arteries
Source and type of arteries
Arteries were removed from pigs in a slaughterhouse. We chose for arteries
from the pig as they are amply available. The external iliac/femoral artery was
used as it has a diameter comparable to the human femoropopliteal artery.
The arteries were collected and transported in medium M199 (Gibco BRL, Life
Technologies, Paisley, Scotland) at room temperature.
Treatment of the arteries
The excess of surrounding tissue was removed from the artery. Subsequently,
the artery was deendothelialized using a stomach tube (Maersk Medical A/S,
Engmosen, Denmark). The tube was moved through the artery, four times up
and down. Then, the ends of the artery were cut and the artery was flushed
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with M199. After this, side branches
were closed using prolene 8-0. During
these procedures the artery was pro-
tected from dehydration using M199.
The static model
The bottom of a 48-wells plate was
removed. The plate was used upside
down. The artery was spread on the
inside part of the lid, after which the
plate was put upside down on top of
the spread artery. Through the holes
(originated after removal of the bot-
tom) the cell suspension was added
to the artery and CO2 exchange was
possible. The holes were covered with
breathing plastic foil.
The cells were added in a volume of in
200µL medium RPMI (Gibco BRL)/
10% fetal calf serum (Gibco BRL)/ 4
µg/ml fungizone (Gibco BRL)/ 100
IU/ml penicillin/ 100 µg/ml strepto-
mycin (Gibco BRL). We chose for this
medium since it is well buffered,
which is especially important for the
long-time perfusion in the dynamic
flow model. After one hour, the medi-
um on top of the seeded artery was
removed, the seeded artery was cov-
ered with new medium and incubation
was performed.
The dynamic flow model
For seeding and perfusion of an circu-
lar artery, we used a special seeding
chamber, following the ideas of Bell et
al.25 The flow chamber was manufac-
Figure 1 
The architecture of the seeding cham-
ber:
A. The seeding chamber closed, out-
side the holder.
B. The seeding chamber opened,
fixed in the special holder, the vessel
can be immobilized between the two
stainless steel cannulas, without tracti-
on;
C. The seeding chamber closed, fixed
in the special holder, after closure the
model can be taken out of the holder
or can be connected in the flow
system using silicon tubes.
A
B
C
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tured by the department of
Biomedical Engineering, University
Medical Center, Utrecht.
The flow chamber consists of a poly-
carbonate (Lexan) cylinder, closed
with two stainless steel (type 216)
caps. In both caps a central hole is
present. Through the hole, two stain-
less steel cannulas (4mm diameter)
can be moved and fixed in place
using ethylene-propylene (EPDM) o-
rings. The two cannulas serve to
attach and perfuse the artery. In the
stainless steel caps another hole is
present in the periphery. This hole
allows the chamber to be filled with
medium and for CO2 exchange (fig
1a). The seeding chamber is fixed in a
special holder, made of aluminium,
when manipulating the artery. In this
way no traction is placed on the
artery. The seeding chamber is
opened and the artery is fixed
between the stainless steel cannulas
(fig. 1b). After attachment of the
artery, the chamber is closed again.
The cylinder can slide over the closer
cap. Attachment to this cap is per-
formed with an u-formed stainless
steel stave that fits in a groove in the
side of the cap, using four holes in the
cylinder. The polycarbonate cylinder
is attached to the farther cap with a
screw thread. Leakage is prevented
using EPDM o-rings. (fig. 1c).
Figure 2
The dynamic flow model:
A. The seeding procedure, the flow
chamber is taken out of the holder
and turned;
B. The flow chamber fixed in the hol-
der, inside the incubator during the
perfusion;
C. The roller pump situated outside
the incubator and connected with the
flow chamber via a hole in the incuba-
tor using silicon tubing.
A
B
C
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Circular arteries were fixed in the perfusion chamber as described above,
using vicryl 4-0. The artery and tubes were filled with the cells suspension.
Both ends were closed using a 3-way stop cock. Subsequently, the chamber
was filled with culture medium to prevent dehydration of the artery, to add
nutrients to the outside part of the artery, and to keep the pressure in and out-
side of the artery equal. The seeding chamber was taken out of the holder and
put in an incubator (37° C, 5% CO2). Different seeding programs were per-
formed until the optimal procedure was found. For all programs the seeding
chamber was rotated to obtain circular attachment of cells (fig. 2a). After the
seeding process the perfusion was started:
The seeding chamber was put in the holder. A 100 ml glass bottle filled with
flow medium, was pre-warmed to 37° C. In the cap of the bottle an outlet and
inlet port were present. The outlet port was connected via a roller pump, capa-
ble of delivering mean flow rates between 2.8-280 ml/min (Model 2010,
Verder, Vleuten, The Netherlands), to the proximal end of the seeding cham-
ber (fig. 2b). The distal end of the chamber was connected to the inlet port to
complete. Tubes between chamber and pump were made of silicon. The roller
pump was situated outside the incubator, connection was made via a hole in
the back of the incubator (fig. 2c).
For all experiments except the last one, a mean flow rate of 15 (range 0-30)
ml/min was used. For the last one a mean flow rate of 120 (range 0-240)
ml/min was used. The flow medium was refreshed every three days and perfu-
sions were continued for a maximum of 7 days.
Cells
Human and pig MVEC
Human and pig MVEC were isolated, and human MVEC were purified as
described before.17 Cells were counted and seeded on human fibronectin-
coated culture plates. Cells were cultured in EBM-MV2 Bulletkit culture medi-
um (EBM-2 supplemented with EGM-2-MV SingleQuots containing hEGF,
hydrocortisone, fetal bovine serum, VEGF, hFGF-B, R3-IGF-1, Ascorbic Acid,
GA-1000) (Clonetics, BioWhittaker, Verviers, Belgium) with 0.5 µM cAMP
(Sigma-Aldrich Chemie, Steinheim, Germany).26 Freshly isolated, or cells of
the first passage were used.
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Human umbilical cord endothelial cells (HUVEC)
HUVEC were isolated according to Jaffe et al27 with some minor modifica-
tions28 and cultured in EBM-2 Bulletkit culture medium (EBM-2 supplemented
with EGM-2 SingleQuots (hEGF, hydrocortisone, fetal bovine serum, VEGF,
hFGF-B, R3-IGF-1, Ascorbic Acid, GA-1000, heparin) (Clonetics). Cells of the
first or second passage cells were used.
Fibroblasts
Normal human Lung Fibroblasts (NHLF) were used (Clonetics) and cultured in
minimum essential medium (Gibco BRL, Life Technologies, Paisley,
Scotland)/ 10% fetal calf serum/ 4 µg/ml fungizone (Gibco BRL)/ 100 IU/ml
penicillin/ 100 µg/ml streptomycin (Gibco BRL)/ sodiumpyruvate (Gibco BRL)/
non-essential amino acids (Gibco BRL).
Microscopy
Scanning electron microscopy
The pieces of graft used for scanning electron microscopy (SEM) were fixed in
2% glutaraldehyde in 0.1M H2PO4 for 1-11/2 hour, postfixed in 1% osmium
tetraoxide for 1 hour, rinsed with destilled water, dehydrated through increas-
ing concentrations of ethanol (50-70-90-100%-100% waterfree) and critical
point dried (CDP020, Balzars Union, Lichtenstein). Finally samples were gold-
sputtered (Sputtercoater 208HR, Thickness Controller MTN, Cressington,
England) and examined with a scanning electron microscope (Philips,
Eindhoven, The Netherlands).
Histopathology & immunohistochemistry
Paraffin slides were made for haematoxylin and eosin (HE) and immunohisto-
chemical stains. Slides were deparafinized, using three xylene steps, two
ethanol 100% steps, one ethanol 90% step and one ethanol 70% step.
Immunohistochemical staining were preceded by endogenous peroxidase
blocking and citrate boiling. Endogenous peroxidase blocking was performed
with 1.5% H2O2 in phosphate-citrate buffer (citric acid mono-hydrate 8.32 g/l,
Na2HPO4 21.52 g/l; pH 5.8±0.1) for 15 min. Citrate boiling was done in citrate
buffer (Na3citrate dihydrate 2.94 g/l; pH 6.0) for 10 min.
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The primary antibodies which were
used were mouse anti-human CD31
and mouse anti-human α-actin
(DAKO). Peroxidase/DAB staining
were done with Vectastain Elite ABC
Kit and DAB kit for peroxidase staining
(Vector Laboratories, Burlingame, CA,
USA), according to the manufactures’
recommendations.
Dehydration was performed with the
same amount of steps as mentioned
above in the opposite direction.
Results
A. Deendothelialization of pig
arteries
Passage of a catheter four times up
and down resulted in a complete
deendothelialization of the total artery
surface (n=3). A subendothelial
matrix was exposed (fig. 3a). After 7
days of culture, no reendothelializa-
tion of the artery surface occurred
from cells that possibly remained after
deendothelialization (n=3) (fig. 3b).
B. Seeding of a denuded artery
segment in the static model
A seeding density of 6x105 cells/cm2
with pig MVEC followed by an incuba-
tion period of 72 h (n=11) resulted in
a confluent surface cover in eight
cases.
Figure 3
SEM of a deendothelialized pig artery
(magnification, x 250):
A. Immediately after the deendothelia-
lization procedure, a complete deen-
dothelialization of the vessel surface
has occured;
B. After 7 days of culture in the static
model, no reendothelialization has
occurred.
A
B
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The same seeding density using pig
MVEC with a shorter incubation peri-
od of 48h (n=2) resulted in a conflu-
ent surface cover in only one case.
An shorter incubation period of 24h
(n=2) did not result in a totally conflu-
ent surface cover.
A seeding density of 2x105 cells/cm2
using pig MVEC (n=1), human non-
purified MVEC (n=2), human purified
MVEC (n=1) or HUVEC (n=1), fol-
lowed by an incubation period of 7
days resulted always in a confluent
surface cover.
C. Seeding of a circular denuded
artery the dynamic flow model
First, an intact (non-
deendothelialized) artery was
tested.
SEM of an intact artery fixed into the
seeding chamber followed by static
incubation for 24h without perfusion
showed that many cells had detached
(fig. 4a). All cells had remained
attached, if immediately after the fixa-
tion of the artery into the seeding
chamber, the artery was perfused with
medium for 24h (fig. 4b).
Subsequently, different seeding
procedures were tested until the
best procedure was found
First, the artery was seeded with pig
MVEC (6x105/cm2) and rotated by
120° every 20 min for a total of one
Figure 4
SEM of an intact vessel (without deen-
dothelialization) fixed in the flow
chamber for 24 hours (magnification,
x 250):
A. Without perfusion, many cells have
detached;
B. With perfusion, all cells have remai-
ned attached.
A
B
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hour. Perfusion was performed for
48h (n=2) and 5 days (n=1). SEM
showed cells only being attached to
the lower half of the artery. The cell
coverage was sub-confluent after 48 h
perfusion and confluent after 5 days
perfusion.
Then, to obtain cell covering of the
upper half of the artery, after each
rotation of the artery new cells were
introduced into the artery. The same
type of cells and seeding density were
used. The artery was rotated by 90°
every 15 min for a total of one hour.
Perfusion was performed for 48h
(n=1). Still only the lower half of the
artery was covered. The cell coverage
was confluent.
After this, the artery was rotated by
180° every 30 min for a total of two
hours. New cells were only introduced
after the first rotation. Again, the same
type of cells and seeding density were
used. Perfusion was performed for 7
days (n=3). This time the whole sur-
face of the artery was covered. The
cell coverage was almost confluent.
Finally, the artery was rotated by 90°
every 5 min for a total of 20 min, fol-
lowed by an incubation period of
another 20 min.29 In contrary to the
experiments mentioned above, no
new cells were introduced after each
rotation. Using this procedure, differ-
ent types of cells were seeded,
human nonpurified MVEC (n=2), a
combination of human MVEC and
Figure 5
SEM of a deendothelialized artery see-
ded with 2.105 cells for 40 min, follo-
wed by 7 days of perfusion
(magnification, x 250):
A. Human nonpurified MVEC, a con-
fluent cell layer is present;
B. Human purified MVEC, an almost
confluent cell layer is present;
C. HUVEC, an almost confluent cell
layer is present.
A
B
C
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fibroblast (n=1), human purified MVEC (n=2), and HUVEC (n=3). The seed-
ing density was 2x105/cm2. Perfusion was performed for 7 days. SEM showed
a circular almost confluent cell coverage (fig. 5). Seeding human purified
MVEC and HUVEC resulted in a thin excentric intimal hyperplasia (fig. 6e-h).
Seeding of human nonpurified MVEC and a mixture of HUVEC and fibroblasts
resulted in a more extended excentric intimal hyperplasia (fig. 6a-d).
In the last experiment with HUVEC, a mean flow rate of 120 (range 0-240)
ml/min was used. The same coverage with EC was attained, but intimal hyper-
plasia was reduced further (fig. 6i-j).
Figure 6 (colour version: addendum, page 191-192)
Immunohistochemistry, using EC-specific anti-CD31 and myofibroblast-specific anti-a-actin of
seeded (40’) and perfused (7 days) denuded arteries (magnification, x70):
A. Anti-CD31 staining of an artery seeded with human nonpurified MVEC (flow 15 ml/min), hardly
any EC are present; 
B. Anti-α-actin staining of the same artery, part of the neointima exists of myofibroblasts, part of
α-actin-negative cells;
C. Anti-CD31 staining of an artery seeded with a combination 75% fibroblasts and 25% HUVEC
(flow 15 ml/min), a subconfluent EC coverage is present and groups of EC are present in the
neointima;
D. Anti-α-actin staining of the same artery, the subendothelial neointima exists of myofibroblasts;
E. Anti-CD31 staining of an artery seeded with human purified MVEC (flow 15 ml/min), a conflu-
ent EC coverage is present; 
F. Anti-α-actin  staining of the same artery, hardly any subendothelial myofibroblasts are present
G. Anti-CD31 staining of an artery seeded with HUVEC (flow 15 ml/min), a confluent EC covera-
ge is present;
H. Anti-α-actin staining of the same artery, hardly any subendothelial myofibroblasts are present;
I. Anti-CD31 staining of an artery seeded with HUVEC (flow 120 ml/min), a confluent EC covera-
ge is present;
J. Anti-α-actin staining of the same artery, hardly any subendothelial myofibroblasts are present.
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Discussion
MVEC seeding related intimal hyperplasia on prosthetic grafts and denuded
arteries18,19,24 might be related to contaminants in the fat derived cell popula-
tion.17 If so, the development of intimal hyperplasia should be reduced after
seeding a purified cell suspension.
In this study we have developed an in vitro flow model to investigate cell seed-
ing on denuded arteries and tested different cell types and cell mixtures in this
model. With this model we hoped to show that the development of intimal
hyperplasia was indeed due to impurities in the cell isolates.
The concept of our model was based on the in vitro model of vascular dam-
age of Thompson et al with some adaptations.25,30 Like Thompson et al, our
dynamic flow model consisted of a roller pump, a reservoir with flow medium
and a seeding chamber. However, instead of putting the reservoir with flow
medium into a water bath and the rest at room temperature,30 we put the
reservoir with flow medium and the seeding chamber into an incubator. In this
way, the risk of infection was reduced. Second, we developed a modification
of the seeding chamber of Bell et al.25 Using a special holder, the artery could
be introduced and removed without unnecessary traction that would damage
the cell coverage.
After testing different seeding procedures a circular covering of a deendothe-
lialized pig artery was obtained using two different seeding programs. The first
program consisted of a seeding density of 6x105/cm2 and rotation by 180°
every 30 min for two hours, with after the first rotation introduction of new
cells. The second program consisted of a seeding density of 2x105/cm2 and
rotation by 90° every 5 min for 20 min, followed by another 20 min incubation.
The second program was performed with different celltypes. The extensive-
ness of intimal hyperplasia was reduced after seeding of purified MVEC and
HUVEC compared to nonpurified MVEC and a combination of HUVEC and
fibroblasts.
The considerable amount of excentric intimal hyperplasia found after seeding
of nonpurified cells and a combination of fibroblasts and HUVEC supports our
hypotheses that contaminating cells play a role. EC are known to inhibit inti-
mal hyperplasia but when simultaneously cells are seeded that contribute to
intimal hyperplasia, the positive effects of EC may be overruled.
Contaminating cells can contribute directly as components of the intimal cell-
layer or indirectly through stimulation of pig SMC to migrate to the intima and
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to proliferate.31 We could not discriminate between these two possibilities as
both pig SMC and contaminating myofibroblast stain with mouse anti-human
α-actin.
The reason that some intimal hyperplasia still occurred after seeding of puri-
fied MVEC and HUVEC might be explained in two ways. The inhibitory func-
tion of freshly seeded EC towards intimal hyperplasia might be incomplete or
the shear stress we have used might have been too low. We have used a low
flow rate with a mean of 15 (range 0-30) ml/min (mean shear rate 40 (range 0-
80) s-1; mean shear stress 0.4 (range 0-0.8) dynes/cm2)32 to prevent cells
detaching from the artery immediately.30,33,34 A higher shear stress inhibits inti-
mal proliferation to a greater extent.35 Using higher shear stresses, promising
results have also been obtained with regard to cell retention.30,33 For this rea-
son, we performed our last experiment with HUVEC with a mean flow rate of
120 (range 0-240) ml/min (mean shear rate 320 (range 0-640) s-1; mean shear
stress 3.2 (range 0-6.4) dynes/cm2) instead of 15 ml/min. The EC cover was
comparable to a flow rate of 15 ml/min but the extend of intimal hyperplasia
was further reduced.
In the dynamic flow model, a lower seeding density (2x105/cm2) and a shorter
seeding time (40 min) produced results comparable to a higher seeding den-
sity (6x105/cm2) and a longer seeding time (120 min). This might be due to the
lack of O2 and nutrient administration and CO2 removal in the absence of per-
fusion. A non-deendothelialized artery perfused for 24h showed an intact EC
layer, but when fixated in the model and subjected to static conditions hardly
any EC remained. Thompson et al stressed that a seeding time over 30 min
does not lead to improved cell retention.36 This results in an additional advan-
tage for the in vivo situation. When seeding a prosthetic graft, the procedure is
performed outside the patient and attachment of cells can be obtained by
pressure of the cells into the crevices of the graft. When seeding a denuded
artery, the procedure needs to be performed inside the patient and the attach-
ment is gravity dependent. The artery needs to be occluded during seeding.
The period of artery occlusion should be kept as short as possible.
Perfusion was continued for 7 days without problems of infection. This is one
of the few studies published in which a artery placed in a flow model was kept
sterile for at least one week.35 Possible other experiments for which this model
might be used is the investigation of gene therapy with respect to reendothe-
lialization and intimal hyperplasia. Furthermore, the imaging of reendothelial-
ization and development of intimal hyperplasia with techniques as
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intravascular ultrasound (IVUS) and magnetic resonance angiography (MRA),
can be investigated.
In this study, we have introduced an in vitro flow model to investigate cell
seeding on denuded arteries. With our model, an artery could be treated and
seeded easily and kept sterile for one week. A complete coverage of a deen-
dothelialized artery could be obtained. We showed that the generation of inti-
mal hyperplasia after seeding nonpurified cells is more pronounced than after
seeding purified cells.
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Abstract
Background: Subcutaneous fat derived microvascular endothelial cells
(MVEC) are seeded on vascular grafts to improve patency. In MVEC isola-
tes, we have demonstrated the presence of contaminating cells contributing
to MVEC seeding related intimal hyperplasia. Purification reduced thrombo-
genicity and prevented intimal hyperplasia in vitro. A combination of
11Fibrau (F11)- and CD14-coated Dynabeads® was used to deplete fibro-
blasts and monocytes/macrophages. Unfortunately, clinical grade F11 is not
available and thus cannot be used for clinical practice. CD34-selection with
clinical grade products is used widely for the isolation of haematopoietic
progenitors. EC express CD34 on their surfaces.
The aims of this study were to test the effectiveness of two different CD34-
selection techniques for purification of MVEC, and to compare the results
with those of the F11/CD14-method.
Methods: Liposuction fat was enzymatically digested and centrifuged twice
to remove adipocytes and collagenase. CD34-selection was performed with
the method from Nexell or from Miltenyi. The purity after isolation and cultu-
re, and recovery was determined by flow-cytometry (CD31-expression) and
compared with that of cells purified with the F11/CD14-method.
Results: Besides MVEC, the contaminating fibroblasts and macrophages/
monocytes also weakly stained with anti-CD34. Enrichment of MVEC could
not be obtained with the Miltenyi-method. Variations in neither the dose of
antibody nor the use of a direct selection, and different separation programs
improved the results. With the Nexell-method, MVEC were enriched to 86%,
a comparable purity as obtained with the F11/CD14-method. However, a
lower recovery was reached with the Nexell-method.
Conclusion: The explanation that enrichment of MVEC could only be obtai-
ned with the CD34-positive selection method from Nexell might be that the
actual enhancement of MVEC-purity is performed by release peptide.
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Introduction
In bypass surgery the patency of prosthetic grafts is less than that of vein
grafts.1 Unfortunately not all patients have suitable veins. An important differ-
ence between vein grafts and prosthetic grafts is the presence of an intact
endothelial cell (EC) layer. In the late seventies the concept of EC seeding was
introduced trying to obtain the same patency with prosthetic grafts as with
vein grafts.2,3
An important condition for the success of EC seeding is that the seeding den-
sity on the graft is high. Two main strategies to enhance seeding density have
evolved.4,5 One approach consists of a two step in vitro endothelialization pro-
cedure with cultured venous EC.6 To increase the amount of cells on the graft,
after an initial isolation step a second culturing step is performed. Vein derived
cells are cultured in culture flasks and subsequently on the prosthetic grafts
themselves. This technique not only increases the amount of cells, but also
allows adaptation of the cells to their new surrounding by maturation of the
cytoskeleton, deposition of extracellular matrix7 and generation of resistance
to shear stress of seeded cells8 Another approach is to isolate enough cells
from the microcirculation to avoid in vitro culturing. Fat is an abundant source
of microvascular endothelial cells (MVEC). The yield is high enough to estab-
lish a confluent EC layer without additional culturing.9
A disadvantage of the first approach is the need for long term culture (4
weeks). An extensive culture facility operating under good manufacturing
practice (GMP) is necessary. The culture period renders the procedure unsuit-
able for urgent cases.6 A disadvantage of the second approach is that the
results of human studies are disappointing compared to animal studies and
compared to the in vitro endothelialization studies with vein derived EC. An
important explanation for the disappointing results of human studies with fat
derived MVEC seems to be the extensive neointimal formation.10-13 This neoin-
timal formation is more progressive than after seeding of fat derived MVEC in
animals and after in vitro endothelialization with vein derived EC.
We have demonstrated the presence of contaminating cells in cell isolates of
fat derived MVEC14 contributing to seeding related intimal hyperplasia.15 We
have developed an additional purification step using a combination of F11-
and CD14-coated Dynabeads® to deplete contaminating fibroblasts and
monocytes/macrophages.14 Further purification of EC reduced thrombogenici-
ty and intimal hyperplasia in vitro.16
120
To prove purification of fat derived MVEC reduces neointimal formation in vivo
and improves patency, clinical trials are necessary. Unfortunately, F11 is not
produced according to GMP criteria. CD34 is an antigen present on the sur-
face of EC.17 Two clinical applicable methods (Nexell&Miltenyi) are available
for selection of CD34-positive stem cells.18,19
The aims of this study were to test the effectiveness of two different CD34-
selection techniques for purification of MVEC, and to compare the results with
those of the F11/CD14-method.
Methods
Isolation of MVEC
Liposuction fat was obtained after informed consent. Fat was centrifuged
(3000 rpm; 15 min) to remove the liposuction fluid. Amounts of fat were mixed
with equal volumes of crude collagenase from Clostridium histolyticum (Sigma
Chemie) (0.4% w/v)/BSA (0.4% w/v) in phosphate buffered saline (PBS), pH
7.4. After incubation for 30 min at 37°C under continuous vigorous shaking,
the digested fat was centrifuged (1200 rpm, 12 min, room temperature (RT)) to
remove adipocytes and collagenase. The pellets were resuspended in
Medium 199 (Gibco BRL, Life Technologies, Paisley, Scotland). The cell sus-
pension was centrifuged again (1100 rpm, 5 min, RT) and the pellets were
resuspended in RPMI/1% Fetal Bovine Serum (FBS) (Gibco BRL). The cell
suspension was sieved through a sterile 100 µm Nylon Cell Strainer (Falcon,
Becton Dickinson, Franklin Lakes, NJ, USA) and the cells were counted
(Haematology Analyzer Cell-Dyn 1700 (ABBOTT, Santa Clara, CA, USA)).9
Enrichment of MVEC
1. F11/CD14-depletion of fibroblasts and monocytes
The depletion technique was used as the standard and was described exten-
sively elsewhere.14 In short: M450 goat anti-mouse IgG Dynabeads® (Dynal
A.S., Oslo, Norway)) were washed twice with sterile phosphate buffered saline
(PBS)/ 0.1% bovine serum albumin (BSA) (Sigma-Aldrich Chemie, Steinheim,
Germany). Beads were coated with mouse monoclonal antibody against
CD14 (DAKO, Glostryp, Denmark) 0.25 µg/107 beads in 100 µL PBS/0.1%
121
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BSA, and with mouse monoclonal antibody 11FIBRAU (F11) (Imgen, ITK
Diagnostics, Uithoorn, the Netherlands/Serotec, Oxford, UK)20 15 µg/108
beads in 1 ml PBS/BSA, for 30 min at 4°C on a roller bank, followed by four
wash steps.
F11-beads (5x107) and CD14-beads (6x106) were added to nonpurified cells
(107 in 5 ml). Incubations were performed for 20 min at 4° C on a roller bank.
‘Bound’ and ‘nonbound’ cells were separated with a Magnetic Particle
Concentrator (MPC) (Dynal) for 2 min. Bound cells were resuspended in
RPMI/1% FBS and cells were separated for a second time. Supernatants with
nonbound cells were transferred into clean tubes and the separation proce-
dure was repeated to remove any remaining bound cells.
Two fractions were obtained. A fraction of cells that bound to the
Dynabeads®, the ‘waste fraction’ and a fraction 2 of cells that did not bind to
the Dynabeads®, the ‘enriched fraction’.
2. CD34-positive selection technique from Milteny
The CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany), consists of reagent A1: human Ig (FcR blocking reagent); Reagent
A2: monoclonal hapten-conjugated IgG1 CD34 antibody and Reagent B: col-
loidal super-paramagnetic activated cell separation (MACS) Microbeads®
conjugated to an anti-hapten antibody. MACS Microbeads® degrade in the
body.18
Human Ig (100 µl) and CD34 antibody (100 µl) were added to 4x106 cells
resuspended to 500 µL with RPMI/1%FBS. Incubation were performed for 15
min at 4°C on a roller bank. After this, cells were washed with 10 ml RPMI/1%
FBS, followed by centrifugation (1200 rpm, 5 min). The cell pellet was resus-
pended in 400 µl RPMI/1% FBS to which 100 µl MACS Microbeads® were
added. Incubations were performed for another 15 min at 4° C on a rollerbank.
After washing and centrifugation, the cell pellet was resuspensed in 500 µl
RPMI/1%FBS.
Cells were separated with the AutoMACS®, using the ‘positive selection’ pro-
gram.
Two fractions were obtained. A fraction of cells that did not bind to the MACS
Microbeads®, the ‘waste fraction’, and a fraction of cells that bound to the
MACS Microbeads®, the ‘enriched fraction’.
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The results obtained with the above mentioned conditions were compared
with the results obtained with different other amounts of antibody, a direct
selection technique, using antibody-precoated MACS Microbeads®
(CliniMACS®), and different other selection programs.
3. CD34-positive selection technique from Nexell
The clinical grade Isolex Stem Cell Reagent Kit (Nexell Therapeutics Inc.,
Irvine, CA, USA) consists of Isolex Anti-CD34 Monoclonal Antibody,
Dynabeads® M-450 Sheep Anti-Mouse IgG (Dynal ASA, Oslo, Norway) and
PR34+ Stem Cell Releasing Agent®.19
CD34-antibody (2 µg), was added 107 nonpurified cells in 1 ml RPMI/1%FBS.
After 10 min incubation at 4° C in a rotator, the antibody-cell suspension was
added to 108 Dynabeads® in 9 ml RPMI/1%FBS (10 beads/cell, 107
beads/ml). Incubations were performed for another 25 min at 4° C on a roller-
bank.
‘Nonbound’ and ‘bound’ cells were separated with a Magnetic Particle
Concentrator (MPC) and bound cells were resuspended in RPMI/1% FBS.
This procedure was repeated twice. After three separations, bound cells were
resuspended in 500µl PR34+® diluted with 750 µl RPMI/1% FBS (50 µl release
peptide + 75 µl RPMI/1% FBS per 107 beads). Incubations were performed for
30 min at 4° C in a rotator. Cells were separated, bound cells were resuspend-
ed in RPMI/1% FBS. This procedure was repeated twice. Supernatants with
nonbound were separated again to remove any remaining bound cells.
In total, three fractions were obtained. A fraction of cells that did not bind to
the Dynabeads®, ‘waste fraction 1’, a fraction of cells that bound to the
Dynabeads® but did not release with PR34+®, ‘waste fraction 2’, and a frac-
tion of cells that bound tot the Dynabeads® and released with PR34+®, the
‘enriched fraction’.
The results obtained with the above mentioned conditions were compared
with the results obtained with different other amounts of antibody, different
other amounts and concentrations of beads, a direct selection technique
using antibody-precoated beads, different other amounts and dilutions of
release peptide, and two cycles with release peptide.
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Yield and purity
The number of cells present in the different fractions were counted using the
Haematology Analyzer Cell-Dyn 1700. The cells that bound to the
Dynabeads® could not be counted in this way, due to the disturbance of the
result by the Dynabeads®. The number of cells that bound to Dynabeads®
was determined by subtraction of the number of cells that were not bound to
the Dynabeads® from the number of starting cells.
The purity of the ‘enriched fractions’, recovery of EC in the ‘enriched fractions’
and loss of EC in the ‘waste fractions’ were calculated.
The purity (%) was defined as the total number of CD31+-cells in the enriched
fraction divided by the total number of nucleated cells in the enriched fraction
times 100. Purity was determined immediately after isolation and after culture.
The recovery (%) was defined as the total number of CD31+-cells in the
enriched fraction divided by the total number of CD31+-cells in the starting
population times 100.
The lost number of EC (%) was defined as the total number of CD31+-cells
present in the waste fraction divided by the total number of CD31+-cells pres-
ent in the starting population times 100.
The percentage of EC marker CD31+-cells was measured by flow cytometry.
Flow cytometry
The identity of the isolated cells was established by flow cytometry using
FITC-conjugated mouse anti-human CD31 (Pharmingen, Leiden, The
Netherlands), PE-conjugated mouse anti-human CD34 (Becton and
Dickinson, Bedford, Mass., USA), mouse anti-human CD14, mouse anti-
human F11 and for visualization of the non-conjugated antibodies, FITC-con-
jugated goat anti-mouse (Becton Dickinson, Bedford, Mass., USA) or
PE-conjugated goat anti-mouse (Southern Biotechnologies, USA).
Cultured cells were trypsinized and washed with PBS/1% BSA twice and trans-
ferred to a 96-well plate (max. 106cells/well).
Antibody-incubation was performed for 30 min at 4° C, followed by two wash
steps with PBS/1% BSA. For double staining of CD31-F and CD34-PE, both
antibodies were added together. For all other double stainings a 4-steps
labelling was performed adding the unconjugated mouse anti-human anti-
body first, the F- or PE-conjugated goat anti-mouse antibody second, 4% nor-
mal mouse serum to block the free binding places on the F- or PE-conjugated
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goat anti-mouse antibody third, and finally the F- or PE-conjugated mouse
anti-human antibody.
Red blood cells present in the cell isolates were lysed after addition of the last
antibody using FACS’ Lysing Solution (Beckton Dickinson) for 10 min at room
temperature in the dark followed by two wash steps.
Cells were analysed with a flow cytometer (Calibur, Becton and Dickinson,
San José, CA, USA).
Quality control through culture of cells
All cells were collected in Microvascular Endothelial Cell Growth Medium
Bulletkit (EGM-MV2) (Endothelial Cell Basal Medium-2 (EBM-2) supplemented
with EGM-2-MV SingleQuots containing hEGF, hydrocortisone, FBS, VEGF,
hFGF-B, R3-IGF-1, Ascorbic Acid, GA-1000) (Clonetics, BioWhittaker, Verviers,
Belgium) with 0.5 dibutyryl cAMP (Sigma).21 Counting was performed
(Haematology Analyzer Cell-Dyn 1700) and cells were seeded in a density of
105/cm2 on human fibronectin-coated 6- or 12-wells culture plates. Culture was
performed to study growth and purity of cells after confluency.
The effect of collagenase treatment on the expression of EC
markers
HUVEC were isolated according to Jaffe et al22 with some minor modifica-
tions23 and cultured in EBM-2 Bulletkit culture medium (EBM-2) supplemented
with EGM-2 SingleQuots (hEGF, hydrocortisone, fetal bovine serum, VEGF,
hFGF-B, R3-IGF-1, Ascorbic Acid, GA-1000, heparin) (Clonetics).
Two first passage HUVEC cultures of the same isolation were used. As soon
as the cells were confluent, one culture was trypsinized. Cells were incubated
with collagenase, as mentioned above. After 30 min cells were washed. At the
same time the other culture was trypsinized. Cells were double stained with
CD31-F and CD34-PE as mentioned above and analysed by flow cytometry.
Statistical analysis
Results are presented as the median (1st-3rd quartile range). In case of less
than three values only the median was given. A non-parametric test was used
to determine significant differences between groups (Mann-Whitney U-test). A
p-value <0.05 was considered significant.
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Results
Immunophenotyping of the
nuclear cell population after
enzymatic digestion (starting
cells)
After enzymatic digestion and cen-
trifugation the yield of cells from
subcutaneous fat tissue was
1.0±0.1 x106/g fat (n=4). Of these
starting cells 39 (31-47) % (n=4)
were EC, as determined by their
CD31-expression, 2% were
macrophages, as determined by
their CD14-expression and all others
fibroblast-like cells, as determined
by their F11-expression.14
When the cells were stained with
CD34 in combination with the above
mentioned antibodies, we found that
besides MVEC, most of the contami-
nating cells also stained with anti-
CD34 (figure 1). The intensity of the
CD34-staining of the contaminating
cells was ten times less than the
intensity of the staining of the MVEC.
In addition a CD34-/F11+-population
was present.
Figure 1 
Immunophenotyping, using flow cyto-
metry, of starting cells, double-stained
with anti-CD34-PE (vertical) and with
anti-CD31-F (A), anti-F11 (B) and anti-
CD14 (C), visualized with a F-labeled
secondary antibody (horizontal).
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Enrichment of MVEC
1. F11/CD14-depletion of fibroblasts and monocytes
After depletion with F11-/CD14-coated Dynabeads®, 61 (56-65) % of the start-
ing cells ended up in the waste fraction, and 40 (35-44) % in the enriched frac-
tion (n=4).
Of enriched cells, the purity after isolation was 71 (70-71) % (n=4), significant-
ly higher than that of the starting cells (p=0.018). The purity after culture was
93 (93-94) % (n=4), significantly higher than that of the starting cells
(p=0.021). The recovery of EC was 73 (60-89) % (n=4), not statistically differ-
ent from the maximum possible recovery (p=0.219) (figure 2).
The lost number of EC in the waste fraction was 30 (23-35) % (n=4).
2. CD34-positive selection method from Miltenyi
After CD34-positive selection with the method from Miltenyi, 15 (11-15) % of
the starting cells ended up in the waste fraction, and 20 (18-25) % in the
enriched fraction (n=3).
F11/CD14 Miltenyi Nexell
0
25
50
75
100
purity after isolation
purity after culture
recovery
cell isolates
%
Figure 2
Purity after isolation, purity after culture, and recovery of the enriched cells obtained with the
F11/CD14-depletion method, the CD34-positive selection method from Miltenyi and the CD34-
positive selection method from Nexell .
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The purity of the enriched fraction after isolation was 32 (30-36) % (n=3), not
statistically different from the starting cells (p=0.480). The purity after culture
was 51 (30-54) % (n=3), not statistically different from the starting cells
(p=0.858) (figure 3). The recovery was 19 (15-21) % (n=3), significantly lower
than the maximum possible recovery (p=0.019) (figure 2).
The loss of EC in the waste fraction was 0.5 (0.25-0.75) % (n=2).
Purity after culture could not be further improved by changing the amount of
antibody added, nor with the direct selection technique using CliniMACS®,
nor with the ‘double positive selection’ or with the ‘positive selection in sensi-
tive mode’ program (table 1).
Table 1
part of method initial conditions variations purity after purity after recovery
isolation (initial culture (initial (initial
value 32%)* value 51%)* value 19%)*
antibody/ 100 µl 5 µl 107 83 119
4.106 cells 50 µl 105 76 116
200 µl 107 102 (94-103) 104
beads indirect method direct method 100 73 115
separation positive selection double positive 93 (92-124) 75 (75-90) 88 (57-90)
selection
positive selection 113 47 110
in sensitive mode
* the initial values were set as 100%
CD34-positive selection method from Miltenyi: Variations towards the amount of antibody, selection
technique and separation program, used initially, were investigated (first column: part of method).
The initial conditions consisted of 100 µl antibody/4x106 cells, the indirect selection technique, using
antibody and beads separately, and the ‘positive selection’ program (second column: the initial
conditions). In the third column the different variations performed with respect to the initial condi-
tions are described. Purity after isolation and culture and recovery of the enriched fractions obtained
with the different variations were calculated as a percentage of the results obtained with the initial
conditions (fourth to sixth column).
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3. CD34-positive selection method from Nexell
After CD34-positive selection with the method from Nexell, 24 (22-26) % the
starting nucleated cells ended up in waste fraction 1, 66 (64-67) % in waste
fraction 2, and 12 (11-12) % in the enriched fraction (n=4).
The purity of the enriched fraction after isolation was 87 (84-89) % (n=4), sig-
nificantly higher than that of the starting cells (p=0.020) and significantly high-
er than that of the cells obtained with the F11/CD14-depletion method
(p=0.017). The purity after culture was 86 (85-89) % (n=4), significantly higher
Figure 3
A. Left: Starting cells. Right: MVEC enriched with the CD34-positive selection method from
Nexell (magnification, x 60).
B. Left: Flow cytometry of starting cells, double-stained with anti-CD34-PE (vertical) and with
anti-CD31-F (horizontal) (figure 1). Right: Flow cytometry of MVEC enriched with the CD34-posi-
tive selection method from Nexell, double-stained with anti-CD34-PE (vertical) and with anti-
CD31-F (horizontal).
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than that of the starting cells (p=0.021) and not statistically different from the
cells obtained with the F11/CD14-depletion method (p=0.059). The recovery
was 24 (23-27) % (n=4), significantly lower than the maximum possible recov-
ery (p=0.014) and significantly lower than the recovery obtained with the
F11/CD14-depletion method (p=0.021) (figure 2).
The loss of EC in the waste fraction 1 was 12 (10-15) % (n=4). The loss of EC
in the waste fraction 2 was 39 (23-55) % (n=4).
The cultured enriched cells showed the classical EC morphology in contrast
to the fibroblast-like morphology of the cultured nucleated starting cells (figure
3a). Flow cytometry using a double staining with CD31 and CD34 showed that
the large population of CD31-negative cells, present in case of the starting
population had disappeared after enrichment (figure 3b).
Recovery and purity could not be increased simultaneously by changing the
amount of antibody, the amount of beads or the concentration of beads dur-
ing incubation, nor by using smaller amounts of release peptide, or undiluted
release peptide. The results of the indirect method were comparable with the
results of the direct method using CD34-precoated beads. Higher amounts
Figure 4
Left: Flow cytometry of HUVEC, double-stained with anti-CD34-PE (vertical) and with anti-CD31-
F (horizontal). Right: Flow cytometry of HUVEC double stained with the same antibodies after
incubation with collagenase for 30 min at 37° C, under continuous vigorous shaking. 
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release peptide, more diluted release peptide or two cycles with release pep-
tide resulted in an increased recovery together with an equal purity (table 2).
The effect of collagenase treatment on the expression of EC
markers
Incubation of HUVEC with collagenase, under the same circumstances as
used for the enzymatic fat digestion, resulted in a reduced amount of cells that
stained positive for CD31 and CD34. The mean fluorescent intensity of
HUVEC, without collagenase pre-treatment, was 86 relative units for CD31 and
Table 2
part of method initial conditions variations purity after purity after recovery
isolation (initial culture (initial (initial
value 87%)* value 86%)* value 24%)*
antibody/ 2 µg 0.2 µg 34 - 20
107 cells 0.4 µg 72 47 73
4 µg 97 101 67
12 µg 96 (90-99) 93 (30-105) 70 (64-90)
beads 10 beads/cell 5 beads/cell 104 (93-116) 104 (54-195) 70 (62-94)
107 beads/ml 2.107 beads/ml 96 (92-99) 98 (90-105) 86 (75-94)
indirect method direct method 101 (96-104) 43 (31-83) 67 (65-70)
release 50 + 75 µl 25 + 100 µl 98 (95-101) 100 (96-110) 86 (82-109)
peptide + 50 µl pure 100 (91-101) 89 (87-90) 100 (97-121)
RPMI/1% 50 + 150 µl 105 98 117
FBS 100 µl pure 82 85 105
100 + 150 µl 106 (103-108) 99 (97-101) 118 (118-138)
50 + 75 µl, 2x 102 98 120
* the initial values were set as 100%
CD34-positive selection method from Nexell: Variations towards the amount of antibody, amount
and concentration of beads, selection technique, amount and dilution of release peptide, and num-
ber of cycles with release peptide, used initially, were investigated (first column: part of method).
The initial conditions consisted of 2 mg antibody/107 cells, 10 beads/cell, 107 beads/ml, using the
indirect selection technique, and 50 ml release peptide + 75 ml RPMI/1% FCS per 107 beads,
using one cycle (second column: initial conditions). In the third column the different variations per-
formed with respect to the initial conditions are described. Purity after isolation and culture and
recovery of the enriched fractions obtained with the different variations were calculated as a percen-
tage of the results obtained with the initial conditions (fourth to sixth column).
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39 relative units for CD34. The mean fluorescent intensity of HUVEC, after col-
lagenase pre-treatment, was 29 relative units for CD31 and 31 relative units for
CD34.
Discussion
In the setting of peripheral arterial occlusive disease, EC seeding has been
introduced to improve the patency of prosthetic vascular grafts.2,3 Fat tissue
can be used as a source of EC, MVEC. The yield of MVEC from fat is high
enough to avoid in vitro culture before seeding.9-13
In previous work we have found that after the isolation of EC from fat tissue,
non-EC are still present in the isolates.14 These cells contribute to the develop-
ment of intimal hyperplasia observed after seeding.15 Using a combination of
F11- and CD14-coated Dynabeads® to deplete fibroblast and monocytes/
macrophages, isolates from fat tissue can be purified further. A recovery over
70% and a purity over 90% are reached.14 We showed that reduction of non-
EC contamination of MVEC seeded grafts decreases thrombogenicity and inti-
mal hyperplasia in vitro.16 Unfortunately, F11 is not produced according to
GMP regulations and thus cannot be used to perform a clinical trial with
patiens.11
Here we investigated whether CD34-positive selection is suitable as an alter-
native approach for purification of MVEC, using the CD34-positive selection
methods from Miltenyi18 and Nexell.19 CD34-selection of haematopoietic pro-
genitor cells with both methods has been used on a large scale in haemato-
logy-oncology with good result.24
We found that besides MVEC, also the contaminating myofibroblasts
expressed CD34. However, the expression of CD34 was ten times as weak as
the CD34-expression of MVEC. Furthermore the contaminating macrophages/
monocytes stained positive with anti-CD34. CD34 is known to be expressed
on some fibroblasts.25-27 Monocytes can be weakly positive for CD34 in case
of an insufficient block of the Fc-receptor.
With the selection method from Miltenyi, existing of a CD34 antibody and
biodegradable beads, we could not increase the purity of MVEC. However,
with the Nexell-method, existing of a CD34 antibody, beads and release pep-
tide, to detach beads from the cells, enrichment of MVEC was achieved. The
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purity was similar to that of our previously published F11/CD14-depletion
method, however the recovery was only one third.
The purity obtained with the method from Miltenyi was not increased com-
pared to the starting cells. The recovery was significantly lower than the maxi-
mum possible recovery. The failure to obtain an increase in purity might be
the binding of anti-CD34 not just to the MVEC but also to the contaminating
cells. The majority of cells disappeared. These cells were not found again in
the ‘waste fraction’, and might have stuck to the selection column.28
The explanation that enrichment of MVEC could, on the other hand, be
obtained with the CD34-positive selection method from Nexell might be that
the actual enhancement of MVEC-purity is performed by release peptide.
It was unexpected that the EC much better released from the beads than the
contaminating cells. Flow cytometry with the anti-CD34-antibody from B&D,
showed that EC expressed ten times as much CD34 on their surface than con-
taminating cells. The affinity of the anti-CD34 antibody from the Nexell method
for CD34 on EC, however, was much lower than for CD34 on the contaminat-
ing cells. The existence of different CD34 epitopes with different specific anti-
bodies is known. The distribution pattern of the different CD34 epitopes differs
per type of cell.29 The following antibodies were used for Nexell method, the
Miltenyi method and flow cytometry, 9C5, Qbend10 and HPCA-2 (clone
8G12), respectively. No data on the specificity of these antibodies for EC or for
the contaminating cells are available at this moment. One publication, how-
ever, showed reactivity of the Qbend10, used for the Miltenyi method, for
HUVEC and kidney and breast capillary endothelium.30 But unfortunately, the
Miltenyi method did not yield the wished results. In addition to a different affi-
nity of the antibodies themselves, a dense glycocalix present on EC but not on
fibroblasts might play a role in the affinity of the antibody for CD34.31
The purity obtained with the Nexell-method was 86%, similar to that obtained
with the F11/CD14-depletion method. The recovery obtained with the CD34-
selection method of Nexell was only one third of the recovery obtained with
the F11/CD14-depletion. We showed that with the selection method from
Nexell part of the EC remained in fraction 1 and 2. So a part did not bind to the
beads and a part did bind to the beads but did not release with release pep-
tide.
An explanation for the loss of EC in ‘waste fraction 1’ with the Nexell method
might be the reduction of EC-specific antigens from the surface because of
enzymatic digestion.32 After culture to confluence the amount of CD31+-EC
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and the amount of CD34+-cells in ‘waste fraction 1’ increased significantly
compared to the situation immediately after isolation (results not shown).
Increase of CD31+-EC occurred whereas the double time of EC is longer than
that of fibroblasts (Clonetics, Biowhittaker). Using the F11/CD14-depletion
method, immediately after enrichment the percentage of CD31+- EC in the
enriched fraction was only 71%. After two days of culture, the amount of
CD31+- EC was 92%. Temporary loss of antigen expression during isolation
must have occurred, as the double time of EC is longer than 2 days and
longer than that of the contaminating fibroblasts. In case of F11/CD14-deple-
tion temporary loss of EC-specific antigens is not a problem since selection is
not based on EC-markers. In case of CD34-positive selection of EC, on the
other hand, temporary loss of CD34-expression results in a lower yield after
selection.
Collagenase treatment of HUVEC, supported the suggestion that enzymatic
digestion induces loss of EC markers.
Another part of the EC remained in the ‘waste fraction 2’. We have tried to find
the optimal balance for selection of EC. Most ideal is to add enough antibody
and beads for all cells to bind and add sufficient amount of release peptide for
only the EC to release from the beads. We obtained the best proportion of
yield and purity for EC with 2 µg antibody/107 cells, 10 beads/cell, and 107
beads/ml. Release peptide should be diluted and be at least 50µl per 107
beads.
Under certain circumstances the results of a direct technique, using beads
pre-coated with antibody, are better than of the indirect technique, using anti-
body and beads separately. The binding of beads might be hampered by are
steric hindrance due to crowding of monoclonal antibodies on the cell surface.
The binding of beads might also be hampered by a configuration of the mono-
clonal antibody molecule that is poorly-accessible to the anti-immunoglobulin
immobilized on the bead.33 We showed in our study that the results of the indi-
rect technique were not worse than the results of the direct technique. The
advantage of the indirect technique above the direct one is that beads do not
have to be pre-coated, which reduces the amount of necessary steps and so
the risk of infection.
CD34-selection has been used for the isolation of EC-precursors from
peripheral blood.34 To our knowledge the use of monoclonal anti-CD34 coated
Dynabeads® for the selection of human MVEC has been only described in
134
one abstract.35 As no technical information was given in the abstract, we could
not compare the results.
In this pre-clinical study we did not use clinical grade material for all steps. For
a clinical study clinical grade culture media and collagenase, allowed for clini-
cal trials, will be used. Furthermore, FBS will be replaced for autologous
serum. The MPC, used for the separation of nonbound cells and cells bound
to Dynabeads®, will be substituted for the automatically clinical grade
Isolex300i®. The yield might be further increased using the Isolex.
The possibility to obtain purified MVEC with a clinical grade system paves the
way for the performance of a clinical trial to test the effect of seeding purified
cells on vascular grafts.
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Background
Prosthetic bypass grafts and deendothelialized surfaces after percutaneous
transluminal angioplasty (PTA) or endarterectomy occlude more easily than
vein bypasses. Reasons for occlusion are thrombus formation and intimal
hyperplasia.1-4 A major cause for thrombus formation and intimal hyperplasia
seems to be the absence of an intact monolayer of endothelial cells (EC), with
anti-thrombogenic and pro-fibrinolytic properties and properties against inti-
mal hyperplasia.5
In the past, successful results were obtained with venous EC seeded on the
luminal surface of prosthetic grafts in animal experiments6,7 as well as patient
studies.8-12 A disadvantage was the limited yield, so that cell culture was ne-
cessary.13-15 For this reason, other cell-types and -sources have been
explored. The past ten years our group has performed research in this field.
Pronk and Verhagen et al investigated whether mesothelial cells were suitable
as an alternative cell type.16 Although promising in vitro results were
obtained,17-22 final in vivo experiments showed that mesothelial cells did not
have the expected anti-thrombogenic and fibrinolytic properties,23 nor inhibi-
ted the development of intimal hyperplasia.24
Fat tissue turned out to contain large amounts of microvascular endothelial
cells (MVEC). Via enzymatic digestion and centrifugation a sufficient yield was
obtained to make cell culture unnecessary.5,25
Hedeman Joosten et al obtained promising in vitro results.26,27 De cells kept
their anti-coagulant properties in culture, also after seeding on prosthetic
grafts.26 They appeared to be scarcely pro-coagulant if perfused with whole
blood27 and resistant against physiological shear stress.
In vivo studies in dogs showed that MVEC seeded grafts had a smooth non-
thrombogenic surface, whereas sham seeded grafts showed activation of
coagulation.28-31
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Introduction
The results of MVEC seeding in human studies have been unsatisfactory until
now.32-35 Progressive concentric intimal thickening, sometimes together with
thrombosis was found in the seeded grafts.32,34,36 Intimal hyperplasia was also
found when the grafts were tested in animals, but not to the same extent as in
humans.6,7,31 In contrast to cultures of venous EC in vitro cultures of MVEC
were found to overgrow with fibroblasts quickly.37-40
We found that intimal hyperplasia after seeding of fat-derived MVEC on pros-
thetic grafts in a dog model consisted of myofibroblasts originating from the
transplanted cells.41 We also found an increased development of intimal
hyperplasia after seeding of fat derived MVEC on damaged native arteries in a
rabbit-model compared to the non-seeded situation.42
Based on these results, we postulated that an improved purity of the MVEC
could reduce neointimal formation. We developed a purification method of
human MVEC. With antibody-coated magnetic spheres, the contaminating
cells (fibroblasts and macrophages) were removed.43 In vitro studies showed
that thrombogenicity of purified cells was increased and seeding related inti-
mal hyperplasia decreased compared to nonpurified cells.44,45
The ultimate step to prove whether seeding of purified cells improves the
results of prosthetic grafts and deendothelialized surfaces, is to perform a clin-
ical trial. For the performance of a clinical trial, two conditions must be fulfilled.
First, the products used for the isolation must be produced according to good
manufacturing practice (GMP) or must have been used in earlier clinical stu-
dies. Second, a model should be taken in which thrombogenicity and intimal
hyperplasia are frequent events, and in which the risk for the patient in case
the cells do not perform well is acceptable.
All products that we use for isolation and purification of MVEC from fat tissue
are produced according to clinical grade regulations or have been used in
earlier clinical studies, except one of the antibodies to select the contamina-
ting cells with. The production of a clinical grade antibody costs at least
100.000 euro’s. We therefore tested another method used for the isolation of
stem cells to be applicable for the purification of fat derived MVEC. The EC are
selected with antibody-coated magnetic spheres. The purity was the same as
with the first method. The yield was lower, but still high enough to perform a
clinical study with an acceptable amount of fat tissue.46
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To study the effect of seeding purified fat derived MVEC, we have chosen arte-
riovenous dialysis grafts (AV grafts). Similar research with venous EC has
shown promising results.10
Haemodialysis shunts are used frequently for haemodialysis-access.
Preferably as a first step a vein is anastomosed to an artery in the forearm
(cimino fistula). In case the procedure fails, an interposition with a prosthetic
graft (expanded Polytetrafluoroethylene (ePTFE)) can be made between the
brachial artery and the ante-cubital vein (AV graft).
At this moment, the primary and secondary patency rates (*: paragraph 9) of
AV grafts are respectively only 40% en 60%, after one year respectively.47,48
The failure of the vascular access is the most frequent cause of an admission
to the hospital of patients with terminal renal insufficiency. The expenses due
to occlusion of the graft are more than 750 million dollars a year. Effective
strategies, which can prevent stenosis and for that reason thrombotic compli-
cations of grafts, could reduce the amount of surgical and radiological inter-
ventions. Until now, no controlled intervention, nor medical, nor surgical or
radiological, has demonstrated to be able to reduce the stenosis rate.49,50.
Our hypothesis is that seeding of an AV graft with autologous purified fat
derived MVEC will result in a decreased development of intimal hyperplasia
and subsequently in an increased patency.
Aim of the study
Purified fat tissue derived MVEC have not been investigated in a clinical study
before. The aim of this study is to asses the following features of the implanta-
tion of an AV graft seeded with autologous purified fat derived MVEC in
patients:
Safety: Can liposuction, isolation, purification, and seeding of MVEC, and
implantation of a MVEC seeded AV graft be performed safely?
Feasibility: Can we provide a patient with an AV graft seeded with autologous
purified fat derived MVEC that stay present also after implantation of the graft?
Effectiveness: Does the presence of a layer of autologous purified fat derived
MVEC result in a better outcome of AV grafts?
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Patient Nephrology
Patient is examined by: 
•vascular surgeon
•plastic surgeon
•main researcher
Agreement with inclusion?
Inclusion criteria:
•end-stage renal failure requiring dialysis;
•eligible for a prosthetic haemodialysis shunt.
Exclusion criteria:
•limited posibilities for construction of a shunt;
•known thrombotic complications (venous thrombo-
embolism, acute arterial occlusion);
•insufficient amount of subcutaneous fat tissue;
•a severe risk for or due to infection;
The nephrologist in attendance asks the 
patient for participation to the ECLIPSE-study
Agreement with inclusion?
Consultation with anaesthetist
Agreement with inclusion?
Planning of the interventions by VP-manager 
surgery, co-ordinator of planning and head of 
anaesthesia ‘day-treatment’
yes
no
yes
present absent
yes
no
no
Figure 1
Flow diagram of patient inclusion in ECLIPSE-study.
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Selection criteria (inclusion- and exclusion-
criteria)
Inclusion-criteria:
- End-stage renal failure requiring dialysis;
- Eligible for a prosthetic haemodialysis shunt.
Exclusion-criteria:
- Limited possibilities for construction of a shunt (i.e. due to the shortage of
vessels for the anastomoses);
- Known thrombotic complications (venous thrombo-embolism, acute arterial
occlusion);
- Insufficient amount of subcutaneous fat tissue;
- A severe risk for (f.e. as a result of medication) or due to (f.e. as a results of
heart valve deficiency) infection (figure 1).
Material and methods
Human autologous serum
Material: table 1.
Method: From each patient 60 ml of blood is taken and collected in 10 ml
coagulation tubes. As soon as the blood has coagulated, the serum on top will
we removed and collected in a sterile tube. Subsequently the serum is cen-
trifuged (5 min, 5000 rpm) to remove the remaining blood cells.
Table 1
Tools:
10 ml blood coagulation tubes
Vacume blood puncture system
Stowage tape
50 ml Falcon tubes
Materials human autologous serum.
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Liposuction
Material: table 2.
Method: Subcutaneous fat tissue, used as a source of MVEC, is obtained via
liposuction. Liposuction is a surgical technique to remove subcutaneous fat
tissue using suction forces. For the technique we will use, tumescent liposuc-
tion, liposuction fluid with diluted anaesthetics and a vasoconstrictor is inject-
ed. The fluid induces a thickening of the fat layer, so that the canula remains in
the right layer. Furthermore, the amount of blood loss is reduced and local
anaesthesia is induced.51
Liposuction will occur under local anaesthesia 4 - 4‘hours before the implan-
tation of the prosthetic shunt. An amount of 110 ml of fat tissue is removed
from the belly, bottom, thighs or hips, dependent on the fat distribution of the
patient.
Isolation and purification of MVEC
Material: table 3.
Method: The entire procedure is performed in a closed system of sterile trans-
fusion bags connected to each other in the Gene and Cell Therapy Facility,
University Medical Center, Utrecht. After removal of the liposuction fluid, via
centrifugation (15 min), the fat is mixed with an equal volume of PBS/0,4% w/v
collagenase/0.4% w/v HAS. PBS and the collagenase solution in PBS are pre-
Table 2
Reagents:
Liposuction fluid:
- lidocaine (0.5-1.0 g/l)
- epinephrine (1.0 mg/)
- sodiumbicarbonate  (12.5 Eq/l)
- physiological salt solution (0,9% NaCl)
Tools:
Liposuction cannula (3‘mm)
Sterile Bag
Materials liposuction.
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pared by the pharmacy department, University Medical Center, Utrecht, under
supervision of Dr. Ph de Vries, hospital pharmacist, head of production. HAS
is added just before start of the isolation. Incubation is performed for 30 min,
followed by centrifugation during 10 min (1200 rpm). After centrifugation, 3
layers are formed: fat- and connective tissue on top, supernatant with rem-
nants of blood cells and connective tissue in the middle, and a cell pellet on
the bottom. The top two layers (fat and supernatant) are removed. The pellet
is resuspended in medium 199, centrifuged again (5 min, 1100 rpm) and
resuspended in medium RPMI/1% HAS.5
A sample of the purified cells is taken for counting. As soon as the amount of
cells is known the necessary amounts of CD34 antibody, sheep anti-mouse
Dynabeads® and PR34+ can be determined for the additional purification
step. First, the antibody is added. Incubation is performed for 10 min at 4° C
on a rollerbank. The Dynabeads® are added and incubation is continued for
another 25 min. Separation is performed with the Isolex 300i® and repeated
two times. PR34+ is added to the bound cells. Incubation is performed for 30
min, again at 4° C on a rollerbank.46 Bound and nonbound cells are separated
and the procedure is repeated twice. The initially bound cells that detach with
PR34+ are the purified MVEC. The purified MVEC are centrifuged and resus-
pended in the necessary volume of medium 199/15% HAS for sodding the
prosthetic grafts. The entire procedure, including the seeding, takes about 3‘ -
4 hours and is performed according to GMP criteria as evaluated by Dr. ICM
Slaper-Cortenbach.
Collagenase does not have a clinical grade. In the past, cells isolated using
collagenase treatment and centrifugation without purification have been seed-
ed on vascular grafts in clinical studies. No adverse reactions towards collage-
nase have been described.10,32-34,36,52 This product has been assessed by Dr.
ICM Slaper-Cortenbach, head of the Gene and Cell Therapy Facility and Dr. A
van Dijk, hospital pharmacist, final responsible person for the release of gene
therapeutics. They determined that collagenase is completely removed after
the digestion procedure. They requested to use the same collagenase as
Meinhart et al used for their clinical study with venous EC in 153 patients.52
They stipulated as a condition the determination of endotoxin content for
every batch.
Both medium RPMI and 199 have a ‘certificate of analysis’ and are also
approved for clinical application by Dr. Wavelmans, hospital pharmacist,
University Medical Center Leiden, The Netherlands.
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The kit we use for the purification of MVEC has been produced according to
GMP criteria. Similar methods, with Dynabeads® and antibodies have been
applied in many clinical studies. Examples of these clinical studies are the
removal of T cells53 and selection of CD34 positive stem cells from bone mar-
row (department of Immunology, University Medical Center Utrecht, The
Netherlands, protocol S-AMI085). Adverse reactions to beads or antibody
Table 3
Reagents:
Phosphate buffered saline (PBS) (Dept. of pharmacy, UMCU, The Netherlands)
Collagenase from Clostridium Histolyticum type 2, filtered (Worthington, LakeWood, NJ, USA)
Human serum albumin (HSA) (Sanguin Blood Supply Foundation, Amsterdam, The Netherlands)
Human autologous serum (HAS)
Culture medium RPMI (Clonetics, BioWhittaker, Verviers, Belgium)
Culture medium 199 (Clonetics)
Clinical grade Isolex Stem Cell Reagent Kit (Nexell Therapeutics Inc., Irvine, CA, USA):
- mouse anti-human CD34 monoclonal antibody
- Dynabeads® M-450 anti-mouse IgG (Dynal ASA, Oslo, Norway)
- PR34+ Stem Cell Reagent Agent®
Tools:
Transfusion bags (Fresenius HemoCare, Bad Homburg, Germany)
100 mm Nylon Cell Strainer (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA)
Pasteurs pipettes
10, 200, 1000 µl pipette tips
15 and 50 ml Falcon tubes
1.5 ml Eppendorf cups
Apparatus:
Cell analyser (Haematology Analyzer Cell-Dyn 1700 (ABBOTT, Santa Clara, CA, USA))
Laminar air flow chamber
Suction pump
Pipetter
Centrifuge
Rollerbank
Automatically clinical grade Isolex 300i® (Baxter, Deerfield, IL, USA)
CO2 incubator
Materials isolation and purification of MVEC.
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remaining on top of the seeded cells have not been described, neither with
the depletion of T cells, nor with the positive selection of stem cells.
Seeding of the shunt
Material: table 4.
Method: To both ends of an ePTFE prosthetic graft with a length of 30 cm and
a diameter of 6 mm a luerlock is connected using vicryl 4-0. One of both ends
is closed and the prosthesis is filled with HAS until it becomes visible as small
drips on the outside part of the prosthetic graft.10,54 Subsequently, the other
end is closed and incubation if performed during at least one hour at 37° C.
As soon as the cells are available, the closure caps are removed from both
ends. The cell suspension is introduced in the prosthetic graft. The seeding
procedure is started. One end is occluded and a surplus of medium 199/15%
HAS (4 times the volume of the graft) is introduced in the graft under pressure.
The surplus of medium drips from the outside of the graft. The other end is
then also closed. The graft is transported to the operating room in a sterile
bottle with a small amount of medium 199.
Table 4
Tools:
EPTFE prosthetic grafts (6mm diameter, 30 cm length) (WL Gore & Associates, Flagstaff, Arizona, USA)
Luerlocks
Closure caps
Suture material (vicryl 4-0)
10, 30 and 60 ml syringes
19 G needles
Materials seeding of the shunt.
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Suturing of the shunt
Material: table 5.
Method: The brachial artery and antecubital vein are exposed. The artery is
clamped and a length incision is made. The prosthetic graft is sutured end to
side to the artery. The venous anastomosis is created in a similar fashion. As
suture material prolene 6-0 is used.
Design of the study
Ten patients are included according to the flow chart depicted in figure 1. A
shunt seeded with autologous purified MVEC obtained from subcutaneous fat
tissue is implanted. For the isolation, purification, and seeding of purified
MVEC, autologous serum is necessary. To obtain autologous serum, the day
before the operation 60 ml of blood is drawn from the patient. All patients are
subjected to a liposuction procedure.55 Under local anaesthesia, 110 ml of fat
tissue is removed. This procedure takes ‘ - 1 hour. The total duration of the
MVEC isolation procedure and the seeding of the shunt is 3‘ - 4 hours. Due to
the length of the isolation procedure, the performance of liposuction and
implantation of the shunt in one single procedure is impossible. The implanta-
tion of the shunt is performed 4 - 4‘hour after the end of the liposuction pro-
cedure. The shunt implantation is performed under regional or general
Table 5
Reagents:
Heparin
Antibiotics (Keflin)
Tools:
Seeded ePTFE grafts
Suture material (prolene 8-0)
Surgical instruments
Blood vessel clips
Materials suturing of the shunt.
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anaesthesia, dependent on the judgement of the anaesthetist (in case of car-
diovascular or respiratory disorders, preferably regional). The patient receives
one dose of antibiotics (Keflin). During the implantation the shunt is filled with
heparinized seeding medium.
The shunt is used for dialysis at least three, preferably four weeks after implan-
tation. Postoperatively, the patient is anticoagulated using Coumarin. Attempts
are made to obtain an international normalisation rate (INR) between 2,5 and
3,5. The anticoagulation is continued throughout the study period.
‘Safety’ monitoring with respect to the liposuction, the isolation, purification,
and seeding of MVEC, and the implantation of the seeded graft is performed
using clinical investigation, blood tests (the first 4 days, daily and afterwards
on demand), culture of a small amount of the isolated cells, and accurate doc-
umentation. One month after the first patient has been treated, continuation of
the study is evaluated.
‘Feasibility’ monitoring with respect to application of autologous purified
MVEC to the AV graft, the behaviour of the seeded graft in vivo, and the per-
manent adhesion of the purified MVEC to the graft is performed using determi-
nation of yield, purity, and seeding density of the purified MVEC, microscopy
of a part of the prosthesis, and observation of the graft after implantation and
during dialysis.
‘Effectiveness’ monitoring of the seeded AV graft is performed using pressure-
and flow-measuring,55 and angiography56,57 the first month and afterwards 3-
monthly. In case of an failure an immediate revision (thrombectomy, PTA or
surgical) is scheduled.
Endpoints: Safety monitoring
Liposuction
Pain: The liposuction fluid contains lidocaine, which serves as a local anaes-
thetic. It is possible that the anaesthetic effect is insufficient. Normally, the pain
can be treated very well with morphine intravenously (i.v.), in some cases
completed with diclophenac i.v.
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The first 24 hours, for every patient, the amount of analgetics used and possi-
ble sleeping problems are noted. Pain is evaluated using the ‘Visual
Analogous Pain scale’, every 3 hours during 12 hours and afterwards daily as
long as pain persists.58-60
Severe complications: Serious complications due to liposuction are rare51,61-
64 depending on the experience of the surgeon (0,1%) (table 6).51 Serious
complications usually occur in the first days after liposuction.61,65-67 The com-
plication ‘fluid excess/lidocaine intoxication’ is further described below (*).
The risks for thrombosis/thrombo-embolism are reduced in a patient with end-
stage renal failure due to uremia and a low haemoglobin-content.
Table 6
Severe complications:
Deep venous thrombosis 0.033%
Lung- or fat embolism <0.007%
Necrosis of the skin of the area involved 0.031%
Hypovolemic shock  <0.007%
Fluid excess, pulmonary edema <0.00001% in a series of more than 15.000 patients - 0.9% in a smaller
series in which only large volumes of liposuction fluid were used (up to 15 litres) (*)
Lidocaine intoxication <0.007% (*)
Perforation of the abdominal wall 0.005%
Mortality <0.007% (local anaesthetics) - 0.01% (general anaesthetics)
Less severe complications:
Haematoma <1%, seroma 2.6%, both 0.17%
Edema 1.4%
Permanent damage of a sensory nerve 0.033%
Hypesthesia 2.6%
Abnormal extended ecchymosis 0.033%, duration more than 6 weeks 0.013%
Temperature >37.8° C 0.052% (*)
Hyperpigmentation 0.039% -  <1%
Excessive postoperative pain 0.059%, <1%
Infection 0.35%, <1% (*)
Disappointing esthetical result:
Induration 0.26%
Difference between left and right
Complications and disappointing results of liposuction.
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Less severe complications: The percentage of less severe complications is
of liposuction is somewhat higher (table 6).51,62,66 The complication ‘infection’
is further described below (*).
Normally, the area of liposuction is swollen and painful during 1 to 2 weeks.51
The risks for a bleeding in a patient with end-stage renal failure are increased
due to uremia and a low haemoglobin-level.
Disappointing esthetical result: The esthetical result may be disappointing
(table 6).62,66 To prevent a disappointing esthetical result, the liposuction is
performed by an experienced plastic surgeon.
A reporting list is filled out during the first week, daily, and afterwards during
two months, weekly. On this list the presence of the above mentioned severe
and less severe complications, and disappointing results are reported.
(*) Fluid excess/Lidocaine intoxication: Part of the liposuction fluid (with
lidocaine and adrenaline) can end up in the circulation. Due to an excess of
lidocaine in the circulation, fluid overload and lidocaine intoxication can
occur.65-68 These signs have only been described after the removal of amounts
of fat, much larger than in this study. The risk for a lidocaine intoxication is not
increased in patients with end-stage renal failure. Lidocaine is metabolised in
the liver.69 For safety the following measures are taken and checkups are per-
formed:
* Prevention of fluid excess: 
- Weighing of the patient pre- and postoperatively. When necessary dialysis
before shunt implantation is performed;
- Restricted postoperative i.v. fluid administration68.
Table 7
Blood level: Symptoms:
3-6 µg/ml Subjective toxicity (dizziness, euphoria, paresthesia, restlessness, drowsiness)
5-9 µg/ml Nausea, vomiting, tremors, confusion, ear ringing, irritation, psychosis, muscle fascicula-
tions
8-12 µg/ml Epilepsy, cardio-respiratory depression
12 µg/ml Coma
20 µg/ml Respiratory arrest
26 µg/ml Cardia arrest
Symptoms of a lidocaine  intoxication in relation to the blood level.
153
ch
a
p
te
r 
9
E
C
L
IP
S
E
-s
tu
d
y
*Prevention of lidocaine intoxication (table 7)
- Reduction of the total dose of lidocaine added by the plastic surgeon (in the
liposuction fluid) and the anaesthetist to a maximum of 35 mg/kg for both
interventions together65,68;
- Determinations of the liver functions. Adaptation of lidocaine dose when nec-
essary;
- Caution for interactions with other medications that reduce the liver perfusion
or otherwise reduce the lidocaine metabolism (cimetidine, β-blocking, pheny-
toine and procainamide).
* Precise documentation of the following parameters during 24 hours
- Liver functions pre-operatively;
- Medication which reduces liver perfusion or otherwise decreases the lido-
caine metabolism;
- Total volume of liposuction fluid added;
- Total volume of i.v. infusion (during and after the liposuction and during and
after the shunt implantation);
- Need for dialysis after liposuction;
- Total amount of lidocaine added (during the liposuction and during the shunt
implantation);
- Measurement of blood pressure each hour for six hours and afterwards every
three hours until discharge;
- Lidocaine blood level:
- One hour after the liposuction;
- 12 hours after the liposuction, the moment the maximum level is obtained 
(maximum acceptable level 2 µg/ml65);
- Checking for symptoms of lidocaine intoxication (during and after the lipo-
suction and during and after the shunt implantation) (table 7).65,70
(*) Contamination and infection
The following measures are taken to prevent and document infection:
- Daily inspection of the liposuction area (wound culture when necessary) as
long as the patient is in hospital;
- Daily blood tests (leucocyte count and cell differention, C-reactive protein,
haemoglobine, thromobcytes) as long as the patient is in hospital, afterwards
when indicated (fever);
- Regular measurement of temperature. In case >38,5° C: a blood-test and -
culture
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Isolation, purification, and seeding of MVEC
Contamination: During the isolation and purification of MVEC from fat tissue,
contamination can occur which might be followed by infection. After long term
culture of MVEC we sporadically saw infections. After implantation of MVEC in
a laboratory animal, we did not see any problems of infection.
The following preventive measures are taken:
- The whole procedure is performed by two persons: one performs the isola-
tion, the other one watches, monitors and reports. Points in time on which dif-
ferent steps start and end are documented accurately;
- Product numbers, lot numbers, utmost sale data and packing material of the
reagents, disposable and non-disposable material are monitored and reported
accurately;
- All actions are performed in a closed system of sterile transfusion bags in a
clean air facility, for cell- and gene therapy, according to GMP guidelines;
- A small amount of cells is used for ‘surveillance culture’. In case an infection
occurs the surveillance culture can be used to determine the pathogen
involved and the suitable antibiotics.
Implantation of the seeded AV graft
Contamination and infection: The largest risk after shunt implantation is that
of infection. This is also true for non-seeded AV grafts. Infection can be a rea-
son for removal of the shunt. Therefore, the following measures are taken:
- One dose of antibiotics preoperatively (Keflin);
- And the measures mentioned for contamination and infection of the liposuc-
tion area.
Endpoints: feasibility
Isolation, purification, and seeding of MVEC
Yield: The yield of MVEC can be lower than on average. In case the yield is
too low, or the removal of a surplus of fat is impossible, the optimal seeding
density is not reached. But also after seeding of smaller densities of cells good
results have been reported.
The exact yield of cells is registered accurately.
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Seeding density: During isolation MVEC can be lost (spill, problems with
reagents, problems with apparatus). Until now, this has never occurred. For
prevention and documentation of spill the following measures are taken:
- The whole procedure is performed in a closed system;
- The whole procedure is performed by two persons: one performs the isola-
tion, the other one watches, monitors and reports. Points in time on which dif-
ferent steps start and end are documented accurately;
- Product numbers, lot numbers, utmost sale data and packing material of the
reagens, disposable and non-disposable material are monitored and reported
accurately;
- The exact seeding density of the graft is documented.
In case all MVEC are lost, a non-seeded shunt is implanted.
Purity MVEC: Using subcutaneous fat of healthy persons after isolation and
purification, MVEC with a purity of 90% were obtained. Per patient included in
this clinical study, the exact purity of isolated and purified MVEC is determined
after the isolation using flow cytometry analysis.
Seeding: The attachment of the cells after seeding is evaluated by histology
and/or scanning electron microscopy (SEM) of a small part of the AV graft.
Behaviour of the seeded graft in vivo
Suitability for surgical implantation: In the animal study, we performed, the
MVEC seeded graft was impermeable to blood, like the non-seeded shunt.
This study must show whether the AV graft seeded with human autologous
purified fat derived MVEC is also impermeable to blood.
Suitability for dialysis: Even when a AV graft is perfectly seeded and
implanted without any problems, the most important question is whether the
shunt can be used for dialysis. Dialysis could be hampered by the failure of
ingrowing of the prosthesis. Furthermore, the seeding process could induce
seroma formation.
Permanent adhesion of purified MVEC to the graft
The ultimate feasibility study would be the investigation whether purified
MVEC stay present on the AV graft after a certain period of follow up. At this
moment, the presence of EC after follow up can only be demonstrated using
microscopy (histology or SEM). We realize that it is impossible to obtain mate-
rial of a patent shunt, but in any revision we will try to obtain material of the
shunt.
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Endpoints: effectiveness
Thrombogenicity or neointimal formation of the shunt is examined the first
month and afterwards three-monthly in two different ways: flow- and pressure
measurement and angiography (magnetic resonance angiography (MRA) is
optional).
Flow- en pressure measurement
Flow measurement is performed as mentioned above. Arterial and venous
blood pressure are measured with the pump stationary, so that resistances
can be determined.71
Angiography
Angiography is the gold standard. This examination is performed in associa-
tion with the dialysis. The graft, venous and arterial anastomoses, the venous
system up to the subclavian vein are visualised. A reduction of the luminal
diameter is determined using each time the first angiogram made.
MRA
MRA includes a 2-dimensional flow technique in the axial, a 3-dimensional
phase constrast technique in the coronal plane and a quantitative flow meas-
urement. Using these data, the thickness of the vessel wall can be measured.
Possible disadvantages of the follow up investigations are:
- Adverse reactions due to the contrast fluid used for angiography are rare.
These adverse reactions, like headache and nausea are usually mild and tran-
sitory.
- The noise the MRA device makes can be irritating. The patient obtains there-
fore the possibility to obtain a headset and to listen to music.
- The MRA investigation uses a strong magnetic field. Therefore this type of
investigation cannot be used for patients with a pacemaker.
- The examinations cost extra time and sometimes the patient needs to be
punctured extra. The examinations are planned as close as possible to the
dialysis.
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A significant flow reduction is defined as a flow < 600 ml/min as measured
with flow measurement and MRA. Flow measurement seems to be a liable
predictor of the occurrence of thrombosis.72 In case of a flow < 600 ml/min
angiography is used to investigate whether a stenosis is present.72 A signifi-
cant stenosis is defined as a reduction of the luminal diameter of >/= 50%
(normally this is always the case). In case of a thrombus, a thrombectomy is
performed, in case of a thickened vessel wall a PTA or when necessary a sur-
gical reconstruction is performed.
The follow up is 1 year for each patient. Primary and secondary patency rates
are calculated. * The primary patency rate is defined as the percentage of
grafts which functions well after implantation without surgical or catheter inter-
vention. The secondary patency rate is the percentage which functions well
after intervention due to failure. Obviously, the group of patients is too small to
compare patency rates with that of non-seeded AV grafts.
Registration and randomisation of patients
The nephrologist in attendence, Prof. Dr. AJ Rabelink (nephrologist, vascular
physician), Dr. PJ Blankestijn (internist-nephrologist) or Dr. WH Boer (internist-
nephrologist) recruit patients. The nephrologist, vascular surgeon, plastic sur-
geon, main researcher, and anaesthetist discuss the possibility of inclusion of
the patient.
Collection of data and administrative
responsibilities
The forms for the collection of all data with respect to ‘safety’, ‘feasibility’, and
‘effectiveness’ monitoring are drawn up and collected by Drs. JMM Heyligers,
physician-investigator, department of Vascular- and Transplantation Surgery
and Thrombosis- and Haemostasis Laboratories, department of Haematology.
He will also analyse the data.
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Since the late seventies research on thrombogenicity and intimal hyperplasia
of prosthetic grafts and de-endothelialized surfaces has been focused on
seeding autologous EC.1,2 Initially, vein derived EC were used. But soon it
became clear that a subconfluent cell coverage of grafts was not enough. For
confluent coverage larger amounts of cells were necessary which required cell
culture techniques.3-5
Subcutaneous fat tissue has been suggested as an alternative source of EC,
so called microvascular endothelial cells (MVEC). The yield is abundant, thus
cell culture is no longer necessary. The initial results were very promising.6,7
However, papers concerning the occurrence of seeding-related intimal hyper-
plasia8-11 and the presence of contaminating cells10,12-16 have raised questions
about the suitability of fat derived MVEC. 
This has led to the following objectives for this thesis:   
- To establish incidence, composition, and progression of intimal hyperplasia
after seeding of MVEC in an in vivo canine model, and to study whether seed-
ed cells contribute to the development of intimal hyperplasia (chapter 3);
- To examine whether it is possible to seed MVEC isolated from fat tissue onto
deendothelialized surfaces after PTA in an in vivo rabbit model (chapter 4);
- To investigate the purity of cells isolated from human fat tissue and whether
these cells can be further purified (chapter 5);
- To determine whether the purity of the seeded human cells influences throm-
bogenicity and intimal hyperplasia of seeded grafts in vitro (chapter 6); 
- To develop an in vitro model to study seeding of deendothelialized vessels,
and to test different types of seeded cells in this model (chapter 7);
- To set up a clinical grade method for the purification of human fat derived
MVEC (chapter 8);
- To make a proposal for a patient study to establish whether the results of
prosthetic grafts in patients can be improved by seeding of purified MVEC
from fat tissue (chapter 9).
From the studies performed in this thesis concerning the suitability of fat
derived MVEC for cell seeding purposes, several conclusions can be drawn:
- Seeding of fat derived MVEC on prosthetic grafts results in a confluent EC
layer on top of a neointima. Contaminating cells from the transplant contribute
to neointima formation (chapter 3). 
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- Seeding deendothelialized arteries after PTA with fat derived MVEC results in
an increased intimal hyperplasia. Again, contaminants from the transplant are
likely to contribute to the intimal hyperplasia seen (chapter 4). 
- Isolates of human fat derived MVEC consist of 40% EC, and 60% contaminat-
ing cells: myofibroblast-like cells and monocytes. A combination of F11- and
CD14-coated dynabeads can be used to deplete these contaminants. Purity is
increased from 40 to over 90% (chapter 5). 
- in vitro experiments show that thrombogenicity and seeding related intimal
hyperplasia on prosthetic grafts are significantly reduced after seeding of puri-
fied cells as compared to nonpurified cells (chapter 6). 
- In an in vitro flow model of cell seeding on denuded arteries, intimal hyper-
plasia is decreased after seeding of purified cells as compared to the seeding
of nonpurified cells (chapter 7).
- Clinical grade F11, necessary for a clinical study, is not available. The CD34-
positive selection method from Nexell, using clinical grade products has
proven to be an appropriate alternative method. It allows for the same purity,
but a smaller yield is obtained (chapter 8). 
- The ultimate proof whether purified MVEC are suitable for seeding purposes
is a clinical (pilot) study. In the last chapter a proposal is written called the
ECLIPSE-study (endothelial cell lining on prosthetic shunt evalutation). Ten
patients will obtain an arteriovenous (AV) graft seeded with purified MVEC
(chapter 9). 
We showed that an additional purification step of fat derived cells is necessary
to obtain MVEC suitable for seeding. Using in vitro experiments better results
were obtained with purified compared to nonpurified MVEC. The ideal experi-
ment to investigate whether purification improves the suitability of MVEC for
seeding purposes would have been a comparison of two grafts in an animal
model. One seeded with purified MVEC and one with nonpurified MVEC.3,17
The problem is that for both the F11/CD14-purification and the CD34-method,
human-specific antibodies are used. Antibodies specific for the animal coun-
terpart proteins are not available, precluding animal experiments on this sub-
ject.
Currently, the ultimate test to prove the suitability of purified MVEC for cell
seeding purposes is a clinical study. For a clinical study, two prerequisites
must be fulfilled. First, all products used for isolation and purification of MVEC
should be produced according to GMP (good manufacturing practice) pre-
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scriptions. Second, in case the seeding procedure leads to graft occlusion,
the risk to the patient must be acceptable. 
The antibody F11 is not clinical grade. The production and testing of a clinical
grade F11 antibody cost over 100,000 euro. Therefore we investigated
whether MVEC could be purified using another method, the CD34 selection.
CD34 selection with clinical grade products is used widely for the isolation of
hematopoietic progenitor cells.18,19 As with haematopoietic progenitors, EC
express CD34 on their surfaces.20 The yield is lower than obtained with the
F11 technique but it is adequate to perform a patient study starting with an
acceptable amount (110 grams) of fat.
We chose to perform a clinical study with AV grafts instead of prosthetic
bypass grafts used for peripheral artery occlusive disease. An AV graft is a
prosthetic connection between an artery and a vein to ease haemodialysis
access. Thrombosis and intimal hyperplasia frequently occur in AV grafts.21,22
The advantage of using AV grafts for the pilot study is that in case of an occlu-
sion, life-threatening ischaemia of a limb will not occur. The disadvantage of
using an AV graft is that unlike a prosthetic bypass graft, the arterial flow and
pressure are translated to a vein. As an adaptation of the vein to the new
haemodynamics intimal hyperplasia develops in the outflow tract.23-25
Although EC are able to inhibit intimal hyperplasia,26 the inhibitory effect of EC
can be overruled by the altered haemodynamics. In case the process of inti-
mal hyperplasia in the outflow tract continues despite EC seeding, the effect of
seeding will be unclear based on a process that does not occur in prosthetic
bypass grafts. Swedenborg et al performed a clinical study with AV grafts
seeded with venous EC.27 Occlusion occurred in two out of seven grafts.
Stenosis of the ouflow tract occurred in three of the four grafts present for fol-
low up. One graft was excised after 5 weeks, due to an aneurysm in the out-
flow vein. Approximately 85% of the surface was covered with EC. Williams et
al performed a canine study with AV grafts seeded with MVEC. As a control
sham seeded AV grafts were implanted on the contralateral side. After 3-9
weeks of follow up, all seeded grafts were patent. All sham seeded grafts were
not. Stenoses of the outflow tract were not reported.
In the few clinical studies performed with fat derived nonpurified MVEC,8-11 inti-
mal hyperplasia developed in a more vigorous fashion than in animal stud-
ies.17,28 We found that contaminating cells co-isolated from fat tissue
contribute to intimal hyperplasia. Why intimal hyperplasia on prosthetic grafts
did not proceed progressively in animal studies, despite the presence of non-
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endothelial cells, is not understood.29 Another example of a difference
between humans and animals is the rate of spontaneous endothelialization of
prosthetic grafts. To date, no reports of spontaneous endothelialization in
humans have ever been made. Even for animals, the endothelialization rate is
species dependent.30,31 Differences in age, purity, and growth velocity of EC
may contribute to this. The increased age of patients as compared to laborato-
ry animals might be accompanied by a higher amount of contaminating cells
and a lower growth velocity of EC.
In our studies, human MVEC were obtained from healthy people who under-
went liposuction for cosmetic purposes. One aspect that needs to be proven
by the planned clinical pilot study is whether the purified fat derived MVEC
from patients with renal (and vascular) disease have the same characteristics
as those of healthy people. Endothelial dysfunction is known to be possible in
patients with chronic renal failure.32,33
In recent years, subject related research has been done in the field of stem
cells, tissue engineering (of whole blood vessels), and gene therapy. In the
second part of this chapter, we will compare our cell seeding technique with
these newly developed fields. 
Emerging data suggest that a subset of circulating CD34+-cells constitute a
phenotypically and functionally distinct population of endothelial precursor
cells (EPC). These EPC share with haematopoietic stem cells a common
ancestral precursor, the putative haemangioblast.34
EPC have been shown to participate in neovascularization of ischaemic
limbs.34 Also these EPC have been shown to contribute to reendothelialization
of prosthetic grafts in animals.35 EPC can be mobilized from bone marrow
using angiogenic cytokines (e.g. for example vascular endothelial growth fac-
tor (VEGF)).34 The resident population of EPC that is competent to an available
level of angiogenic growth factors, however, may potentially limit the extent to
which cytokine supplementation enhances tissue neovascularization. A recent
study reported an inverse correlation between the number of cardiovascular
risk factors and the number and migratory activity of EPC.36 In addition, spon-
taneous reendothelialization of prosthetic grafts and denuded surfaces has
not been reported in humans. To solve this problem EPC can be isolated from
peripheral blood, and after ex vivo expansion,37 administrated systematically
for the purpose of enhancing neovascularization.34 But again, it is unknown
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whether expanded EPC in humans home to denuded surfaces and prosthetic
grafts. The coating of grafts with anti-CD34 antibodies might potentiate hom-
ing in future. An alternative solution is the seeding of expanded EPC on pros-
thetic grafts.38
The advantage of using EPC over MVEC is that they are easily obtained by
venopuncture rather than by an operation. A disadvantage is that ex vivo
expansion of EPC takes on average two weeks. The drawbacks of in vitro cul-
ture are the same as mentioned before for mature EC. This includes the risk of
infection, change of phenotype, the need for a GMP culture facility, and
inavailability for emergency situations.10,39,40 EPC are a subset of the pluripo-
tent CD34+-cells. As an alternative, CD34+-bone marrow cells and even bone
marrow blood have been seeded on grafts. Bone marrow and CD34+-cells do
not have to be expanded in culture for two weeks. But, after seeding of CD34+
-cells, a neointima developed as with seeding of nonpurified MVEC.41 After
seeding of bone marrow, osteocytes and microcalcifications were generated
in the graft wall.42 
Other advances have been made in the field of tissue engineering. In fact,
EC seeding conceptually can be considered a form of tissue engineering,
although it does not form a blood vessel with all its components. Recently, the
first studies have been published about completely engineering blood ves-
sels. Three models have been investigated.43
The collagen based model consists of an adventitia-like layer of fibroblasts, a
media-like layer of smooth muscle cells, and a monolayer of EC.44 However,
Dacron sleeves are required to withstand physiological pressures. In the self-
assembly model, cells are cultured to form a continuous sheet of cells and
extracellular matrix and then rolled over a permeable solid bar. Later, the EC
can be seeded.45 These constructs exhibit adequate mechanical strength, but
the long culture time is a considerable limitation. In the third model, a polymer-
ic biodegradable scaffold is seeded with cells and matured using dynamic cul-
ture. This allowing cells to proliferate and produce an organized extracellular
matrix as the scaffold degrades.46 After the maturing process, EC are seeded.
This construct remains patent up to 24 days in Yucatan miniature swine. Also,
for this third type of construct several issues must still be addressed. Eight
weeks of in vitro development are required to exhibit the desired characteris-
tics. This caries all of the disadvantages previously mentioned. From current
reports, it is not clear whether such a construct is able to support a stable EC
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layer under flow conditions. And the presence of residual polymer might
cause an inflammatory response. So far only short term studies have been
performed.47 Only one human study has been done in a child.48
The advantage of a tissue engineered vessel over a cell seeded prosthetic
graft is its ability to dilate and constrict. In fact, the behaviour of a normal ves-
sel can also be expected from a seeded denuded vessel after PTA and
endarterectomy. But, a disadvantage of seeding a denuded vessel is that the
EC layer must be applied in vivo, so that temporary occlusion of the vessel is
necessary.
At this moment, we do not know whether intimal hyperplasia develops in tis-
sue engineered vessels. Development of intimal hyperplasia in tissue engi-
neered vessels can be expected since a combination of smooth muscle cells
(SMC), (myo)fibroblasts, and EC are used. In fact this combination of cells is
comparable to nonpurified fat derived MVEC, which have been shown to
induce seeding related intimal hyperplasia. Possibly, intimal hyperplasia will
not develop in tissue engineered vessels since cells are layered instead of
mixed.
Rapid advancements have been made in the field of gene therapy. Gene
transfer is accomplished using either viral (retro- or adenoviral) or non-viral
vectors (liposomes) since most cells are resistant to the uptake of foreign
DNA. The advantage of cationic liposomes is that they do not contain any viral
coding sequences and are safer. Their utilily is limited by the low efficiency of
gene transfer in vivo and by the short period of gene expression (<1 month).
Using adenoviral vectors, an efficient gene transfer in non-dividing cells in vitro
and in vivo is obtained. Adenoviral particles, however, can induce a significant
and immediate inflammatory response, limiting the gene-expression in vivo. At
present, these vectors are most useful for short term (2-3 weeks) therapy. With
retroviral vectors, efficient transfer into relatively large cell populations and
appropriate gene expression has been obtained.49 Retroviral gene transfer is
efficient provided that the cells are in a proliferative state. Retroviral transfer in
vivo is inefficient because cells are quiescent and the virus is inactivated by
complement.50-53
Genes for therapy of peripheral artery occlusive disease can be introduced to
the damaged vessel wall indirectly by using EC seeding of in vitro genetically
modified EC,54,55 or directly by means of gene-application to the remaining
cells in the vessel wall. The advantage of local application could be that cell
170
seeding is unnecessary in the future. Currently, only the adenoviruses and the
liposomes can be used for in vivo application of genes. Therefore, only short
term gene expression can be obtained. 
The inhibition of thrombus formation and intimal hyperplasia is a multifactorial
process involving multiple genes. In contrast, the amount of genes introduced
with gene therapy is limited. At this moment, an imaginary goal could be the
inhibition of the intimal hyperplasia occurring at the outflow tract of AV grafts.56
This process might be inhibited by the seeding EC. On the other hand, cimino
fistulas are also prone to intimal hyperplasia of the outflow tract. Cimino fistu-
las are direct anastomoses between an artery and a vein. In this case the
entire fistula is covered with EC. Therefore, intimal hyperplasia of the outflow
tract seems to be related for a major part to the local haemodynamics and not
to the absence of a confluent EC layer. The introduction of a gene coding for a
protein that inhibits intimal hyperplasia could supply additional value. One
example is endothelial Nitric Oxide Synthase.50,57
Gene therapy may have further implications than just for patency of grafts and
denuded arteries. Since the EC is situated in direct contact with the blood, EC
can also be used as a producing cell to release the desired gene product to
the blood stream. 
EC seeding has a greater than 20 year history in the treatment of small diame-
ter vessel occlusion. The techniques of stem cell seeding, tissue engineering,
and gene therapy have developed only recently. When one compares our
technique of cell seeding with these newer techniques, we can conclude the
following: 
Although the use of stem cells for tissue regeneration is promising, the use of
stem cells as an alternative for seeding adult EC is not yet possible. Currently,
the major drawback is the necessity of ex vivo expansion and differentiation of
EPC into mature EC. This process takes a long time. As soon EC can be
matured faster from EPC, they can be tested in the same clinical setting that
we will use for our purified MVEC.
The first tissue engineered blood vessels have been constructed using EC,
SMC and fibroblasts obtained from veins after expansion. As mentioned earli-
er, the yield from veins is limited. We saw that fat tissue contains an abundant
amount of MVEC but also myofibroblast-like cells. In vitro, they behave like
fibroblasts. In vivo, they behave like smooth muscle cells. In the future, it is
possible that all components of tissue engineered vessels may be obtained
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from fat tissue instead of peripheral veins. This would make expansion of the
individual cell types harvested from peripheral veins unnecessary. Still, matu-
ration of the total vessel under dynamic circumstances will be needed to
obtain the necessary burst strength.
To obtain long term gene expression, a gene introduction technique using
dividing cells is necessary at this moment. EC can be used to express the
gene product. So gene therapy is not necessarily used as an alternative to cell
seeding, but can be used in addition. 
Overall conclusion: Fat derived MVEC are feasible for cell seeding purposes
of prosthetic grafts and denuded arteries, provided that a purified cell suspen-
sion is used. With the development of a clinical grade method to obtain puri-
fied MVEC, we are ready to investigate the cells in a clinical trial.
1 Herring M, Gardner A, Glover J. A single-
staged technique for seeding vascular
grafts with autogenous endothelium.
Surgery 1978;84:498-504.
2 Mansfield PB, Wechezak AR, Sauvage LR.
Preventing thrombus on artifical vascular
surfaces: true endothelial cell linings. Trans
Am Soc Artif Intern Organs 1975;21:264-72.
3 Williams SK. Endothelial cell transplantation.
Cell Transplant 1995;4:401-10.
4 Zilla P, Deutsch M, Meinhart J. Endothelial
cell transplantation. Semin Vasc Surg
1999;12:52-63.
5 Meinhart JG, Deutsch M, Fischlein T et al.
Clinical autologous in vitro endothelialization
of 153 infrainguinal ePTFE grafts. Ann
Thorac Surg 2001;71:S327-S331.
6 Williams SK, Jarrell BE, Rose DG et al.
Human microvessel endothelial cell
isolation and vascular graft sodding in the
operating room. Ann Vasc Surg 1989;3:146-
52.
7 Williams SK, Jarrell BE, Rose DG. Isolation
of Human Fat-Derived Microvascular
Endothelial Cells for Use in Vascular Graft
Endothelialization. In: Zilla P, Fasol R,
Deutsch M, eds. Endothelialization of
Vascular Grafts. 1st Eur. Workshop
Advanced Technologies in Vascular
Surgery. Basel: Karger, 1986:211-7.
8 Schmidt SP, Meerbaum SO, Anderson JM
et al. Evaluation of expanded
polytetrafluoroethylene arteriovenous
access grafts onto which microvessel-
derived cells were transplanted to “improve”
graft performance: preliminary results. Ann
Vasc Surg 1998;12:405-11.
9 Park PK, Jarrell BE, Williams SK et al.
Thrombus-free, human endothelial surface
in the midregion of a Dacron vascular graft
in the splanchnic venous circuit—
observations after nine months of
implantation. J Vasc Surg 1990;11:468-75.
10 Zilla P, von Oppell U, Deutsch M. The
endothelium: a key to the future. J Card
Surg 1993;8:32-60.
11 Williams SK. Human clinical trials of
microvascular endothelial cell sodding. In:
Zilla P, Greisler HP, eds. Tissue engineering
of vascular prosthetic grafts. Austin, Texas:
R.G. Landes company, 1999:143-7.
12 Cha MS, Rah DK, Lee KH. Isolation and
pure culture of microvascular endothelial
cells from the fetal skin. Yonsei Med J
1996;37:186-93.
13 Rubens FD, Labow RS, Meek E et al. Tissue
factor expression by cells used for sodding
of prosthetic vascular grafts. J Surg Res
1997;72:22-8.
14 Jackson CJ, Garbett PK, Nissen B et al.
Binding of human endothelium to Ulex
europaeus I-coated Dynabeads: application
to the isolation of microvascular
endothelium. J Cell Sci 1990;96:257-62.
15 Meerbaum SO, Sharp WV, Schmidt SP.
Lower Extremity Revascularisation with
Polytetrafluoroethylene Grafts Seeded with
Microvascular Endothelial Cells. In: Zilla P,
Fasol R, Callow A, eds. Applied
Cardiovascular Biology 1990-91. Int Soc
Appl Cardiovasc Biol. Basel: Karger,
1992:107-19.
16 Gupta K, Ramakrishnan S, Browne PV et al.
A novel technique for culture of human
dermal microvascular endothelial cells
under either serum-free or serum-
supplemented conditions: isolation by
panning and stimulation with vascular
endothelial growth factor. Exp Cell Res
1997;230:244-51.
17 Williams SK, Rose DG, Jarrell BE.
Microvascular endothelial cell sodding of
ePTFE vascular grafts: improved patency
References
172
and stability of the cellular lining. J Biomed
Mater Res 1994;28:203-12.
18 Tseng-Law J, Szalay P, Guillermo R et al.
Identification of a peptide directed against
the anti-CD34 antibody, 9C5, by phage
display and its use in hematopoietic stem
cell selection. Exp Hematol 1999;27:936-45.
19 Richel DJ, Johnsen HE, Canon J et al.
Highly purified CD34+ cells isolated using
magnetically activated cell selection provide
rapid engraftment following high-dose
chemotherapy in breast cancer patients.
Bone Marrow Transplant 2000;25:243-9.
20 Fina L, Molgaard HV, Robertson D et al.
Expression of the CD34 Gene in Vascular
Endothelial Cells. Blood 1990;75:2417-26.
21 The economic cost of ESRD, vascular
access procedures, and Medicare spending
for alternative modalities of treatment.
USRDS. United States Renal Data System.
Am J Kidney Dis 1997;30:S160-S177.
22 Klein JA. Tumescent technique for regional
anesthesia permits lidocaine doses of 35
mg/kg for liposuction. J Dermatol Surg
Oncol 1990;16:248-63.
23 Hodges TC, Fillinger MF, Zwolak RM et al.
Longitudinal comparison of dialysis access
methods: risk factors for failure. J Vasc Surg
1997;26:1009-19.
24 Clowes AW, Gown AM, Hanson SR et al.
Mechanisms of arterial graft failure. 1. Role
of cellular proliferation in early healing of
PTFE prostheses. Am J Pathol 1985;118:43-
54.
25 Sterpetti AV, Hunter WJ, Schultz RD et al.
Healing of high-porosity
polytetrafluoroethylene arterial grafts is
influenced by the nature of the surrounding
tissue. Surgery 1992;111:677-82.
26 Clowes AW, Clowes MM, Reidy MA.
Kinetics of cellular proliferation after arterial
injury. III. Endothelial and smooth muscle
growth in chronically denuded vessels. Lab
Invest 1986;54:295-303.
27 Swedenborg J, Bengtsson L, Clyne N et al.
in vitro endothelialisation of arteriovenous
loop grafts for haemodialysis. Eur J Vasc
Endovasc Surg 1997;13:272-7.
28 Baitella-Eberle G, Groscurth P, Zilla P et al.
Long-term results of tissue development
and cell differentiation on Dacron
prostheses seeded with microvascular cells
in dogs. J Vasc Surg 1993;18:1019-28.
29 Kleinert LB, Hoying JB, Williams SK. The
neointima formed in endothelial cell sodded
ePTFE vascular grafts results from both
cellular-hyperplasia and extracellular-
hypertrophy. Cell Transplant  1996;5:475-
82.
30 Berger K, Sauvage LR, Rao AM et al.
Healing of arterial prostheses in man: its
incompleteness. Ann Surg 1972;175:118-
27.
31 Sauvage LR, Berger KE, Wood SJ et al.
Interspecies healing of porous arterial
prostheses: observations, 1960 to 1974.
Arch Surg 1974;109:698-705.
32 Jacobson SH, Egberg N, Hylander B et al.
Correlation between soluble markers of
endothelial dysfunction in patients with renal
failure. Am J Nephrol 2002;22:42-7.
33 Vaziri ND. Effect of chronic renal failure on
nitric oxide metabolism. Am J Kidney Dis
2001;38:S74-S79.
34 Kalka C, Masuda H, Takahashi T et al.
Transplantation of ex vivo expanded
endothelial progenitor cells for therapeutic
neovascularization. Proc Natl Acad Sci U S
A 2000;97:3422-7.
35 Shi Q, Wu MH, Fujita Y et al. Genetic tracing
of arterial graft flow surface
endothelialization in allogeneic marrow
transplanted dogs. Cardiovasc Surg
1999;7:98-105.
173
G
e
n
e
ra
l 
in
tr
o
d
u
ct
io
n
ch
a
p
te
r 
1
0
36 Vasa M, Fichtlscherer S, Aicher A et al.
Number and migratory activity of circulating
endothelial progenitor cells inversely
correlate with risk factors for coronary artery
disease. Circ Res 2001;89:E1-E7.
37 Boyer M, Townsend LE, Vogel LM et al.
Isolation of endothelial cells and their
progenitor cells from human peripheral
blood. J Vasc Surg 2000;31:181-9.
38 Bhattacharya V, McSweeney PA, Shi Q et al.
Enhanced endothelialization and
microvessel formation in polyester grafts
seeded with CD34(+) bone marrow cells.
Blood 2000;95:581-5.
39 Zilla P, Deutsch M, Meinhart J et al. Clinical
in vitro endothelialization of femoropopliteal
bypass grafts: an actuarial follow-up over
three years. J Vasc Surg 1994;19:540-8.
40 Zwaginga JJ, de Boer HC, IJsseldijk MJ et
al. Thrombogenicity of vascular cells.
Comparison between endothelial cells
isolated from different sources and smooth
muscle cells and fibroblasts.
Arteriosclerosis 1990;10:437-48.
41 Bhattacharya V, McSweeney PA, Shi Q et al.
Enhanced endothelialization and
microvessel formation in polyester grafts
seeded with CD34(+) bone marrow cells.
Blood 2000;95:581-5.
42 Fujita Y, Wu MH, Ishida A et al.  Accelerated
healing of Dacron grafts seeded by
preclotting with autologous bone marrow
blood. Ann Vasc Surg 1999;13:402-12.
43 Nerem RM, Seliktar D. Vascular tissue
engineering. Annu Rev Biomed Eng
2001;3:225-43.
44 Weinberg CB, Bell E. A blood vessel model
constructed from collagen and cultured
vascular cells. Science 1986;231:397-400.
45 L’Heureux N, Paquet S, Labbe R et al. A
completely biological tissue-engineered
human blood vessel. FASEB J 1998;12:47-
56.
46 Niklason LE, Gao J, Abbott WM et al.
Functional arteries grown in vitro. Science
1999;284:489-93.
47 Watanabe M, Shin’oka T, Tohyama S et al.
Tissue-engineered vascular autograft:
inferior vena cava replacement in a dog
model. Tissue Eng 2001;7:429-39.
48 Shin’oka T, Imai Y, Ikada Y. Transplantation
of a tissue-engineered pulmonary artery. N
Engl J Med 2001;344:532-3.
49 Staal FJ, Res PC, Weijer K et al.
Development of retrovirally marked human T
progenitor cells into mature thymocytes. Int
Immunol 1995;7:1301-9.
50 von der Leyen, Gibbons GH, Morishita R et
al. Gene therapy inhibiting neointimal
vascular lesion: in vivo transfer of
endothelial cell nitric oxide synthase gene.
Proc Natl Acad Sci U S A 1995;92:1137-41.
51 Clowes AW. Vascular gene therapy in the
21st century. Thromb Haemost
1997;78:605-10.
52 Lee S, Clark T, Chen J et al. Correct
identification of genes from serial analysis
of gene expression tag sequences.
Genomics 2002;79:598-602.
53 Schulick AH, Newman KD, Virmani R et al.
in vivo gene transfer into injured carotid
arteries. Optimization and evaluation of
acute toxicity. Circulation 1995;91:2407-14.
54 Zwiebel JA, Freeman SM, Kantoff PW et al.
High-level recombinant gene expression in
rabbit endothelial cells transduced by
retroviral vectors. Science 1989;243:220-2.
55 Wilson JM, Birinyi LK, Salomon RN et al.
Implantation of vascular grafts lined with
genetically modified endothelial cells.
Science 1989;244:1344-6.
174
56 Pareek SK, Malhotra V. Angio-access for
haemodialysis—current perspective. J
Indian Med Assoc 2001;99:382-4.
57 Kader KN, Akella R, Ziats NP et al. eNOS-
overexpressing endothelial cells inhibit
platelet aggregation and smooth muscle
cell proliferation in vitro. Tissue Eng
2000;6:241-51.5
175
G
e
n
e
ra
l 
in
tr
o
d
u
ct
io
n
ch
a
p
te
r 
1
0
176
Summary
178
In peripheral arterial occlusive disease, a vein bypass has a better patency
rate than a prosthetic bypass, endarterectomy, or percutaneous transluminal
angioplasty (PTA). An important advantage of the venous conduit is the pres-
ence of an endothelial cell (EC) lining. EC can inhibit thrombosis as well as
intimal hyperplasia. EC seeding has been developed in an effort to improve
the results of prosthetic grafts.
For a long time, veins have been used as a source of EC. In vitro culture of
cells for several weeks is however necessary to obtain enough cells for the
desired seeding density. Disadvantages of in vitro culture are the increased
costs due to good manufacturing practice (GMP)-restrictions, growth and
infectious problems. Also, the cells are not available in emergency cases.
Subcutaneous fat tissue is an alternative source for EC. Fat tissue contains an
abundant amount of microvascular endothelial cells (MVEC) rendering addi-
tional culturing unnecessary.
The seeding of fat derived MVEC on prosthetic grafts in animal models results
in a confluent EC layer without visible platelet aggregation and fibrin deposi-
tion leading to good patency. However, until now the results in humans have
been disappointing because of the development of intimal hyperplasia and
thrombus formation. Intimal hyperplasia also developed in animals, but not to
the extent of an occlusion. It has been suggested that contaminating cells that
are co-isolated with MVEC from fat tissue may lead to the development of inti-
mal hyperplasia.
The central question of this thesis is whether subcutaneous fat tissue is suit-
able as an alternative source of EC for the seeding of prosthetic grafts and
deendothelialized surfaces.
To investigate the effect of seeding fat derived MVEC on prosthetic grafts,
both MVEC and sham seeded grafts were implanted as carotid interposition
grafts in a canine model. We found that MVEC seeding resulted in a covering
EC layer on top of a multilayer of myofibroblasts in all patent grafts. Sham
seeded grafts were covered with thrombus or occluded. We also found that
during isolation of EC from fat tissue fibroblast-like cells were obtained. Using
a genetic marker (low affinity nerve growth factor receptor (LNGFR)), we
demonstrated that these contaminating fibroblast-like cells from the transplant
contributed to intimal hyperplasia associated with MVEC seeding (chapter 3).
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After our results obtained with prosthetic grafts, we were interested in the
effect of seeding MVEC on denuded arteries after PTA. PTA was performed in
rabbits and MVEC seeding was compared with sham seeding. Instead of
inducing intimal hyperplasia, fat derived MVEC seeding resulted in an
increased intimal hyperplasia. Non-endothelial cells (non-EC) were suggested
to be involved in the increased development of intimal hyperplasia (chapter 4).
Since our final goal was the seeding of autologous fat derived MVEC in
humans, and non-EC seemed to be co-isolated from fat, we were interested in
the composition of human fat derived MVEC. Cell isolates obtained from
human fat tissue with the traditional isolation procedure, enzymatic digestion
and wash steps consisted of 40% EC, 2% macrophages and almost 60%
myofibroblasts. We developed a purification method to remove contaminating
fibroblasts and macrophages using dynabeads (magnetic spheres) coated
with cell specific antibodies, F11 and CD14. The purity was increased to over
90% EC (chapter 5).
Due to the use of human specific antibodies we could not perform an in vivo
animal study to prove the advantage of seeding purified MVEC over nonpuri-
fied MVEC. Therefore, we performed in vitro studies. Tissue factor activity of
purified cells was significantly reduced compared to the nonpurified cells.
Purified cells showed thrombomodulin activity and endothelial Nitric Oxide
Synthase expression. Levels of fragment 1+2 (a measure for thrombin gener-
ation) and fibrinopeptide A (a measure for fibrin generation) after perfusion of
purified cells with whole blood were significantly lower than after perfusion of
nonpurified cells. Only nonpurified cells were covered with platelets and fibrin.
Prostheses seeded with nonpurified cells showed an EC monolayer on top of
a multiplayer of myofibroblasts. Prostheses seeded with purified cells only
showed an EC monolayer. Experiments with a mixture of human umbilical vein
EC (HUVEC) and fibroblasts showed that when more than 25% HUVEC were
present, a confluent EC monolayer was formed. When the percentage of
fibroblasts was 25% or less, a multilayer of myofibroblasts did not develop
within three weeks of culture (chapter 6).
We developed an in vitro flow model to investigate cell seeding on denuded
arteries from pigs, and tested different types of cells in this model. With this
model we hoped to prove whether development of intimal hyperplasia on
180
denuded arteries was indeed reduced after seeding of purified MVEC as com-
pared to nonpurified MVEC. Cells were seeded on denuded arteries and per-
fused for 7 days. The extent of the intimal hyperplasia was reduced after
seeding of purified MVEC and HUVEC as compared to nonpurified MVEC and
varying mixtures of HUVEC and fibroblasts (chapter 7).
Definitive evidence for the suitability of purified MVEC for cell seeding purpos-
es is a clinical study. A clinical study requires that all products meet the GMP
criteria. All of the products we used to isolate MVEC from fat tissue are clinical
grade products, except for the antibody F11. Therefore, a change was made
to CD34 selection in preparation for clinical investigation. CD34 is widely used
for the isolation of haematopoietic progenitors. EC express CD34 on their sur-
faces. We tested the effectiveness of two different CD34-selection techniques
for purification of MVEC and compared the results to those of the F11/CD14-
method. One of the techniques worked. This technique resulted in a smaller
yield of purified MVEC than the F11/CD14 technique, but the same purity was
obtained (chapter 8).
In the last chapter, we describe a proposal for a clinical study to investigate
purified MVEC seeded on prosthetic vascular grafts. The ideal scenario is to
utilize a graft for which thrombus formation and intimal hyperplasia are fre-
quently events. In addition, the risk to the patient in case the procedure fails
must be as low as possible. For this reason, we chose prosthetic arteriove-
nous (AV) grafts instead of lower extremity bypass grafts, for which the cell
seeding procedure was originally developed. In ten patients, an AV graft will
be implanted that is seeded with purified autologous fat derived MVEC. This is
the ECLIPSE-study (endothelial cell lining on prosthetic shunts evaluation)
(chapter 9).
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Tot op heden levert de omleiding met een ader, als behandeling voor afslui-
ting van vaten met een kleine diameter in de benen, de beste resultaten op.
Deze resultaten zijn beter dan die van een omleiding van kunststof materiaal,
het verwijderen van de vernauwing uit een vat, of een ballonverwijding (dotte-
ren). De betere resultaten worden voor een belangrijk deel toegeschreven aan
de aanwezigheid van een bekleding met endotheelcellen (EC). Deze cellen
kunnen stolselvorming en verdikking van de vaatwand tegen gaan. Om de
resultaten van kunststof vaten te verbeteren is het idee om de binnenzijde te
bezaaien met EC ontstaan.
Lange tijd zijn aders gebruikt als bron voor EC. Kweken van cellen is daarbij
noodzakelijk om genoeg cellen voor de gewenste zaaidichtheid te verkrijgen.
Nadelen zijn toegenomen kosten omdat de kweekomstandigheden aan speci-
ale (good manufacturing practice (GMP)) regels moeten voldoen, groei- en
infectieproblematiek en het feit dat de cellen niet beschikbaar zijn voor spoed-
gevallen. Onderhuids vetweefsel is een alternatieve bron voor EC. Het bevat
een ruime hoeveelheid microvasculaire endotheelcellen (MVEC). De
opbrengst is ruim voldoende om kweken onnodig te maken.
Het zaaien van MVEC op kunststof bloedvaten in dier-modellen leverde een
bedekkende EC laag op zonder stolselvorming. De resultaten in de mens zijn
tot nu toe tegengevallen, ten gevolge van verdikking van de vaatwand en uit-
eindelijk stolselvorming. Een verdikte vaatwand werd ook bij de hondenproe-
ven gevonden, maar was niet zo progressief dat afsluiting van het vat optrad.
Er is gesuggereerd dat non-endotheliale cellen (non-EC) die samen met
MVEC uit vetweefsel worden geïsoleerd een rol spelen bij het ontstaan van
een verdikte vaatwand.
De centrale vraag in dit proefschrift is of vetweefsel geschikt is als alternatieve
bron voor het zaaien van EC.
Protheses gezaaid met MVEC en ongezaaide protheses werden geïmplan-
teerd in de halsslagaders van honden om het effect van het zaaien van MVEC
uit vetweefsel op kunststof vaten te onderzoeken. Het zaaien van MVEC resul-
teerde in alle open vaten in een EC laag bovenop meerdere lagen bindweef-
selcellen en dus in een verdikking van de vaatwand. Ongezaaide protheses
waren bedekt met stolsels of afgesloten. We ontdekten dat tijdens isolatie uit
vetweefsel niet alleen EC maar ook non-EC/verontreinigende cellen werden
verkregen. Door de geïsoleerde cellen voor het zaaien van een label te voor-
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zien, toonden we aan dat de verontreinigende cellen bijdroegen aan verdik-
king van de vaatwand geassocieerd met het zaaien van MVEC (hoofdstuk 3).
Nadat we het effect van MVEC gezaaid op kunststof vaten hadden onder-
zocht, waren we geïnteresseerd in het effect van MVEC gezaaid op vaten na
een dotterprocedure. Door de dotterprocedure zijn de EC, die stolling rem-
men en verdikking van de vaatwand tegengaan, van de vaatwand verdwenen.
Een dotteroperatie werd uitgevoerd bij konijnen en het zaaien van MVEC werd
vergeleken met niet zaaien. Zaaien van MVEC uit vetweefsel resulteerde in
vergelijking met niet zaaien in een toename van de verdikking van de vaat-
wand in plaats van een afname. Ook hier werd de betrokkenheid van non-EC
in de populatie gezaaide cellen gesuggereerd bij het ontstaan van een verdik-
king van de vaatwand (hoofdstuk 4).
Ons uiteindelijke doel was het zaaien van MVEC uit lichaamseigen vetweefsel
bij de mens. Omdat er mogelijk naast EC verontreinigende cellen werden ver-
kregen uit vetweefsel, waren we geïnteresseerd in de samenstelling van de cel
isolaties uit vet. Cel isolaties verkregen uit vetweefsel van de mens bleken te
bestaan uit 40% EC en 60% verontreinigende cellen. We ontwikkelden een
methode waarbij verontreinigende cellen werden verwijderd met magneetbol-
letjes met daarop speciale antistoffen die deze cellen herkennen en binden.
De zuiverheid werd verhoogd tot boven de 90% (hoofdstuk 5).
Bij de door ons ontwikkelde zuiveringsmethode wordt gebruik gemaakt van
mens-specifieke antilichamen. We konden daarom geen dier studie gebruiken
om het voordeel van gezuiverde boven ongezuiverde MVEC aan te tonen. Om
die reden werden laboratorium proeven gedaan. We vonden dat de stollings-
stimulerende activiteit van gezuiverde MVEC duidelijk verminderd was ten
opzichte van ongezuiverde MVEC. De gezuiverde MVEC brachten tevens stol-
lingsremmende eigenschappen tot expressie. Na overstroming van gezuiver-
de MVEC met bloed was stolselvorming duidelijk verminderd vergeleken met
overstroming van ongezuiverde MVEC. Na zaaien en kweken van ongezuiver-
de MVEC op een prothese werd een sluitende laag EC gevonden bovenop
meerdere lagen bindweefselcellen, bij gezuiverde MVEC alleen een sluitende
EC laag (hoofdstuk 6).
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We ontwikkelden een laboratorium model om bloedvaten te bezaaien en te
overstromen. Met dit model wilden we bewijzen dat verdikking van de vaat-
wand minder uitgesproken was na zaaien van gezuiverde MVEC dan na zaai-
en van ongezuiverde MVEC. Het was mogelijk vaatjes te bezaaien en
gedurende zeven dagen te overstromen. De verdikking van de vaatwand was
minder na zaaien van gezuiverde dan na zaaien van ongezuiverde MVEC
(hoofdstuk 7).
Het uiteindelijke bewijs dat moet aantonen of gezuiverde MVEC geschikt zijn
om te zaaien is een patiënten studie. Hiervoor is van belang is dat alle produc-
ten, nodig om cellen te isoleren, speciaal gemaakt en getest zijn volgens GMP
voorwaarden. Alle producten die we gebruiken om MVEC uit vetweefsel te iso-
leren, worden onder de noodzakelijke condities geproduceerd, behalve de
antistof die nodig is om de verontreinigende cellen te verwijderen. We hebben
daarom getest of het mogelijk was EC te selecteren met magneetbolletjes
gecoat met een EC specifieke antistof. Met deze methode worden ook stam-
cellen (moedercellen) geïsoleerd. Een speciaal eiwit zorgt ervoor dat de bol-
letjes na selectie van de EC weer loslaten. Deze methode leverde een
geringere opbrengst van MVEC op dan de in hoofdstuk 3 genoemde metho-
de, maar eenzelfde zuiverheid (hoofdstuk 8).
In het laatste hoofdstuk hebben we een voorstel voor een patiëntenstudie
geschreven om het effect van gezuiverde MVEC gezaaid op kunststof bloed-
vaten te onderzoeken. Het meest ideaal is te kiezen voor een toepassing van
kunststof vaten waarbij veel stolselvorming en verdikking van de vaatwand
optreedt. Tevens is het van belang dat het risico voor de patiënt zo klein
mogelijk is als de procedure faalt. Daarom hebben we gekozen voor een dia-
lyse shunt en niet voor een omleiding in een been, waarvoor het zaaien van
EC eigenlijk is ontwikkeld. Een dialyse shunt is een verbinding tussen een
ader en een slagader, die bij nierpatiënten wordt aangelegd. Deze verbinding
dient als toegang tot de bloedbaan om het bloed te kunnen spoelen. Tien
patiënten zullen een kunststof dialyse shunt krijgen bezaaid met gezuiverde
MVEC uit lichaamseigen vetweefsel, de ECLIPSE (endothelial cell lining on
prosthetic shunt evaluation) studie (hoofdstuk 9).
Addendum ‘figures in colour’
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Chapter 3, Figure 2
Histopathology and immunohistochemistry of the open seeded graft (4 months).
A. HE staining: The cell density of the neointima (magnification, x 85)
B. EvG staining: The fibers present in the intima are elastin (grey) and collagen (red) (magnifica-
tion, x 85).
C. vWF-staining: All cells present in the luminal monolayer are positive (brown) and so identified
as EC (magnification, x 85). 
D. α-actin-staining: All cells present in the intima are positive (brown) and so classified as myofi-
broblasts (magnification, x 85). 
E. vimentin-staining: All cells present are positive (brown) (magnification, x 85).
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Chapter 3, Figure 4
A. Immunohistochemistry of a graft sodded with GFP-transduced cells. The intima is visible with
positive cells (brown) (magnification, x 250). 
A'. Flow cytometry analysis of GFP-transduced cells. Fluorescence of transduced cells (filled)
compared with that of mock-transduced cells (open).
B. Immunohistochemistry of a graft sodded with LNGFR-transduced cells. Positive cells (black)
are visible in the EC monolayer, the intima and the luminal part of the prosthesis (magnification,
x 165). 
B'. Flow cytometry analysis of LNGFR-transduced cells. Fluorescence of transduced cells (filled)
compared with that of mock-transduced cells (open). 
C. Immunohistochemistry of a graft sodded with transduced cells. A large T-cell infiltrate is pre-
sent (brown) (magnification, x 165). 
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Chapter 4, Figure 3
Immunohistochemistry of a patent MVEC and sham seeded deendothelialized artery of the
same rabbit with 4 weeks follow up (magnification, x85):
A. Anti-CD31 staining of the MVEC seeded artery: Most of the cells present in the luminal mono-
layer are positive (brown) and so identified as EC.
B. Anti-α-actin staining of the same artery: The cells present in the intima are positive (brown)
and so classified as myofibroblasts.
C. Anti-CD31 staining of the sham seeded artery: Most of the cells present in the luminal mono-
layer are positive (brown) and so identified as EC.
D. Anti-α-actin staining of the same artery: The cells present in the intima are positive (brown)
and so classified as myofibroblasts.
A
C
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Chapter 5, Figure 2
A. Immunohistochemistry of frozen sections of subcutaneous fat tissue. On the left, two sections
stained with mouse anti-human CD31; on the right, two identical sections stained with mouse
anti-human F11 (magnification, x 85);
B. Flow cytometry analysis of nonpurified cells. Cells were double-stained with FITC-conjugated
mouse anti-human CD31 (horizontal) and with mouse anti-human F11, visualized with PE-conju-
gated goat anti-mouse (vertical). 
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190 Chapter 6, Figure 4
Immunohistochemistry of cell sodded and cultured grafts (magnification, x 95).
A. Grafts sodded with nonpurified cells, the cells present in the multilayer stained positive with
mouse anti-human a-actin antibody.
B. Grafts sodded with nonpurified cells, the cells present in the covering monolayer stained
positive with mouse anti-human vWF antibody.
C. Grafts sodded with nonpurified cells, groups of cells present in the multilayer stained positive
with mouse anti-human CD31 antibody.
D. Grafts sodded with purified cells, covered with a monolayer of cells positive for mouse anti-
human vWF antibody.
A
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Chapter 7, Figure 6
Immunohistochemistry, using EC-specific anti-CD31 and myofibroblast-specific anti-a-actin of
seeded (40’) and perfused (7 days) denuded arteries (magnification, x70):
A. Anti-CD31 staining of an artery seeded with human nonpurified MVEC (flow 15 ml/min), hardly
any EC are present; 
B. Anti-α-actin staining of the same artery, part of the neointima exists of myofibroblasts, part of
α-actin-negative cells;
C. Anti-CD31 staining of an artery seeded with a combination 75% fibroblasts and 25% HUVEC
(flow 15 ml/min), a subconfluent EC coverage is present and groups of EC are present in the
neointima;
D. Anti-α-actin staining of the same artery, the subendothelial neointima exists of myofibroblasts;
E. Anti-CD31 staining of an artery seeded with human purified MVEC (flow 15 ml/min), a conflu-
ent EC coverage is present; 
F. Anti-α-actin  staining of the same artery, hardly any subendothelial myofibroblasts are present
G. Anti-CD31 staining of an artery seeded with HUVEC (flow 15 ml/min), a confluent EC covera-
ge is present;
H. Anti-α-actin staining of the same artery, hardly any subendothelial myofibroblasts are present;
I. Anti-CD31 staining of an artery seeded with HUVEC (flow 120 ml/min), a confluent EC covera-
ge is present;
J. Anti-α-actin staining of the same artery, hardly any subendothelial myofibroblasts are present.
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Dankwoord
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Nu het promotie boekje bijna af is wil ik graag iedereen bedanken die bijge-
dragen heeft aan de totstandkoming ervan. Dank voor de begeleiding en
adviezen, het enthousiasme in goede tijden en de steun en afleiding als het
even tegenzat.
Prof. Eikelboom, beste Bert, bedankt voor alle mogelijkheden die u me gebo-
den heeft op dit basaal wetenschappelijk onderwerp te promoveren.
Prof. de Groot, beste Flip, jouw kennis op het gebied van stolling en endo-
theelcel functie is zeer groot. Jij wist altijd weer een verklaring voor onver-
wachte resultaten. 
Dr. Blankensteijn, beste Jan, jouw analytisch vermogen is enorm. Ook bij voor
jou onbekende proeven wist je kritische vragen te stellen en opmerkingen te
plaatsen. Dank voor je grondige beoordeling van het manuscript en al het
meedenken. 
Prof. Sixma, beste Jan, als arts en wetenschapper was je in staat dit onder-
zoek dat zich niet beperkte tot ‘kliniek’ of ‘basale wetenschap’ in alle facetten
te overzien. 
Beste Prof. van Vroonhoven, heel veel dank voor de richtlijnen die ik van u
kreeg toen ik als ‘jonge’ co-assistent aangaf graag chirurg te willen worden. 
Dr. Slaper-Cortenbach, beste Ineke, toen ik dacht dat er echt niemand in het
UMC was die me kon helpen bij het opzetten van de door ons geplande
patiëntenstudie volgens GMP richtlijnen, was jij daar ineens. De samenwer-
king met jou heeft zelfs nog tot een extra hoofdstuk en een congres in Canada
geleid. Je bent in staat complexe materie tot een eenvoudig probleem terug te
brengen.
Glenda, we hardly had any differences in opinion. I really enjoyed to work with
you as a technician. You were a very good teacher. Thanks for all your help,
but especially for the fun we had when we were on tour for the collection of
material for research. 
Hence Verhagen en Paul Hedeman Joosten, mijn beide voorgangers, ik kan
me nog goed herinneren hoe mijn onderzoek begon. We reisden met z’n
drieën naar Duitsland voor het eerste ‘ISACB congres’, een erg leuke start.
Paul, dank voor je hulp bij de ‘honden experimenten’. Hence, ik heb veel
gehad aan je adviezen tijdens werkbesprekingen.
EMC Bartelski Bosch en Duin en afdeling plastische chirurgie, ooit kreeg ik
een kaartje toegestuurd met de tekst ‘In Amerika werd vorig jaar 750.000 kilo
vet weggezogen door plastisch chirurgen. Dit is gelijk aan 3 miljoen pakjes
boter. Wat zouden ze met al dat vet doen?’ Endotheelcellen isoleren dus!
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Zonder jullie medewerking en die van de cliënten/patiënten was ik niet zover
gekomen.
Nico, Hans, Janny, Herman, en Evelien, en andere medewerkers van het GDL,
bedankt voor al jullie hulp bij de dierexperimenten en de goede zorg voor de
dieren. Nico, jij in het bijzonder, dank voor je overwerkuren en steun toen de
‘konijnen experimenten’ absoluut tegenzaten en voor de gezelligheid tijdens
de ‘operatie’ dagen. 
Doggies en bunnies, jullie waren bijzonder. 
Afdeling pathologie, met name Dr. Marguérite Schipper, Marina, Jop en
Thomas en Gerry, afdeling haematologie, ik heb veel gehad aan jullie kennis
en medewerking met betrekking tot het vervaardigen van immuunhistochemi-
sche coupes.
Afdeling celbiologie, met name George Posthuma, dank voor het gebruik
maken van jullie apparatuur en de benodigde uitleg hierbij.
Henk Pluigers en Pim van Maurik, bedankt voor jullie hulp bij de ‘scanning
electronen microscoop’. Henk, bij jou kon ik altijd terecht voor een (oplos)
koffie-pauze. 
Frank Staal, bevriende atleet, soms heeft het ook een voordeel het buiten
werktijd over werk te hebben. Jij bleek me te kunnen helpen om cellen van
een label te voorzien. Na je vertrek naar Rotterdam kreeg ik de benodigde
hulp van Peter Ng. Veel dank voor jullie inspanningen.
Roland Govers bedankt voor de materialen voor en informatie over eNOS
bepalingen. 
Rik Mansfeld Beck, je bent geniaal in het ontwerp van catheters. Je interesse
voor de praktijk maakt dat je direct weet hoe je verbeteringen kunt aanbren-
gen.
Slachthuizen Oudewater, Montfoort, en Gorinchem, de periode van varkens-
pest, BSE en mond- en klauwzeer was een zeer zware tijd voor jullie. Bedankt
voor de mogelijkheid die we kregen om al interfererend in het slachtproces
ons materiaal te verzamelen.
Prof. Dr. AJ Rabelink, afdeling vasculaire geneeskunde en Dr. PJ Blankestijn,
afdeling nefrologie, Dr. AH Schuurman, afdeling plastische chirurgie, Drs. PT
Kasander en Drs. Schouten, afdeling anaesthesie, Dhr. H Langeweg, divisie
peri-operatieve zorg, anaesthesie en pijnbestrijding, Dr. A van Dijk en Dr. Ph
de Vries, divisie apotheek, jullie bijdrage in het opzetten van een
patiënten-studie was en is nog steeds zeer waardevol. 
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Ross Milner, I appreciate your effort in reading and correcting the general dis-
cussion and summary thoroughly. 
Jan Heyligers, ik vind het geweldig dat dit onderzoek zo’n enthousiast vervolg
krijgt, succes!
Onderzoekers, analisten, stafleden en secretaresses lab I, II, III, Jordan en
speciële haematologie, nadat ik gewend was aan mijn transfer vanuit de kli-
niek naar een lab heb ik een leuke tijd gehad. Wonderbaarlijk hoe TL-verlichte
borrels toch zo gezellig kunnen zijn. Ger Boonen, als post-doc op het ‘Jordan
lab’ leerde je mij gedegen proeven opzetten (controles hoezo??). Dank voor
al je geduld als de cellen weer eens ‘verdwenen waren’. Erik, Ton en Marion,
jullie waren mijn reddende engelen als ik weer eens ruzie had met de compu.
Assistenten, onderzoekers, stafleden en secretaresses van de afdeling chirur-
gie in Utrecht, de sfeer was zo dat je als onderzoeker toch deel uitmaakte van
de ‘chirurgisch groep’. Monique het was gezellig om samen met jou als de
‘meiden van de vaten’ onderzoek te doen. Marijke Liemborg, jij was een enor-
me steun als er weer een financieel verslag weg moest.
Assistenten, stafleden chirurgie en overige collega’s in Den Bosch, bedankt
voor jullie interesse in de voortgang van de laatste loodjes, maar vooral voor
de gezellige werksfeer.
Leden van de beoordelingscommissie (Prof. Dr. AJ Rabelink, Prof. Dr. EE
Voest, Prof. Dr. JH van Bockel, Prof. Dr. HJ Jongsma) dank voor uw interesse. 
Medewerkers AVD, met name wil ik Eva bedanken voor het ontwerp van de
lay-out en de kaft, en Ingrid voor de tekeningen in hoofdstuk 1. Ik vind het
geheel zeer mooi geworden.
Mijn vrienden, in het bijzonder Bernard, ik ben jullie erg dankbaar voor de
vriendschap die ik met eenieder van jullie heb en hoe jullie hebben meege-
leefd met de perikelen van deze promotie. Mede atleten, dit boekwerk was
dus de reden van mijn frequente afwezigheid de laatste tijd.
Glenda, je hebt me drie jaar met raad en daad bijgestaan, Janou, in april
stond ik in jouw schoenen. Ik vind het erg leuk dat jullie mijn paranimfen zijn,
zet hem op meiden. 
Mijn ouders en broer, lieve pap, mam en Jim, bedankt voor jullie interesse,
steun en enthousiasme. Zonder jullie zou ik niet zover gekomen zijn. 
Curriculum vitae
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Cora Arts werd op 18 augustus 1972 geboren te Boxmeer.
Zij behaalde in 1990 het VWO diploma aan het Elzendaal college te Boxmeer.
Hetzelfde jaar startte ze met de studie Geneeskunde aan de Universiteit van
Utrecht. Tijdens haar studie werkte ze als student-assistent bij de vakgroepen
‘Anatomie’ en ‘Acute Hulpverlening’ en bij het Nationaal Vergiftigingen
Informatie Centrum. Ze deed een stage op de afdeling Chirurgie van het Sint
Elisabeth Hospitaal te Curaçao. Ze slaagde cum laude voor de studie
Geneeskunde (1996). 
Aansluitend werkte ze als AGNIO op de afdeling Kinderchirurgie van het
Universitair Medisch Centrum Utrecht. 
In maart 1998 begon ze als arts-onderzoeker bij de afdeling Vaat- en
Transplantatiechirurgie en Thrombose en Haemostase Laboratoria, afdeling
Haematologie van het Universitair Medisch Centrum Utrecht aan het onder-
zoek dat heeft geleid tot dit proefschrift, onder begeleiding van Prof. Dr. BC
Eikelboom, Prof. Dr. PhG de Groot en Dr. JD Blankensteijn. 
Vanaf 1 juli 2001 volgt ze de opleiding tot chirurg in het Jeroen Bosch
Ziekenhuis, locatie Groot Ziekengasthuis, ‘s-Hertogenbosch (opleider Dr. J
Wever).


